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1. Introduction 
1.1 Breast cancer 
Despite early detection methods and advanced conventional treatments, breast cancer is one of 
the most frequently diagnosed malignancies and the second leading cause of cancer deaths 
among women worldwide (DeSantis et al., 2011; Jemal et al., 2011; Thomas et al., 2006).  The 
chance of being diagnosed for women is 1 in 8 (http://seer.cancer.gov/csr/1975_2009_pops09/).  
Every year more than 192,000 women are diagnosed as positive for breast cancer in the United 
States (Jemal et al., 2010); the incidence rate for breast cancer is still high in the United States 
as well as Australia/ New Zealand, and Western and Northern Europe (Jemal et al., 2011).  
Since the last 25 years, breast cancer death rates decreased in several European countries and 
Northern America due to early detection methods.  However, the number of estimated new 
cases of breast cancer in 2012 is about 226,870 in the United States and the estimated number 
for breast cancer death is 39,510 (Siegel et al., 2012).  According to the Surveillance, 
Epidemiology, and End Results (SEER) program of the National Cancer Institute, responsible 
for collecting breast cancer data in the United States, 1 in 3 cancers diagnosed in women is 
breast cancer (DeSantis et al., 2011).  Therefore, novel therapies designed with alternative and 
complementary strategies are sorely needed.   
 
1.1.1 Pathophysiology of breast cancer  
The breast contains 15-20 lobes which radiating from the nipple surrounded by fibrous 
connective tissue and fats.  Each lobe can be separated into several lobules.  The lobules supply 
milk to the ducts and therefore are also referred to as ductual-lobular.  The basic structural 
units of the breast are the lobules which are surrounded by epithelial cells.   
The most common breast cancer originates either in the epithelial cells of the inner lining of the 
milk ducts (ductal carcinoma) or in the lobules (lobular carcinoma).  As with every other 
cancers, breast cancer developes from different genetic aberrations or aberrant growth factor 
receptor signaling (Madigan et al., 1995; Taylor et al., 2008; Wosikowski et al., 2000; Ziegler 
et al., 1993).  Furthermore, breast cancer can be inherited, most commonly resulting from a 
genetic defect in the DNA repair genes BRCA1 and BRCA2 (breast cancer susceptibility gene 
1, 2) (Chappuis et al., 1999; Struewing et al., 1997).  Besides inherited genetic aberrations and 
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defects, breast cancer can be initiated through environmental factors (Davis and Sieber, 1997; 
Madigan et al., 1995; Ziegler et al., 1993). 
Development of breast cancer is a multiple process that can be divided into several steps.  
Precursor lesions that are benign can be divided into non-proliferative and proliferative lesions.  
For example, non-proliferative lesions are duct ectasia or mild hyperplasia of the normal and 
simple type (Beckmann et al., 1997).  Proliferative lesions can be further divided into 
proliferative phase without atypia and with atypia.  Cells found in regions of proliferative 
changes without atypia show an extreme cell growth without any abnormal cell structure.  
Proliferative changes with atypia on the other hand are characterized by regions of cell 
expansion containing some cells with an abnormal cell structure.  Lesions of this type are also 
called atypical hyperplasia and cells demonstrate a few characteristics of a carcinoma in situ 
(Beckmann et al., 1997).  Carcinoma in situ originated from proliferation of the glandular 
epithelium demonstrating cellular malignancy and is restricted to a specific area.  Carcinoma in 
situ can be separated in either ductal carcinoma in situ (DCIS) or lobular carcinoma in situ 
(LCIS).  Tumors that aquire the ability to penetrate into the surrounding breast cancer tissue 
and metastasize to other organs are called invasive breast carcinomas (Lakhani, 1999).  The 
most common type is invasive ductal carcinoma (IDC) (Beckmann et al., 1997). 
 
1.1.2 Breast cancer treatments 
Several treatment options for breast cancer have been developed during the last decade.  These 
treatment approaches are divided into surgery, chemo-, radiation-, hormonal and targeted 
therapy.  The breast cancer treatment is chosen depending on stage and type of cancer.  Most 
women diagnosed with breast cancer undergo surgery to remove as much cancer tissue as 
possible.   
Breast conservation surgery is the most common surgery, in which depending on the stage of 
the breast tumor, the breast tumor and a small region of tumor surrounding breast tissue are 
removed.  Segmental or partial mastectomy is another option of surgery during which a larger 
section of the tumor surrounding breast tissue is removed.  Breast cancer patients with more 
advanced tumor stage need to undergo a radical mastectomy, by removing the entire breast as 
well as several lymph nodes under the arm.  Although, surgery is still the preferred method to 
remove a tumor successfully, it also bears some disadvantages.  The most common 
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complications observed after breast cancer surgery is the collection of serous fluid under the 
skin, seroma formation and axillary dead space (Pogson et al., 2003), (Hashemi et al., 2004).   
Chemotherapy is another option to treat breast cancer.  It involves the use of drugs to kill 
cancer cells, inhibit cancer cell growth or to avoid cancer recurrence.  Some of the commonly 
used drugs for chemotherapy to treat breast cancer patients are adriamycin (also called 
doxorubicin), cyclophosphamide, and paclitaxel (Ibrahim et al., 2003); (Hutchins et al., 2005).  
Usually, chemotherapy can be divided into three different types: 1) Neoadjuvant, given before 
surgery to shrink the tumor; 2) Adjuvant, given after surgery to prevent recurrence; and 3) 
Palliativ, given to control cancer in the stage where it is already metastatic.  However, 
treatment with chemotherapeutic reagents induces some mild side effects like fatigue, nausea, 
hair loss and vomiting and several severe ones such as cardiotoxicity, necrosis of the colon, 
leukemia and severe infections (Ewertz and Jensen, 2011; Lemieux et al., 2008; Lindley et al., 
1999; Sitzia and Huggins, 1998; Yood et al., 2012).  The severe side effects can be fatal and 
cause the death of the breast cancer patient.   
Radiation therapy on the other hand exploits high energy X-rays to destroy breast cancer cells 
or inhibit their proliferation.  High energy radiation damages the DNA of cancer cells or forms 
charged particles like free radicals causing cancer cell killing.  There are two types of radiation 
therapy, external and internal radiation therapy.  External radiation therapy is performed with a 
machine outside of the body whereas internal radiation utilizes radioactive substances injected 
directly into the tumor or near the cancer occurrence.  Radiation therapy is usually given after 
surgery either alone or in combination with chemotherapeutic reagents to avoid breast cancer 
recurrence, to kill metastasized breast cancer cells in other organs or residual cancer cells.  
Radiation therapy is painless but can induce severe side effects like skin irritation, hair loss, 
and damage to the salvery glands.  Those side effects appear because healthy cells can be 
harmed during this treatment as well (Rutqvist et al., 2003).  One of the severe side effects of 
radiation therapy is the induction of sarcoma.  The occurrence rate is very low, but if sarcoma 
occurrs after the radiation therapy, it is associated with poor clinical outcomes (Sheth et al., 
2012). 
Besides chemo- and radiation therapy, hormonal therapy is another treatment utilized to treat 
breast cancer by using drugs to inhibit production of steroid hormones that stimulate cancer 
cell proliferation.  Many breast cancer types express high levels of estrogen and/or 
progesterone receptors on their cell surface.  Breast cancer patients suffering from tumors with 
high expression of estrogen receptors can undergo hormonal therapy.  Drugs usually used for 
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hormonal therapy include aromatase inhibitors like exemestane (Tomao et al., 2011) and 
selective estrogen modulators like Tamoxifen (Smith et al., 2000).  These drugs block the 
hormone activity or repress their expression to inhibit breast cancer cell proliferation. Besides 
killing of cancer cells these drugs show several side effects.  For example, treatment with 
Tamoxifen can cause weight gain, hot flashes, vaginal discharge and severe late side effects 
such as increasing the risk for blood clots, stroke and invasive endometrial cancer (Perez, 
2007).  Aromatase inhibitors are most commonly given to postmenopausal women suffering 
from hormone dependent breast cancer requiring the hormone estrogen to proliferate.  
Aromatase inhibitors block the aromatase enzyme that converts androgen to estrogen in the 
body and therefore, prevent cancer cell proliferation (Gibson et al., 2009).  Typical aromatase 
inhibitor side effects are skeletal fractures, hot flashes and development of osteoporosis (Perez, 
2007).   
Targeted therapy is another therapeutic treatment of breast cancer employing drugs or 
monoclonal antibodies to recognize and destroy specific cancer cells without damaging healthy 
cells.  For example, monoclonal antibodies are used to recognize specific cancer cell surface 
markers or factors that are stimulating the tumor growth.  Binding of monoclonal antibodies to 
their target destroys the cancer cell or inhibits cancer cell proliferation/migration.  One 
example of a therapeutic monoclonal antibody is Trastuzumab that acts by blocking the signal 
cascade of the growth factor protein HER2.  HER2 activates a signal cascade that in return 
induces proliferation of cancer cells (Higgins and Baselga, 2011).  Targeted therapy drugs like 
tyrosine kinase inhibitors are administered to inhibit tumor growth signaling.  Lapatinib, a 
tyrosine kinase inhibitor, prevents the effect of HER2 protein and other proteins inside the 
tumor cells.  PARP inhibitors on the other hand inhibit DNA repair and may trigger cancer cell 
death.  PARP inhibitors are widely studied for triple negative breast cancer (Higgins and 
Baselga, 2011).  Triple negative breast tumors are lacking the expression of estrogen receptors 
(ER-), progesterone receptors (PR-) and HER2 (HER2-). 
Thus, beside several of breast cancer treatment options currently available, there remains a 
need for novel treatments to reduce mortality rate of breast cancer.  
 
1.2 Gene therapy for breast cancer 
Gene therapy is a therapeutic approach that involves the delivery of genetic material to cancer 
or defective cells and its surrounding tissue.  The goal of cancer gene therapy is to cause tumor 
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cell death or prevent tumor growth.  For cells that cause a disease due to a gene defect, gene 
therapy provides these cells permanently with the missing gene and ideally curing the disease 
(Cross and Burmester, 2006).  Over the last decades, gene therapy became a powerful tool to 
treat metabolic disorders, cardiovascular diseases and cancer with great success while 
traditional therapies were limited due to their severe side effects (Kay and Woo, 1994); 
(Mulavisala et al., 2001; Rakhmilevich et al., 2004; Zhang et al., 1996).  Gene therapy can be 
categorized into five different groups: 1) genetic immunopotentiation, 2) pro-apoptotic gene 
therapy, 3) anti-angiogenic gene therapy, 4) mutation compensation, and 5) molecular 
chemotherapy/suicide gene therapy (Cross and Burmester, 2006).   
Genetic immunopotentiation increases the immune response against specific tumor antigens.  
Genes that have been analyzed to use for breast cancer immunotherapy are HER-2/neu protein 
(Disis et al., 1999; Kawashima et al., 1999), carcinoembryonic antigen (CEA) (Kawashima et 
al., 1999) and MAGE-1 (Toso et al., 1996).   
Pro-apoptotic gene therapy encompasses the combination of a therapeutic drug and specific 
surface cell death molecules like tumor necrosis factor-related apoptosis-inducing ligands 
(TRAIL) (Griffith et al., 2000; Lin et al., 2002).  This combination increases the apoptotic cell 
death and at the same time it can improve the therapeutic effect in drug-resistant tumor cells.   
Anti-angiogenic therapy, on the other hand, uses the knowledge of the role of angiogenesis in 
tumor cell growth.  Angiogenesis facilitates cancer cell growth by providing them with new 
blood vessels (Atiqur Rahman and Toi, 2003; Marty and Pivot, 2008).  Angiostatin and 
endostatin were found to have an anti-angiogenic function.  It was demonstrated that liposomes 
complexed to plasmids containing angiostatin and endostatin inhibited breast tumor 
development in nude mice (Chen et al., 1999; Oga et al., 2003).  Breast cancer was induced by 
the injection of either human breast cancer cells or mice breast cancer cells into the mammary 
fat pats.  Injection of liposome:plasmid complexes was performed intratumorally, intravenous 
or intramuscular (Chen et al., 1999; Oga et al., 2003). 
Mutation compensation is based on the idea to restore defects in a cancer cell that are causing 
the malignant transformation.  For example, one strategy for mutation compensation employs 
the replacement of a defected tumor-suppressor gene in cancer cells with a working copy such 
as p53 (Chen and Mixson, 1998) or Rb (Wang et al., 1993).  Another strategy is to decrease the 
tumor cell development by ablating the oncogene function of c-myc (Watson et al., 1991) and 
c-fos (Arteaga and Holt, 1996) which are used in breast cancer.   
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Suicide gene therapies are designed to treat cancer cells by delivering a gene that can convert a 
non-toxic prodrug into a toxic form.  Besides killing the targeted cancer cells, suicide gene 
therapy can also affect surrounding cells of the region.  This has been termed a bystander 
effect, providing the opportunity to destroy cancer cells that might have migrated into the 
tumor surrounding tissue.  Clinical trials were performed with erbB-2 (Pandha et al., 1999) and 
MetXia-P450 (Braybrooke et al., 2005) as suicide gene therapy for breast cancer.   
 
1.3 Adenovirus 
Over the past several years, the field of gene therapy has emerged with a broad variety of 
applications.  Throughout this progress, the use of non-viral and viral vectors as delivery 
vectors has also widened.  One of the most promising candidates for gene therapy is the 
adenovirus (Ad).  Ads were first isolated back in the 1950’s and since then their biology has 
been extensively studied (Hilleman and Werner, 1954; Rowe et al., 1953).  Ads have specific 
features that make them a suitable gene therapy vector (Russell, 2000; Zhang, 1999).  First, the 
generation of high titers required for clinical administration, is no longer a major problem.  
Furthermore, the Ad genome is really easy to manipulate and large DNA sequences can be 
inserted without any complications.  In addition, Ads are capable to infect a large variety of 
dividing and non-dividing cells and they are not integrating their viral genome into host 
chromosomes.  Moreover, they show also a low pathogenicity in humans and are causing only 
mild symptoms during their infection.  All these characteristics of Ads for gene therapy as 
vectors offer a new therapeutic intervention to target breast cancer.   
 
1.3.1 Adenoviral structure 
At present, there are 53 known human Ad serotypes classified into six species (A-F subgroup) 
based on their neutralization by specific animal antisera, oncogenic potential and their DNA 
GC content (Davison et al., 2003; Madisch et al., 2005).  Ads are non-enveloped, icosahedral 
viruses that contain a linear double stranded DNA genome of 36,000 base pairs (Rux and 
Burnett, 2004).  The outer protein layer of the Ad virion is called the capsid that encloses the 
DNA-protein core complex.  The capsid structure is composed of seven polypeptides: the three 
major proteins hexon (II), penton base (III) and fiber (IV) and the minor proteins IIIa, VI, VIII 
and IX (Vellinga et al., 2005) as seen in Figure 1.  252 capsomeres are forming the Ad capsid 
of which 240 are consisting of the hexon protein whereas the remaining 12 capsomeres are 
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composed of pentons and are found at the 12 vertices.  Penton capsomeres are formed by 
pentameric penton bases and a protruding trimeric fiber (Valentine and Pereira, 1965).  Penton 
bases are important for the capsid stabilization and together with the fiber they initiate and 
mediate viral attachment and internalization into the host cells.  All fiber proteins can be 
divided into three domains: the N-terminal tail domain, the shaft region of variable length, and 
the C-terminal knob domain.  The trimeric structure of the fiber is formed by sequences of the 
knob and the shaft domain (Rux and Burnett, 2004).  Besides pentons and hexons, the capsid 
structure is stabilized by the minor proteins IIIa, VI, VIII and IX.  Furthermore, the capsid 
contains also a virus-encoded protease (adenain) that cleaves several precursor proteins like VI, 
VII, VII, X, and terminal protein (TP) and is essential for the assembly of newly infectious 
viral particles (Russell, 2009).   
The viral genome is enclosed by the capsid and associates with the polypeptides V, VII, X 
(mu) and TP.  This complex builds a condensed core structure.  Inverted terminal repeats (ITR) 
are located at each end of the Ad genome and each 5’-terminus is associated with the TP.  Both 
associations are essential for viral genome replication (Russell, 2000).  The Ad genome is 
separated into regions: the early genes encoding for E1A, E1B, E2A, E2B, E3 and E4; the 
delayed early genes encoding IX and IVa2 and the late genes encoding L1-L5.  Early gene 
products play an essential role in adenoviral transcription, DNA replication, suppression of 
host immune response and inhibition of host cell apoptosis whereas the late genes encode for 
viral structure proteins which are necessary for viral assembly (Russell, 2000).  In addition, 
two genes encode for virus-associated RNAs I and II (VAI and VAII RNAs) which have an 
important function to inhibit the host protein synthesis during viral replication in infected cells 
(O'Malley et al., 1986).   
  Introduction 
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1.3.2 Adenoviral infection pathway 
The Ad infection pathway can be separated into several steps: attachment, internalization, 
endosome escape, viral replication, assembly and lysis.  Ad infection of a host cell is initiated 
by binding of the fiber knob domain to a cellular attachment receptor on the host cell surface.  
For most Ad serotypes (except for subgroup B) the primary cellular attachment receptor is the 
Coxsackie and Adenovirus receptor (CAR) (Bergelson et al., 1997; Roelvink et al., 1998).  The 
expression pattern of CAR on the surface of tissue-specific cells plays a crucial role for the 
adenoviral tropism.  CAR is highly expressed on parenchymal cells in the liver but not 
exclusively, thus explaining high liver infectivity of Ad vectors upon systemic administration 
but also the wide Ad vector tropism in vitro (Yee et al., 1996).   
The first step of Ad infection is the binding of the Ad fiber knob domain to the N-terminal 
domain of CAR.  Besides the binding of the fiber knob to CAR, a second interaction of virion 
and the cell surface is essential to initiate viral uptake.  The interaction between integrins ανβ3 
and ανβ5 on the host cell surface and the Arg-Gly-Asp (RGD) motif on the penton base of the 
 
Figure 1: Adenovirus structure.   
General structure of the Ad: displaying hexons, penton bases, fibers and cement proteins of the Ad capsid.  The 
capsid encompasses the Ad genome and core proteins associated with the Ad genome forming the core of the 
Ad.  Figure was adapted from (Russell, 2000). 
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Ad vector is necessary to mediate internalization of the Ad virions (Mathias et al., 1998; 
Wickham et al., 1993.).  Binding of integrins is followed by rapid endocytosis of the virions 
through clathrin-coated vesicles driven by a cytosolic GTPase (Meier et al., 2002; Roelvink et 
al., 1998; Roelvink et al., 1999).  Once the viral particles are taken up by clathrin-coated 
vesicles, the endosome acidification process is causing conformational changes of the Ad 
vector capsid resulting in the release of the virions into the cytoplasm (Wang et al., 1998).  The 
process of viral uptake until viral release into the cytosol is completed within 15 min and 
therefore rapid (Greber et al., 1993).   
Next, the virions are translocated to the nuclear pore complex by a microtubule-dependent 
trafficking.  Subsequently on arrival at the nucleus, Ad vectors interact through hexons with 
the nuclear pore complex and release their genome into the host cell nucleus to start viral 
replication.  Within one hour more than 90% of Ad vectors are transported to the nucleus and 
about 18 hours post infection transgene expression can be detected reaching a maximum at 48 
hours (Greber et al., 1993).  The Ad infection pathway is schematically displayed in Figure 2.   
After viral genome replication and translation of the viral mRNA transcripts, Ad vectors need 
to assemble.  Therefore, viral proteins are transported back from the cytoplasm into the nucleus 
for particle assembly.  Final maturation of Ad vectors is achieved by the adenain protease that 
cleaves the precursor polypeptides of VI, VII, VIII, Mu and TP to obtain infectious virion 
particles.  In the final step of the Ad replication pathway, cells are lysed by the accumulation of 
ADP (Ad death protein) (Tollefson et al., 1996) and the cleavage of cellular cytokeratins by the 
L3 protease.  Cleaved cytokeratins cause an increased susceptibility of the cell to lyse by 
disrupting cell integrity (Chen et al., 1993).  In addition, in the past several years it has been 
suggested that autophagy aids the release of progeny virions (Jiang et al., 2008).   
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1.4 Oncolytic virotherapy of breast cancer 
Because of safety concerns, only replication incompetent viruses were used as vehicle vectors 
in the beginning of gene therapy.  However, clinical studies have shown that using replication 
incompetent viruses resulted in only a minor proportion of tumor cells infected and did not 
proffer for therapeutical success (Alvarez and Curiel, 1997).  Therefore, employing replication 
competent viruses to treat malignant tumors was referred to as a virotherapy procedure instead 
of gene therapy (Alemany et al., 2000; Kirn et al., 2001).  Virotherapy exploits tumor specific 
characteristics for a specific cell targeting, viral infection and replication in tumor cells to kill 
them while leaving healthy cells unaffected (Alemany et al., 2000; Mathis et al., 2005).  The 
principle of virotherapy is based on the idea that a replication competent virus infects a tumor 
cell and replicates tumor cell specific leading to tumor cell oncolysis and spread of progeny 
virions to adjacent tumor cells.  Ideally, the tumor specific replication is repeated until all 
tumor cells are destroyed but not the healthy cells (Alemany et al., 2000; Kirn et al., 2001) 
(Figure 3).   
 
Figure 2: Ad serotype 5 infection pathway. 
Illustrated are the principal steps of the adenoviral infection.  Binding of the Ad fiber knob to the primary cellular 
attachment receptor is followed by the interaction of penton base with integrins.  Binding of integrins initiates 
viral uptake through clathrin-coated vesicles. In the endosome Ad dissociates in the low pH environment and up 
on acidification Ads are dismantled and viral particles are released into the cytosol.  Viral particles are then 
transported to the nucleus where they release their viral genome and start viral replication.  Figure was adapted 
from (Kanerva and Hemminki, 2005). 
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Besides the promising results of virotherapy in the mouse models, the first results in clinical 
trials revealed a reduced efficiency of Ads to target cancer cells (Douglas et al., 2001; Vasey et 
al., 2002).  It was shown that expression of CAR on the surface of the targeted cell type was a 
limiting factor.  Most tumor types including breast carcinoma displayed a reduced expression 
of CAR on their cell surface compared to normal cells (Li et al., 1999; Shayakhmetov et al., 
2002; Zabner et al., 1997).  This was leading to an unspecific targeting of normal cells instead 
of cancer cells (Glasgow et al., 2006).  Ad serotype 2 (Ad2) and Ad serotype 5 (Ad5) are used 
as vectors for oncolytic virotherapy by the majority of investigators because those two 
serotypes are the ones which genomes were first sequenced and efficiently studied.  
Theretofore, modifying the native Ad tropism by altering the Ad fiber structure, the 
transductional targeting, was developed.  Moreover, the Ad targeting can be changed by 
modifying the Ad replication efficiency on the genetic level.  Transcriptional targeting is really 
important because Ad serotype 5 (Ad5) is able to replicate in a wide variety of cell types.  To 
avoid Ad replication in normal healthy cells, the Ad5 vector can be genetically modified to 
replicate only tumor specific by incorporating a tumor specific promoter into the Ad genome.  
In addition to transductional and transcriptional targeting, a third targeting strategy, 
 
Figure 3: Oncolytic virotherapy of replicative viruses. 
A replication competent virus infects the target cell, replicates tumor specific and kills the tumor cell by lysis. 
Progeny virions are spread and can infect neighboring tumor cells.  This infection cycle is repeated until all 
tumor cells are destroyed leaving the healthy cells uninfected.  Figure was adapted from (Mathis et al., 2005). 
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translational targeting, was recently established. Ad replication is restricted by controlling the 
initiation of E1A mRNA translation. 
 
1.4.1 Different targeting strategies 
1.4.1.1 Transductional targeting 
A successful oncolytic virotherapy depends on the efficient binding of the Ad5 vector to the 
target cancer cells.  Low expression of CAR on most cancer types including breast cancer was 
reported by several investigators to be responsible for reduced infectivity of Ad5 (Glasgow et 
al., 2006; Li et al., 1999; Shayakhmetov et al., 2002; Zabner et al., 1997).  CAR is usually 
expressed on healthy cells because CAR can induce cell to cell contact, a phenotype that is lost 
in malignant tumors (Walters et al., 2002).  Furthermore, it was shown that Ad vectors were 
rapidly interacting with factors of the blood system and accumulated in the liver upon 
intravenous injection (Shayakhmetov et al., 2004).  Thus, to provide effective Ad delivery to 
targeted cells, a large dose of Ad5 was necessary to administer which could induce toxicity. 
To circumvent low Ad5 infection efficiency and high accumulation of Ad5 in the liver, the 
transductional targeting was developed.  This targeting strategy alters the native Ad5 tropism 
to re-target Ad5 vectors to cancer cells.  Transductional targeting can be divided into two 
different categories: 1) genetic targeting and 2) physical targeting (Glasgow et al., 2006). 
The concept of adapter-based targeting of Ad vectors is based on the idea that the adapter is 
forming a molecular bridge between adenoviral vectors and cell receptors.  Adapters are 
composed of bispecific molecules and are used to bypass the native Ad5 CAR tropism.  This 
targeting strategy was explored on the fact, that Ad attachment and entry are two separate 
steps.  Thus, altering the Ad attachment receptor is not changing the entry pathway because 
entry of Ad vectors is initiated by the binding of cell surface integrins to the Ad penton base 
(Mathias et al., 1998; Wickham et al., 1993).  Bi-specific antibodies, antibody fragments (Fab)-
peptide ligand conjugates, Fab antibody conjugates, recombinant fusion proteins (composed of 
Fabs and peptide ligands), and chemical conjugates between Fabs and cell-specific ligands 
(Glasgow et al., 2006) are employed as adapters to retarget Ad vectors. 
The first successful retargeting of Ad vectors to cancer cells overexpressing folate receptor was 
established by using a bispecific conjugate that contained an anti-knob neutralizing Fab that 
was chemically associated to folate (Douglas et al., 1996).  Besides this study several other 
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Fab-ligand conjugates targeted against several cell surface markers such as EGFR (Miller et 
al., 1998), CD40 (Tillman et al., 1999) and EpCAM (Haisma et al., 1999) have been published 
to successfully retarget Ad vectors.  However, adapter-based delivery systems have a big 
disadvantage.  They are more complex in their kinetics and pharmacodynamics, and their 
stability has not been investigated in humans so far.  That is why a one-component system is 
preferable to administer into humans for clinical trials (Glasgow et al., 2004). 
The second strategy of transductional targeting employs genetical modification of the Ad 
capsid to circumvent the native CAR-based tropism without destroying molecular functions 
that are essential for accurate viral replication.  Upon basic understanding of Ad attachment, 
the Ad fiber knob domain became the major site for modifications.  Genetical modifications of 
the Ad capsid can be further divided into three categories: 1) ligand incorporation into the fiber 
knob, 2) de-knobbing of the fiber and 3) fiber-pseudotyping (Glasgow et al., 2004). 
Ligand incorporation into the Ad fiber knob domain was shown to successfully retarget Ad 
vectors to specific cells. Integrating a polylysine motif (pK7) into the C-Terminus of the fiber 
knob increased the infection efficiency of tumor cells upon high affinity binding to poly anions 
like heparansulfate proteoglycans (Wickham et al., 1996).  Another integration side for ligands 
is the HI-loop located in the fiber knob domain.  It is possible to incorporate up to 83 amino 
acids without inhibiting or influencing the adenoviral replication (Belousova et al., 2002).  
Integration of an Arg-Gly-Asp (RGD)-motif into the HI-loop demonstrated an enhanced 
binding to integrins and retargeting the modified Ad vector to tumor cells like in ovarian 
cancer cells (Dmitriev et al., 1998).  
De-knobbing of Ad includes the displacement of the entire fiber and substitution with a 
chimeric knobless fiber.  This targeting strategy was developed upon the investigation that Ads 
without a fiber could be generated (Falgout and Ketner, 1988; Von Seggern et al., 1999).  Fiber 
knob-deleted Ads ablate the native CAR-tropism and can be retargeted to different cell types 
by incorporating a ligand into the knobless fiber.  The maintainance of the fiber trimerization is 
of main importance for this type of modification because otherwise the modified Ad is unable 
to assemble correctly and attach to the receptor.  Incorporation of a trimeric CD40 ligand 
resulted in a 100-fold improvement of transduction to human dendritic cells (Belousova et al., 
2002).  In addition, it is also possible to insert targeting ligands into the capsid proteins like 
hexon or pIX.  A successful insertion of a RGD-motif in the hypervariable region 5 of the 
hexon protein showed an increased fiber-independent targeting to low-CAR expressing 
vascular smooth muscle cells (Vigne et al., 1999). 
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Another category to retarget Ad vectors is fiber-pseudotyping in which the whole fiber or only 
the fiber knob domain of serotype 5 is exchanged with one of a different human Ad serotype.  
It was shown that subgroups B and D of human Ads do not use CAR as their primary cellular 
attachment receptor.  CD46, CD80 and CD86 have been identified as cellular attachment 
receptors for subgroup B Ads like Ad serotype 3, 35 and 7 (Fleischli et al., 2007; Short et al., 
2004; Sirena et al., 2004).  Binding of Ad3 to these receptors has been brought into question, 
because several investigators failed to confirm these receptors for Ad3 (Marttila et al., 2005; 
Segerman et al., 2003).  Recently, Wang et al. published that Desmoglein-2 is the cellular 
attachment receptor of Ad3 (Wang et al., 2011).  Desmoglein-2 is a transmembrane 
glycoprotein which binds calcium and is a member of the cadherin protein family (Steinberg et 
al., 1987). 
The fiber chimera Ad5/3, in which fiber knob of serotype 5 was exchanged with the one of 
serotype 3, was first established by Krasnykh and colleagues (Krasnykh et al., 1996).  Ad5/3 
ablated CAR binding in the same manner as Ad3 by itself.  Studies including this fiber chimera 
demonstrated an increased targeting of Ad to the low-CAR ovarian cancer cell lines (Kanerva 
et al., 2002; Kanerva et al., 2002).  In addition, the Ad3 serotype has the same biodistribution, 
liver toxicity and clearance profile as Ad5 serotype. This suggests that Ad3 has a good safety 
profile, an important feature for human clinical administration (Kanerva et al., 2002).  
 
1.4.1.2 Transcriptional targeting 
In addition to alter the native Ad tropism with transductional targeting, there is still a need to 
enhance the cancer cell specific Ad replication due to the wide variety of Ad5 wild type (WT) 
tissue replication efficiency.  Transcriptional targeting involves the genetic modification of the 
Ad genome to restrict Ad replication to a specific cancer cell type.  This method involves the 
use of a human tumor- or tissue-specific gene promoter (TSP) exchanged with the endogenous 
E1A gene promoter.  Since Ad virions can broadly infect multiple cell types, Ad replication 
can be restricted by inserting a TSP in place of the E1A promoter.   
The E1A protein is needed for initiating Ad transcription and replication and is therefore 
expressed very early after Ad infection.  Incorporation of a TSP upstream of the E1A gene is 
leading to a promoter-controlled Ad replication in the cells where the TSP is active (Pelka et 
al., 2008).  Ads that are genetically modified to restrict Ad replication are named conditionally 
replicating adenoviruses (CRAds).  
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In the last decade, a great number of TSPs were identified for several cancer types.  One of the 
first TSP that was identified and shown to be over expressed in a number of pancreatic, gastric 
and lung cancers was the carcinoembryonic antigen (CEA) promoter (Tanaka et al., 1996).  It 
was shown that upon the insertion of the CEA promoter liver toxicity after intravascular Ad 
administration was reduced compared to a control vector (Tanaka et al., 1996).  
Moreover, several TSP have been reported to be highly activated in breast cancer cells such as 
CXCR4 (Zhu et al., 2004), survivin (Zhu et al., 2004) and DF3/MUC1 (Ring et al., 1997).  
Recent publications suggested a role of the CXCR4/SDF-1α signaling to play a role in 
progression of numerous cancer types (Moore, 2001; Murakami et al., 2002).  In particular, a 
study performed by Muller et al. revealed that CXCR4 was highly expressed in breast cancer 
cells and metastases while expression in their normal counterparts was low (Muller et al., 
2001).  Therefore, several groups utilized the CXCR4 promoter and exchanged it with the E1A 
promoter to successful restrict Ad replication to a specific cancer type such as breast cancer 
(Haviv et al., 2004; Stoff-Khalili et al., 2005; Zhu et al., 2004). 
Besides limiting the Ad replication by controlling the E1A expression through a TSP, another 
procedure to restrict Ad replication is to delete specific base pairs in the Ad genome.  Upon the 
deletion of specific base pairs, Ad requires tumor-specific cellular factors to restore Ad 
replication.  The first deletion mutant CRAd was ONYX-015 carrying two deletions in the E1B 
gene, encoding for a 55 kDa protein (Bischoff et al., 1996).  Usually the functional protein 
binds p53, inactivates it and induces S-phase entry upon Ad infection.  Mutating two sites in 
the E1B gene, Ad virions can only replicate in cells that possess an aberrant p53 pathway 
(Bischoff et al., 1996). 
Another deletion mutant CRAd is Ad5 ∆24 that carries a 24 base pair deletion in the constant 
region 2 (CR2) of the E1A gene (Bischoff et al., 1996).  This region is necessary to bind 
retinoblastoma (Rb) protein to induce S-phase entry.  CRAds containing the ∆24bp deletion 
can only replicate efficiently in cells where this interaction is not necessary because cells are 
defective in the Rb-p16 pathway (Bischoff et al., 1996). 
 
1.4.1.3 Translational targeting 
Besides transductional and transcriptional targeting, there is a clear need for additional and new 
targeting strategies to optimize the tumor specific Ad replication.  Transcriptional targeting 
bears the disadvantage that most TSPs demonstrate a low background activity in normal and 
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liver tissues.  This background activity could induce problems during clinical studies by 
increasing the Ad hepatotoxicity.  Therefore, there is a clear need for additional and new 
targeting strategies to optimize the tumor specific Ad replication.  
Recently, Stoff-Khalili et al. introduced the translational targeting strategy to the virotherapy 
field (Stoff-Khalili et al., 2008).  Translational targeting involves the insertion of a control 
element upstream of the E1A gene to restrict E1A mRNA translation to a specific cell type.  In 
cancer cells, translational regulation has become a well-recognized mechanism contributing to 
the neoplastic phenotype.  In normal cells eIF4E protein concentration is low, it is bound to the 
4E-Binding Protein (4E-BP) and gets inactivated and therefore, translation initiation is 
regulated.  Phosphorylation of 4E-BP results in the release and activation of eIF4E causing the 
formation of the translation initiation complex and translation initiation itself (De Benedetti 
and Graff, 2004).  Clearly, the eukaryotic initiation factor 4E (eIF4E) is a key player in 
translational regulation and is critical to the genesis and/or progression of cancer cells based on 
the fact that it is overexpressed in the majority of solid tumors studied to date (DeFatta et al., 
1999; Miyagi et al., 1995; Rosenwald et al., 1999; Stoff-Khalili et al., 2008).  In this context, 
increased expression of eIF4E is leading to elevation of basic fibroblast growth factor (FGF-2) 
(Kevil et al., 1995) and vascular endothelial growth factor (VEGF) protein synthesis (Kevil et 
al., 1996).  The mRNAs of those two proteins have a long and complex GC-rich structure, 
named also “weak mRNA”.  The structure of weak mRNAs reduces the translation efficiency 
due to time that the translation initiation complex needs to scan the weak mRNA for the start 
codon.  Therefore, weak mRNAs are usually poorly translated in normal cells due to the 
limited translation initiation whereas strong mRNAs have a short UTR sequence and are highly 
translated into proteins.   
Besides the significance of eIF4E in the early changes of a primary tumor, it has been 
identified as one of the eight genes which when increased, exhibit a molecular signature of 
metastatic potential (Ramaswamy et al., 2003).  In tumorigenic cells and during cellular 
transformation the concentration of free eIF4E is increased (DeFatta et al., 1999), causing an 
enhanced translation of weak mRNAs in cancer cells as seen in Figure 4 (De Benedetti and 
Graff, 2004).  Translational targeting was realized by incorporating of the 5’UTR sequence of 
rat fibroblast growth factor 2 (FGF2) producing a weak mRNA upstream of the E1A gene. 
This incorporation is then restricting the E1A mRNA translation to the cells with high 
concentration of free eIF4E (Stoff-Khalili et al., 2008).  
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1.4.1.4 Combination of targeting strategies 
Although, an enhancement of tumor specificity was gained by every single targeting strategy, 
all targeting strategies have some disadvantages.  Hence, combining targeting strategies was 
reasonable to increase the safety for infection and replication in normal cells.  The feasibility of 
combining either transductional and transcriptional or transcriptional and translational 
regulation strategies (dual-level targeting CRAd) for the key goal of oncolytic adenovirus 
replicative specificity has recently been established (Stoff-Khalili et al., 2008; Stoff-Khalili et 
al., 2007).  Both dual-level viruses showed a specific gain in safety of normal cells and 
controlled viral replication (Stoff-Khalili et al., 2008; Stoff-Khalili et al., 2007), suggesting that 
the combination of several targeting strategies in a single CRAd is enhancing cancer cell 
specific replication and safety of normal cells.  The US Food and Drug Administration is still 
anxious about the specific replication of tropism modified Ads due to the possibility of 
infecting a wide range of normal cells carrying the receptor to which the modified virus can 
bind (Yamamoto and Curiel, 2010).  Consequently, there is still a need to even increase the 
cancer cell specific replication due to the fact that several TSPs show a background activity in 
several cell types.  Furthermore, translational restriction of E1A would be even more effective, 
if the virus would be targeted directly to a specific cancer cell type. 
 
 
Figure 4: mRNA translation efficiency in tumor progression. 
Protein synthesis rate of weak mRNAs is increased in a proportional manner with increasing free eIF4E 
concentration and tumor progression.  Modified from De Benedetti and Graff (De Benedetti and Graff, 2004).  
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1.4.2 Animal models for oncolytic virotherapy 
After a successful engineering of an Ad vector and gaining cancer cell specificity in vitro, a 
newly created Ad vector needs to be investigated in an adequate in vivo animal model.  Thus 
far, the most common animal model used to analyze oncolytic efficiency of newly generated 
Ad vectors is the human xenograft model in immunodeficient mice (Yamamoto and Curiel, 
2010).  Disruption of foxn1 gene in nude mice is causing deficiency in B-cell development and 
T-cell activity.  Nude mice are usually used as an animal model for oncolytic virotherapy 
because the immunosuppressed mice allow human cancer cells to from tumors and to treat the 
developed tumors with different anti-cancer treatments (Davis and Fang, 2005).  Certainly, the 
reliability on data received from this animal model is questionable because the immune system 
and the associated inflammation are impaired in nude mice.  Furthermore, the species specific 
Ad replication is a disadvantage for the nude mouse model (Ginsberg et al., 1991; Paielli et al., 
2000; Rustia and Shubik, 1979).  It was shown, that mice are poorly permissive for human Ad 
replication leading to a limited possibility for investigating human Ad replication in normal 
organs and hepatotoxicity resulting from virus replication (Duncan et al., 1978; Ginsberg et al., 
1991; Hjorth et al., 1988). 
Recently, the “Tissue-Slice-Model” was introduced using three-dimensional precision tissue 
slices from human tissues to evaluate preclinical oncolytic vectors.  Tissue slices can be 
obtained from normal liver and tumor tissue by the Krumdieck tissue slicer (Krumdieck et al., 
1980).  The “Tissue-Slice-Model” represents an active metabolic system displaying the 
heterogeneity of the investigated tissue.  It was shown, that human CRAds can successfully 
replicate on those tissue slices and hepatotoxicity of CRAds can be investigated on liver tissue 
slices (Kirby et al., 2004; Stoff-Khalili et al., 2006, Stoff-Khalili et al., 2007; Stoff-Khalili et 
al., 2005).  This newly invented technique makes it possible to analyze CRAds pre-clinical 
efficiently and fast (Kirby et al., 2004; Stoff-Khalili et al., 2006).  Unfortunately, analyzing the 
interaction of CRAds with the immune system is impossible with the “Tissue-slice-model”.  
Hence, other pre-clinical animal models are necessary that are permissive to Ad replication and 
immunocompetent.  
It was reported in the past, that Cotton rats’ species Sigmodon hispidus is permissive for the 
replication of several human respiratory viruses including Ad5 (Niewiesk and Prince, 2002).  
Cotton rats were shown to allow Ad5 replication in lungs, nasal passages and cornea and 
display the same pathology seen in Ad5 infected-humans (Ginsberg et al., 1989; Pacini et al., 
1984; Prince et al., 1993; Tsai et al., 1992).  Based on these findings, the cotton rat animal 
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model was employed to investigate in vivo spread and toxicity of Ad5 based vectors (Rojas-
Martinez et al., 1998).  Recently, the cotton rat model was introduced as a semi permissive 
animal model in the field of oncolytic virotherapy by establishing transplantable cotton rat 
tumor cell lines (Steel et al., 2007; Toth et al., 2005).  Both groups reported that Ad5 
replication and spread to neighboring tumor cells is possible in the generated cotton rat cancer 
cell lines in vitro and in vivo.  Consequently, the cotton rat tumor model was suggested as an 
animal model to determine replication efficiency, hepatotoxicity and immune response of the 
Ad5 vectors for oncolytic therapy of tumors.  However, a big disadvantage of the use of cotton 
rats is the difficulty in handling them because they are more aggressive and bite frequently 
(Niewiesk and Prince, 2002). 
Besides the cotton rat model and the tissue slice model, another method to analyze the safety 
profile of Ads and the immune response, is the exploitation of conditionally replicative canine 
Ads to investigate in spontaneous dog osteosarcoma treatment (Hay, 2003; Hemminki et al., 
2003). This model offers the possibility to gain valuable results about oncolytic activity and 
toxicity in a natural host and transferable to human application. Nevertheless, employing the 
canine model is expensive and a connection to veterinarian facilities is essential (Ternovoi et 
al., 2005), reducing the availability of the canine model for most investigators. 
Lately, Thomas et al. introduced the Syrian hamster as a permissive immunocompetent animal 
model to analyze oncolytic Ad5 vectors (Thomas et al., 2006). 
 
1.5 The Syrian hamster animal model 
Previously, the Syrian hamster (Mesocricetus auratus) has been introduced to be permissive 
for human Ad5 replication on the contrary to mainly other species examined (Eggerding and 
Pierce, 1986; Ginsberg et al., 1991; Silverstein and Strohl, 1986).  In cancer cell lines of this 
animal Ad5 is competent to infect those cells, replicate in them and spread from cell-to-cell 
(Bortolanza et al., 2007; Thomas et al., 2006; Ying et al., 2009).  In addition, it was shown that 
the adenovirus has important antitumor efficacy after injection in Syrian hamster tumors in 
vivo (Spencer et al., 2009).  Significantly, the Ad replicates not only in the tumors, but also in 
the lungs, liver and other organs (Thomas et al., 2006).  Therefore, the “Recombinant DNA 
Advisory Committee (RAC)” has suggested using the Syrian hamster model to further 
optimize adenovirotherapy and characterize/identify the basic mechanisms in tumor killing 
(Lichtenstein et al., 2009). 
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To date, several established hamster cancer cell lines are available to study oncolytic CRAds 
but not for all cancer cell types (Bortolanza et al., 2007; Thomas et al., 2006).  Recently, 
Spencer et al. developed a new pancreatic carcinoma model to study CRAds in the Syrian 
hamster (Spencer et al., 2009).  In this study transplantable tumors of the Syrian hamster from 
the National Cancer Institute were employed to establish a permanent pancreatic cancer cell 
line.  It was shown, that the Syrian hamster pancreatic carcinoma (SHPC9) cell line was 
permissive for Ad5 replication and could induce tumor growth upon subcutaneous injection 
into the hamsters (Spencer et al., 2009).  
Nonetheless, up to now no Syrian hamster breast cancer cell line is available because hamsters 
are somehow resistant to mammary cancer and only two studies have been reported to induce 
mammary tumors in hamsters (Della Porta, 1961; Rustia and Shubik, 1979). 
 
1.5.1 Induction of breast cancer in female Syrian hamsters 
In the past, several different studies of carcinogenesis and cancer chemoprevention have been 
performed using the Syrian hamster as animal model except for mammary carcinogenesis. The 
hamster cheek pouch model is one of the studies that was performed in Syrian hamster 
(Gimenez-Conti, 1993). This model uses the polycyclic aromatic hydrocarbon 7,12-
dimethylbenz[a]anthracene (DMBA) applied either as an initiating agent in combination with a 
tumor promoter such as benzoyl peroxide or as a total carcinogen. Usually, squamous cell 
carcinomas containing a mutation in the Ha-ras gene are developed after this treatment 
(Gimenez-Conti, 1993). Furthermore, it was reported that diethyl-stilbestrol (DES) treatment of 
Syrian hamsters leads to the development of renal carcinomas (Devanesan et al., 2001). Based 
on this treatment result, Laurent et al. developed a Syrian hamster renal carcinoma cell line 
(Laurent et al., 1999). In addition to the development of renal carcinomas, Syrian hamsters are 
capable of developing cholangiocarcinomas, pancreatic cancer and bile duct hyperplasia after 
exposition to aromatic amines like N-nitrosobis(2-oxopropyl)amine (BOP) (Kaneko et al., 
2004; Miyauchi et al., 2000).  Pancreatic cancer on the other hand can also be introduced by 
injecting two to three rounds of ethionine-methionine-BOP into the hamsters and feed them a 
choline-deficient diet (Mizumoto et al., 1988).  
To date, only a few studies reported the development of mammary tumors (Della Porta, 1961; 
Rustia and Shubik, 1979), but none could establish a breast cancer cell line so far.  Hence, it 
was of great interest to establish a breast cancer cell line that could be used to evaluate the 
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potency of newly designed oncolytic vectors alone or in combination with chemotherapy or 
radiation therapy.  Therefore, Coburn et al. induced mammary tumor formation in female 
Syrian hamsters by exposing the hamster to the carcinogen N-methyl-N-nitrosurea (MNU) 
(Coburn et al., 2011).  This study was based on the induction of mammary tumors in rat upon 
MNU treatment (Steele et al., 1994).  Treatment with MNU induced mammary tumors in 
female Syrian hamster, but only in a limited number (Coburn et al., 2011).  Histology of these 
primary mammary tumors showed abnormal ducts containing secretory products separated by 
poorly differentiated epithelial cells (Coburn et al., 2011).  Mammary tumors and premalignant 
lesions (ADH) were stained positive for HER-2/neu and pancytokeratin, indicating that the 
lesions and tumors were of epithelial cell and mammary origin (Coburn et al., 2011).  
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Aim of Thesis 
Virotherapy employing conditionally replicating adenoviruses (CRAds) represents a promising 
tool for a wide array of neoplastic diseases and especially to treat breast cancer.  Ideally, cancer 
specific replication of CRAds results in virus mediated oncolysis of infected tumor tissues and 
release of the progeny virions capable to further propagate in surrounding tumor cells but not 
in those of normal tissues.  Critical for a therapeutic index is selective killing of tumor cells 
while avoiding killing normal cells.  It was recently shown in our group that combination of 
targeting strategies (dual-level CRAds) increase the tumor on/liver off ratio for breast cancer 
cells (Stoff-Khalili et al., 2008; Stoff-Khalili et al., 2007). 
Based on these findings, the first aim of this study was to generate a new CRAd combining 
three targeting strategies that are used in oncolytic virotherapy to further increase breast cancer 
specific replication.  For this purpose, it was planned to construct a novel 5/3 fiber  chimeric 
(transductional targeting) virus containing the human tumor-specific promoter CXCR4 as a 
transcriptional control element and the 5’-untranslated region (5’-UTR) of rat FGF-2 
(Fibroblast Growth Factor-2) mRNA as a translational control element upstream of the E1A 
gene.  Background replication efficiency and breast cancer specificity were determined by 
using cytotoxicitiy assays, quantitative realtime polymerase chain reaction (qRT-PCR) and 
immunoblot analyses comparing infected breast cancer cells to normal cells.  
However, the preclinical evaluation of human Ad vectors has been limited due to the poor 
replication of human Ads in mice.  In this regard, the Syrian hamster has been lately introduced 
as an immunocompetent and Ad replication permissive animal model.  Due to the lack of a 
breast cancer model in the Syrian hamster to evaluate newly constructed oncolytic Ad vectors, 
our group recently succeeded in inducing mammary tumors in female Syrian hamsters.  Thus, 
the second aim of this study was to characterize the first Syrian hamster breast cancer cell line 
for its cancerous and tumorigenic character.  Furthermore, this cell line was investigated 
whether it is a suitable in vitro cell line to evaluate oncolytic Ad vectors for their cancer 
specificity.  Therefore, several established CRAds such as Ad5 ∆24 RGD and Ad5/3 WT were 
used to determine their infection and replication efficiency in this newly established Syrian 
hamster breast cancer cell line.  The final goal is to use the Syrian hamster as a novel breast 
cancer model for preclinical evaluation that is immunocompetent and permissive for human 
Ad5 replication. 
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2. Materials 
2.1 Bacterial Strains 
BJ 5183 (Stratagene, Agilent Technologies, La Jolla USA) 
This bacterial strain is a recombinant competent strain in which the recombination between a 
vector containing the adenoviral genome and a transfer vector containing the gene of interest 
takes place only if both vectors share appropriate regions of homology.  
Genotyping endA1 sbcBC recBC galK met thi-1 bioT hsdR (Strr) (Hanahan, 1983). 
 
XL10 Gold (Stratagene, Agilent Technologies, La Jolla, USA) 
The bacterial strain XL10 Gold is used commonly for transformation of large DNA molecules 
as the adenoviral genome with high efficiency.  Genotyping: TetrD(mcrA)183 D(mcrCB-
hsdSMR-mrr)173 endA1 supE44 thi-1 recA1 gyrA96 relA1 (lac Hte [F´ proAB lacIqZDM15 
Tn10Tetr) Amy Camr]. 
 
2.1.1 Media for cultivation of bacteria 
LB-Medium      LB-Agar 
Trypton    10 g/l   Trypton   10 g/l 
Yeast extract    5 g/l   Yeast extract   5 g/l 
NaCl     8 g/l   NaCl    8 g/l 
adjust pH to 7.5 with NaOH    Agar    15 g/l 
→ add H2O up to 1 liter    adjust pH to 7.5 with NaOH 
       → add H2O up to 1 liter 
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2.2 Eukaryotic cells 
 A549 (ATCC, CCL-185TM) 
A549 is a human lung carcinoma cell line, isolated from a lung carcinoma of a 58 year 
old Caucasian man in 1972. 
 Hamster Fibroblasts 
Fibroblasts were dissected from the lower back a Syrian hamster as a normal control 
cell line (Kindly provided by Dr. M. Mathis, LSU Health Sciences Center, Shreveport, 
USA; Present work). 
 HEK-293 (ATCC, CRL-1573™) 
HEK-293 cells were isolated from human embryonic kidneys of a healthy aborted fetus.  
This cell line expresses the left end of the adenoviral genome of serotype 5 and is 
excellent for titrating human adenoviruses.  The left arm sequence of the Ad5 genome 
was incorporated through transfection into the human chromosome 19. 
 HMAM4 spindle and round 
This hamster breast cancer cell line was developed by MNU-treatment in the Syrian 
Hamster. (Kindly provided by Dr. M. Mathis, LSU Health Sciences Center, Shreveport, 
USA Present work) 
 HMAM5 
Hamster breast cancer cell line was developed by MNU-treatment in the Syrian 
Hamster. (Kindly provided by Dr. M. Mathis, LSU Health Sciences Center, Shreveport, 
USA Present work) 
 HMEpC – Human mammary epithelial cells (PromoCell, C-12650) 
HMEpC were isolated from human adult mammary glands and stained positive for 
cytokeratin.  
 MCF-7 (ATCC, HTB-22™) 
This breast cancer cell line was developed from the mammary glands from an 
adenocarcinoma of a 69-years old Caucasian woman.  Growth of MCF-7 cells is 
inhibited by tumor necrosis factor alpha (TNF alpha).  Furthermore, MCF-7 cells 
express the estrogen receptor on their surfaces. 
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 MDA-MB-231 (ATCC, HTB-26™) 
MDA-MB-231 cells were obtained from the mammary glands from an adenocarcinoma 
of a 51-years old Caucasian woman. MDA-MB-231 cells express the WNT7B 
oncogene and are immortalized. 
 MDA-MB-231/N (Meric et al., 2000) 
MDA-MB-231 cells were stable transfected with a control plasmid pSV-neo. 
 MDA-MB-231/E1A (Meric et al., 2000) 
MDA-MB-231 cells were stable transfected with pE1A-neo that was carrying the WT 
E1A gene of Adenovirus serotype 5. 
 NHDF - Normal human dermal fibroblasts (PromoCell, C-12300 juvenile foreskin) 
To isolate NHDFs the dermis of juvenile foreskin was used from different locations like 
the breast, the thighs, the face and the abdomen.  This primary cell line is not 
immortalized and can be maximal passaged 16 times. 
 PHF PA2 und PHF 25M 
Human fibroblasts isolated from human cutaneous skin. (Kindly provided by Dr. B. 
Akgül, University of Cologne) 
 SK-BR-3 (ATCC, HTB-30™) 
This cell line is a breast cancer cell line, derived from the mammary glands of a 46 year 
old Caucasian woman.  The cell line is immortalized and over expresses the HER2/c-
erb-2 gene product (Hudziak RM, et al. Monoclonal antibodies directed to the Her2 
receptor. US Patent 5,677,171 dated Oct 14 1997). 
 ZR-75-1 (ATCC, CRL-1500™) 
ZR-75-1 is a breast cancer cell line established from the mammary glands of a ductal 
carcinoma of a 63-years old Caucasian woman.  
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2.2.1 Cell Culture Media 
 
Table 1: Cell culture media 
Cell lines Cell Culture Medium 
MDA-MB-231, SK-BR-3, ZR-75-1, MCF-7 DMEM + 10% FBS + 1% Penicillin/Streptomycin  
MDA-MB-231/E1A; MDA-MB-231/N DMEM + 10% FBS + 1% Penicillin/Streptomycin  
+ 250µg/ml G418 
HEK-293 DMEM + 10% FBS + 1% Penicillin/Streptomycin 
A549 DMEM + 10% FBS + 1% Penicillin/Streptomycin 
HMEC Mammary Epithelial Cell Growth Medium® (PromoCell) 
NHDF, PHF 25M, PHF PA2 DMEM + 10% FBS + 1% Penicillin/Streptomycin 
HMAM5 DMEM + 2% FBS + 1% Penicillin/Streptomycin 
HMAM4 spindle and round DMEM + 10% FBS + 1% Penicillin/Streptomycin 
Hamster Fibroblasts RPMI + 10% FBS + 1% Penicillin/Streptomycin 
 
 Dulbecco´s modified Eagle´s Medium (DMEM) (Invitrogen, Karlsruhe, Germany) 
plus GlutamaxTM, 4500 mg/l Glucose without sodiumpyruvate 
FBS 10 % (Invitrogen, Karlsruhe, Germany) 
Penicillin 100 units/ml (Invitrogen, Karlsruhe, Germany) 
Streptomycin 100 μg/ml (Invitrogen, Karlsruhe, Germany) 
 Freezing medium for all cells except HMEC and NHDF 
DMSO 10% (Invitrogen, Karlsruhe, Germany) 
FBS 90% (Invitrogen, Karlsruhe, Germany) 
 Freezing medium for HMEC and NHDF 
DMEM 70% (Invitrogen, Karlsruhe, Germany) 
FBS 20% (Invitrogen, Karlsruhe, Germany) 
DMSO 10% (Invitrogen, Karslruhe, Germany) 
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2.3 Nucleic Acids 
2.3.1 Synthetic Oligonucleotides 
The Oligonucleotides used for polymerase chain reaction (PCR), Sequencing and quantitative 
PCR (qPCR) were ordered from Operon, Invitrogen, Bioneer, and TIB MOLBIOL. 
Table 2: PCR and sequencing oligonucleotides 
Name Method Sequence 5’ → 3’ 
Human CXCR4 promoter forward PCR CCTCCTTCCTCGCGTCTG 
5’UTR rat FGF-2 reverse PCR ATGCAACTTTCTCCCTTCCTGC 
Ad3 fiber knob forward PCR TTATGGACAGGTCCAAAACCA 
Ad3 fiber knob reverse PCR TTTTCATTATCTGTTCCCGCA 
Human CXCR4 promoter forward Sequencing TATTGGCCATTGCATACGTT 
Human CXCR4 promoter reverse Sequencing TGGTAACCGCTGGTTCTCCA 
5’UTR sequence of FGF-2 forward Sequencing TTTGTTTAAACGGCACCCAT 
5’UTR sequence of FGF-2 reverse Sequencing TGTGCTGGAATTCAGGGCAG 
 
Table 3: Oligonucleotides used for qPCR 
Name Sequence 5’ → 3’ 
Ad5 E4 gene forward (E4 copy number determination) GCAAGGCGCTGTATCCAA 
Ad5 E4 gene reverse (E4 copy number determination) GGGTCGCCACTTAATCTACCT 
Ad5 E4 gene forward (viral entry and viral titer) TCCCGCGTTAGAACCA 
Ad5 E4 gene reverse (viral entry and viral titer) GCACTCCGTACAGTAGG 
Ad5 E1A gene forward CAGTTGCCGTGAGAGTTGGT 
Ad5 E1A gene reverse TGCCCAGGCTCGTTAAGC 
Ad5 pTP gene forward GAGGTGCTGCTGATGATG 
Ad5 pTP gene reverse CAAGGACATGGTGCTTCT 
Human HPRT1 forward TGACACTGGCAAAACAATGCA 
Human HPRT1 reverse GGTCCTTTTCACCAGCAAGCT 
Human GAPDH forward GAAGGTGAAGGTCGGAGT 
Human GAPDH reverse GAAGATGGTGATGGGATTTC 
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2.3.2 Plasmids used to generate the Ad5/3 CXCR4 UTR 
Table 4: Plasmids used in this study 
Name of Plasmid Reference 
pVK 500 FB5/3 Kindly provided by Dr. D.T. Curiel, Washington 
University, St. Louis, USA 
pShuttle.CXCR4-UTR-E1A (Stoff-Khalili et al., 2008) 
 
2.3.3 Plasmids used for the standard curve of the qPCR 
 pJET1-hHPRT1 (3,2 kb) human HPRT1 PCR product cloned into pJET1/Blunt to 
prepare serial dilutions to generate a standard curve in qPCR experiments provided by 
Dr. B. Akgül. 
 AdEasy-1 (33,5kb) (Agilent Technologies, Santa Clara, CA, USA), standard plasmid 
for E4 and pTP gene. 
 pShuttle WT pIX RFP (10,7kb), standard plasmid for E1A gene (kind gift of Prof. 
David Curiel). 
 pCMV-SPORT6 hGAPDH (5,7kb), human GAPDH cDNA clone 3869809 cloned 
into pCMV-SPORT6 to prepare serial dilutions to generate a standard curve in qPCR 
experiments (Open Biosystems, Lafayette, CO, USA). 
 
2.3.4 Transfection reagents 
Mammalian Transfection Kit   (Agilent Technologies, Santa Clara, CA, USA) 
 
2.3.5 RT-PCR 
FastStart Universal SYBR Green Master Mix (ROX) (Roche, Indianapolis, IN, USA) 
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2.3.6 Loading dyes and DNA Markers 
Blue/Orange 6x Loading Dye  (Promega, Madison, WI, USA)  
1kb DNA Ladder     (Promega, Madison, WI, USA) 
1kb DNA plus Ladder   (Life Technologies, Grand Islands, NY, USA) 
 
2.4 DNA Preparation 
Plasmid Maxi Kit      (Qiagen, Valencia, CA, USA) 
PureLink™ HiPure Plasmid Filter Maxiprep Kit   (Invitrogen, Karlsruhe, Germany) 
QIAmp Blood Tissue Minikit     (Qiagen, Hilden, Germany) 
QIAquick Gel Extraction Kit     (Qiagen, Valencia, CA, USA) 
 
2.5 RNA Preparation and cDNA Synthesis 
RNeasy Mini Kit       (Qiagen, Valencia, CA,USA) 
RNase-free DNAse Set     (Qiagen, Valencia, CA, USA) 
iScript
TM
 cDNA Synthesis Kit    (BioRad, Hercules, CA, USA) 
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2.6 Viruses 
Table 5: Viruses used in this study 
Description Modification Reference 
Ad5 WT No changings Vectorlogics 
Ad5/3 WT Fiber chimera, fiber tail and shaft of serotype 5, 
fiber knob of serotype 3 
Kindly provided by Dr. D.T. 
Curiel, Washington University, St. 
Louis, USA 
Ad5 LacZ LacZ gene instead of E1A gene Clontech 
Ad5/3 luc Fiber knob of Ad3, Luciferase in the E1A gene Kindly provided by Dr. D.T. 
Curiel, Washington University, St. 
Louis, USA 
Ad5 CXCR4 Human CXCR4 promoter upstream of E1A gene (Stoff-Khalili et al., 2008) 
Ad5/3 CXCR4 Human CXCR4 promoter upstream of E1A gene, 
Ad3 fiber knob 
(Stoff-Khalili et al., 2007) 
Ad5/3 CXCR4 UTR Human CXCR4 promoter upstream of E1A gene, 
Ad3 fiber knob, 5’UTR sequence of rat FGF-2 
upstream of E1A gene 
Present study 
Ad5 ∆24 24bp deletion in the E1A gene Kindly provided by Dr. D.T. 
Curiel, Washington University, St. 
Louis, USA 
Ad5 ∆24 RGD 24bp deletion in the E1A gene, RGD motif in the 
H1-loop of the fiber knob 
Kindly provided by Dr. D.T. 
Curiel, Washington University, St. 
Louis, USA 
 
2.7 Proteins 
2.7.1 Enzymes 
Restriction enzymes were purchased from the following companies: New England BioLabs 
(Ipswich, MA, USA) and Fermentas (St. Leon-Rot, Germany). 
T4-DNA Ligase       (NEB, Ipswich, MA, USA) 
Herculase II Fusion Enzyme with dNTPs Combo                (Agilent Technologies, Santa Clara,        
CA, USA) 
Platinum
®
 Taq DNA Polymerase                                          (Invitrogen, Karlsruhe, Germany) 
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2.7.2 Molecular weight markers 
PageRuler
TM
, prestained protein ladder 170-10 kDa (Fermentas, St. Leon-Rot, Germany) 
PageRuler
TM
, unstained protein ladder 200-10k Da (Fermentas, St. Leon-Rot, Germany) 
 
2.7.3 Antibodies 
Table 6: Specific antibodies used in this study 
Antibody Antigen Dilution Reference 
4EBP-1 Synthetic N-terminal peptide human  
4E-BP1 
1:1,000 
5% milkpowder TBS-T  
Epitomics 
eIF4E Full length of human eIF4E 1:1,000 
5% milkpowder TBS-T 
Santa Cruz 
E1A full length Adenovirus 13S E1A fusion 
protein 
1:1,000 
5% milkpowder TBS-T 
Santa Cruz 
β-actin SDS extract from human myocardium 1:2,000 
5% milkpowder PBS-T 
Millipore 
Goat anti-mouse IgG, F(ab’)2 Fragment specific 1:2,500 
5% milkpowder PBS-T 
Dianova 
Goat anti-rabbit IgG, F(ab’)2 Fragment specific 1:10,000 
5% milkpowder TBS-T 
Dianova 
Anti-Hexon Adenovirus hexon protein 1:1,000 
1% BSA PBS 
Clontech 
Laboratories 
 
2.8 Staining reagents 
Crystal Violet (CV)     (Sigma-Aldrich, Steinheim, Germany) 
MTT Cell Growth Kit Assay    (Millipore, Schwalbach, Germany) 
 
 
 
 
  Materials 
 
32 
2.9 Solutions and Buffers 
PBS (Phosphate Buffered Saline)    50x TAE buffer (pH 8,0) 
NaCl    137 mM    Tris-Acetate 2 M 
KCl    2.7 mM    EDTA  50 mM 
Na2HPO4  4.3 mM 
KH2PO4   1.4 mM 
 
TE-buffer (pH 8,0)      Saturated Caesium Chloride 
Tris   10 mM     95-100 g Caesium Chloride 
EDTA  1 mM      100 ml TE-buffer 
 
Adenoviral dialysis buffer     10x Running Buffer (1 L) 
Tris pH 7.4   10 mM   Tris-base  30 g 
NaCl    75 mM   Glycine  144 g 
Sucrose   5%    SDS   10 g 
Polysorbate 80 (Tween 80) 0.020% 
MgCl2    1 mM  
EDTA pH 8.0   100 µM 
EtOH    0.5% 
L-Histidine   10 mM 
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Cell Lysis Buffer I     Cell Lysis Buffer II 
NP-40     0.1%  NP-40            1% 
Tris-HCl pH 8.0   50 mM Tris-HCl pH 8.0          20 mM 
KCl     100 mM NaCl            150 mM 
PMSF     1 mM  EDTA pH 8.0            5 mM 
DTT     1 mM  PMSF             1 mM 
Protease Inhibitor Mix w/o EDTA 1x  Protease Inhibitor Mix w/o EDTA  1x 
 
Stacking-Gel       Separating Gel 
Tris-HCl pH 6.8  0.5 M    Tris-HCl pH 8.8  1.5 M 
SDS    0.4%    SDS    0.4% 
29.2% Acrylamide/0.8% Bis-acrylamide 
TEMED, 10% APS 
 
10x Transfer Buffer (1 L)  1x Transfer buffer (1 L) 
Tris-base   30 g    10x Transfer Buffer   100 ml 
Glycine   144 g    MeOH    20% 
        dH2O   adjust to 1 L 
 
4x LÄMMLI-Buffer      Strip-Buffer for Western Blots 
Tris-HCl pH 6.8  200 mM   β-mercaptoethanol 100 mM 
SDS    8%    SDS   2% 
Bromphenolblue  0.4%    Tris-HCl pH 6.7 62.5 mM 
Glycerol   40% 
β-mercaptoethanol  10% 
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2.10 Chemicals and reagents 
 Acrylamide (Roth, Karlsruhe, Germany) 
 Actinomycin D (Sigma-Aldrich, St. Louis, MO, USA) 
 Agarose (Sigma-Aldrich, Steinheim, Germany) 
 Ampicillin (Sigma-Aldrich, Steinheim, Germany) 
 ß-Mercaptoethanol (AppliChem, Darmstadt, Germany) 
 Bradford Reagent (Bio-Rad Laboratories GmbH, Munich, Germany) 
 Bromophenol blue (Merck KGaA, Darmstadt, Germany) 
 Caesium-Chloride (Sigma-Aldrich, St. Louis, MO, USA) 
 Crystal Violet (Sigma-Aldrich, Steinheim, Germany) 
 Dimethyl Sulfoxide (DMSO) (AppliChem GmbH, Darmstadt, Germany) 
 Di-Sodium hydrogen phosphate (Merck KGaA, Darmstadt, Germany) 
 Ethidiumbromide (Roth, Karlsruhe, Germany) 
 Fetal Bovine Serum (FBS) (Invitrogen, Karlsruhe, Germany) 
 Glycerol (AppliChem GmbH, Darmstadt, Germany) 
 Glycine (Roth, Karlsruhe, Germany) 
 Isoflurane (Halocarbon products corporation, River Edge, NJ, USA) 
 Kanamycin (Gibco, Life Technologies, Grand Island, NY, USA) 
 Potassium dihydrogen phosphate (Merck KGaA, Darmstadt, Germany) 
 Sodium Dodecyl Sulfate Polyacrylamide (SDS) (Roth, Karlsruhe, Germany) 
 Sucrose (Sigma-Aldrich, Steinheim, Germany) 
 TEMED (AppliChem GmbH, Darmstadt, Germany) 
 Tween 20 (Caesar & Loretz GmbH, Hilden, Germany) 
 Tween 80 (Polysorbate 80) (Sigma-Aldrich, Steinheim, Germany) 
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Plastic ware was purchased from the following companies: Eppendorf (Hamburg, Germany), 
Falcon BD (Heidelberg, Germany), Greiner (Solingen, Germany), Sarstedt (Nümbrecht, 
Germany) and TPP (Trasadingen, Switzerland). 
 
2.11 Machines used in this study 
 ABI 7900HT (Applied Biosystems, Carlsbad, CA, USA) 
 iCycler (BioRad, Hercules, CA, USA) 
 LightCycler System (Roche Diagnostics, Mannheim, Germany) 
 Microscope (Diavert, Leica Microsystems, Wetzlar, Germany) 
 Nano-Drop (PEQLAB, Erlangen, Germany) 
 SmartSpec 3000 (BioRad, Hercules, CA, USA) 
 SpectraMax 190 (Molecular Devices, Sunnyvale, CA, USA) 
 Wallac Victor2 1420 Multilabel Counter (Perkin Elmer life Sciences, Rodgau, 
Germany) 
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3. Methods 
3.1 Molecular Biology 
Molecular biology methods were performed according to the established protocols (Sambrook, 
2001)  
 
3.1.1 Generation of the triple-level targeted adenovirus (Ad5/3 CXCR4 
UTR) 
According to recent established dual-level targeted CRAds Ad5/3 CXCR4 and Ad5 CXCR4-
UTR which showed an increase in tumor specific replication (Stoff-Khalili et al., 2008; Stoff-
Khalili et al., 2007), in this study a triple-level targeted CRAd (Ad5/3 CXCR4 UTR) was 
established. The purified Ad5/3 CXCR4 UTR was used to infect breast cancer cells and 
analyzed for oncolytic activity and viral replication. 
 
3.1.1.1 Generation of Ad5/3 CXCR4 UTR plasmid 
To construct a triple level targeted Ad containing a fiber knob chimera (5/3), the human 
CXCR4 promoter and the 5’UTR sequence of rat fibroblast growth factor 2 (FGF-2) upstream 
of the E1A gene, a shuttle vector containing the modified E1A region (pShuttle.CXCR4-UTR-
E1A) and the backbone vector pVK500 vector containing the FB5/3 fiber were recombined.  
The fiber gene of the plasmid pVK500 is composed of the Ad5 serotype tail and shaft sequence 
and the Ad3 serotype knob sequence.  The Ad5/3 CXCR4 UTR plasmid was generated by 
transforming the bacterial strain BJ5183 with both vectors.  Beforehand, the pShuttle.CXCR4-
UTR-E1A was FseI linearized and recombined in BJ5183 with ClaI digested pVK500 FB5/3 
backbone.  After recombination a large scale preparation of the DNA was performed by 
transforming the DNA into XL10 Gold bacteria.  Subsequently, the plasmid was verified by 
sequencing and PCR analyses (3.1.1.2). 
To rescue the CRAd virions of Ad5/3 CXCR4 UTR, the pAd.CXCR4-UTR-E1A.FB5/3 
plasmid was linearized with PacI and transfected into HEK-293 cells using the calcium 
phosphate transfection method (3.2.3).  The vector was successfully rescued on HEK-293 cells 
and expanded by several rounds of propagation on sequentially increasing flask size and 
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numbers.  The virus was purified by double CsCl density gradient centrifugation (3.1.1.4) and 
subsequently dialyzed against Ad dialysis buffer.  Final aliquots of virus were analyzed for 
infectious units (ifu) with the Adeno-X Rapid Titer Kit (Clontech; St-Germain-en-Laye, 
France) (3.2.4.1).  Viruses were finally stored at -80°C. 
 
3.1.1.2 Polymerase Chain Reaction (PCR) and sequencing 
To analyze whether both targeting elements, the human CXCR4 Promoter and the 5’UTR-
sequence of rat FGF-2 were correctly inserted upstream of the E1A gene, a polymerase chain 
reaction (PCR) was performed (Saiki et al., 1988).  Human CXCR4 promoter forward primer 
was designed to align only to the human CXCR4 promoter sequence and 5’UTR sequence 
reverse primer was designed to anneal only to the 5’UTR sequence of rat FGF-2.  Due to the 
design of both primers, only Ads that contain the CXCR4 promoter and the 5’UTR sequence 
would reveal a PCR product.  Furthermore, the presence of the Ad3 fiber knob in the triple 
level targeted adenovirus was confirmed by performing a PCR.  Oligonucleotides are listed in 
(2.3.1; Table 2) and reactions were performed in Thermocyclers (BioRAD). 
Recombinant plasmids and DNA of the triple-level virus after rescue were sequenced 
according to established the methods (Sanger et al., 1977), to confirm the presence and correct 
sequence of all inserts.  
 
3.1.1.3 Isolation of plasmid DNA from bacterial strains 
Plasmid DNA from transformed bacteria strains was isolated with an alkaline lysis method 
(Birnboim, 1983) according to previously described protocols.  
 
3.1.1.4 Cesium chloride extraction of adenovirus 
To isolate viral particles after assembly of virus in cell culture, infected cells were collected 
and pelleted by centrifugation for 10 min at 600 x g.  The cell pellet was then resuspended in   
5 ml of supernatant and three freeze/thawing cycles were performed.  During those cycles the 
cell pellet was thawn in a 37 °C water bath and afterwards, directly frozen again at -80 °C.  
Those freeze/thawing cycles were lysing the cells, so that the Ads within those cells was 
released into the supernatant.  After the third cycle, a 1/10 volume of 5% sodium deoxycholate 
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was added and the suspension was incubated for 30 min on ice to further disrupt the cells 
without destroying the virions.  Then, the cellular DNA was sheared by using a probe-type 
homogenizer.  Afterwards, 1.8 ml of saturated CsCl for each 3.1 ml of virus suspension was 
added.  Viral suspension was distributed into tubes and centrifuged for 16-20 h at 4 °C and 
99,000 x g.  After centrifugation, the virus band was collected in a small volume and dialysed 
against Ad dialysis buffer overnight (ON) at 4 °C.  The next day, dialysed Ad was aliquotted 
and stored at -80 °C. 
 
3.1.2 Quantitative polymerase chain reaction (qPCR) 
DNA levels were quantified by qPCR and cDNA levels after reverse transcription of mRNA 
(qRT-PCR) using the LightCycler System (Roche Diagnostics, Mannheim) and the ABI 
7900HT (Applied Biosystems, Carlsbad, CA, USA).  To determine viral entry and to titer the 
viral stock solutions, the LightCycler System was used with the following reaction mix: 1.25 
units Platinum Taq Polymerase and the associated buffer (Invitrogen, Karlsruhe), 4 mM 
MgCl2, 5% DMSO (Applichem, Darmstadt), 1.6 µl of a 1:1,000 dilution of SybrGreen I 
(Sigma-Aldrich, Steinheim), 500 ng/µl non-acetylated bovine serum albumin (Fermentas, St. 
Leon-Rot), 0.5 µM forward and backward primer each and 0.2 mM deoxynucleotide 
triphosphates each (Fermentas, St. Leon-Rot).  To analyze E1A and pTP mRNA levels and Ad 
replication efficiency the ABI 7900HT system was used.  To perform this qPCR, the FastStart 
Universal SYBR Green Master Mix (ROX) of Roche diagnostics was employed.  Each 
reaction mix contained 10 µl SYBR green mix and 0.5 µM of each primer.  All samples used in 
this study were analyzed in duplicates or triplicates together with a plasmid dilution series of 
plasmids described in (2.3.3).  These dilution series were used to generate standard curves.  
The cycling protocol conditions were as follows: 10 min at 95 °C (ABI 7900HT) or 60 sec at 
95°C (LightCylcer), followed by 40 cycles of 1 sec at 95 °C (20 °C/s), 5 sec at 50 °C (pTP) or 
55 °C (20 °C/s), and 15 sec at 72 °C (20 °C/s).  At the end of each elongation step the 
fluorescence was quantified once per cycle.  Subsequently, a melting curve protocol was 
carried out for 15 sec at 95 °C, followed by 20 sec at 70 °C (20 °C/s) and 1 sec at 95 °C       
(0.2 °C/s).  During the heating process at 95 °C, fluorescence was measured continuously.  At 
the end, samples were cooled down to 40 °C for 10 sec.  All DNA and cDNA levels were 
normalized to HPRT1 or GAPDH except for the E4 copy number results, the half life of E1A 
mRNA and the E1A mRNA levels in the hamster cell lines.  
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3.2 Cell Biology 
3.2.1 Cultivation of Cell lines 
All human breast cancer cell lines, the Syrian hamster breast cancer cell lines and all human 
fibroblasts used in this study, were cultured in Dulbeccos Modified Eagle´s Medium containing 
stable glutamine (DMEM + Glutamax
TM
, 4,500 mg/l glucose, Invitrogen) supplemented with 
10% (v/v) FBS (Invitrogen), 100 U/ml penicillin and 100 µg/ml streptomycin (Invitrogen).  
HMEC cells were cultured in Human Mammary Epithelial Growth Medium (PromoCell) 
supplemented with 0.004 ml/ml Bovine Pituitary Extract, 10 ng/ml Epidermial Growth Factor 
(recombinant human), 5 µg/ml insulin (recombinant human) and 0.5 µg/ml hydrocortisone.  
The HMAM5 cell line was additionally cultured in DMEM containing 4,500 mg/l glucose 
(Invitrogen) supplemented with 100 U/ml penicillin, 100 µg/ml streptomycin and only          
2% (v/v) FBS (Invitrogen).  Hamster fibroblasts were cultured in RPMI (Invitrogen) 
supplemented with 10% (v/v) FBS, 100 U/ml penicillin and 100 µg/ml streptomycin.  All cell 
lines were cultivated in an atmosphere of 5% CO2 and 90% humidity at 37 °C.  FBS containing 
10% DMSO were used to stepwise freeze down the cell lines. 
 
3.2.2 Adenoviral infection of cell lines 
Cell lines were plated one day prior of viral infection.  The next day, cells were infected with 
the indicated viral concentrations.  Viruses were diluted in 2% FBS DMEM and added in the 
specific concentrations on the cell lines, followed by a two hours incubation time at 37 °C in an 
atmosphere with 5% CO2 and 90% humidity.  After the incubation time, the virus containing 
media was removed and fresh 10% FBS DMEM was added.  Cells were then incubated at      
37 °C in an atmosphere containing 5% CO2 and 90% humidity until the collection day. 
 
3.2.3 Transfection of Ad5/3 CXCR4 UTR vector into HEK-293 cells 
For the generation of a functional Ad, the Ad5/3 CXCR4 UTR plasmid was transfected into 
HEK-293 cells using a calcium phosphate transfection kit from Agilent Technologies 
(Mammalian Transfection Kit).  HEK-293 cells are carrying the left arm of the Ad5 genome 
incorporated in their genome.  Therefore, those cells provide the perfect environment for viral 
replication and assembly.  
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Ad5 plasmid DNA was linearized by PacI to reveal the Ad inverted terminal repeats (ITR).  
Then, the linearized DNA was transfected with a calcium phosphate transfection according to 
the manufacturer’s instructions.  Briefly, 0.7 x 106 cells were plated on a T-25 tissue culture 
flask and grown until 50-70% confluency.  15 µg of PacI digested DNA were diluted with 
dH2O until a final concentration of 450 µl.  Then, 50 µl of Solution 1 (CaCl2) were added to 
the DNA sample followed by the addition of 500 µl Solution 2 (BBS), the mixture was gently 
mixed by tapping the side and then incubated for 10-20 min at RT.  Subsequently, cell culture 
medium was aspirated of the T-25 flask, cells were washed twice with PBS and 5 ml of 
DMEM without FBS containing 5% of Solution 3 (MBS) was added.  Afterwards, the DNA 
mixture was added drop wise in a circular manner to the flask and cells were incubated for 
three hours at 37 °C.  After incubation, cell culture medium was removed, cells were washed 
twice with PBS, and fresh medium was added and incubated at 37 °C until 50% of the cells 
were killed by the newly replicated virus.  
 
3.2.4 Titer determination of Adenoviral stocks 
3.2.4.1 Infectious units per ml 
Infectious units per ml were determined using the Ad titer kit of Clontech (St-Germain-en-
Laye, France) according to the manufacturer’s instructions.  Briefly, 1.25 x 105 HEK-293 cells 
were plated per well on a 24-well tissue culture plate one day prior to infection.  Then, serial 
dilutions of viral stock solutions were added to the cells and incubated for two hours at 37 °C. 
After the incubation time, additional 800 µl of 10% FBS DMEM were added and the plate was 
incubated for 48 h at 37 °C in an atmosphere of 5% CO2 and 90% humidity.  At 48 h post 
infection, medium was removed, cells were dried and fixed with 500 µl ice-cold                
100% methanol for 10 min at -20 °C.  Subsequently, methanol was removed, cells were 
washed three times with 1% BSA PBS and then a 1:500 dilution of mouse anti-Hexon antibody 
was added on each well followed by one hour incubation at 37 °C.  After removal of the first 
antibody, cells were again washed three times and a 1:1,000 dilution of rat anti-mouse antibody 
(HRP-conjugate) was added for one hour at 37 °C.  Before adding the DAB working solution 
which stains the positively infected cells, the secondary antibody was aspirated, cells were 
washed and DAB working solution was added for 10 min at RT. Afterwards, positively stained 
cells were counted per field with the microscope and the infectious units were calculated after 
the following formula: 
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3.2.4.2 Copy number per µl 
Copy number of viral stock solutions was verified with qRT-PCR (3.1.2).  DNA was isolated 
form viral stocks by using the QIAamp
®
 DNA Blood Mini Kit from Qiagen (Hilden, 
Germany).  After DNA isolation, the copy number of the viral genome was determined of 1 µl 
of a 1:100 dilution using the qRT-PCR.  A standard curve was generated using the pAdEasy 
vector containing the E4 gene.  E4 copy number/µl of the viral stock solution was calculated 
according to the standard curve.  
 
3.2.5 Defining oncolytic activity 
To determine virus-mediated cytotoxicity two assays were performed the crystal violet (CV) 
(Sigma Aldrich, Munich, Germany) staining and the MTT Cell Growth Kit (Millipore, 
Schwalbach, Germany). 
 
3.2.5.1 Crystal Violet Analysis 
1 x 10
4
 cells were seeded in a 24-well tissue culture plate and infected with the indicated 
adenoviruses at different titers or mock infected on the next day.  Cell killing was visualized by 
staining the cells with 0.1% crystal violet (CV) in 70% ethanol for 20 min.  Residual CV was 
removed by washing the wells with tab water, after drying, images of the plates were taken 
with a Canon EOS D30 digital camera (Canon, Krefeld, Germany). 
 
3.2.5.2 MTT-Assay 
1 x 10
3
 cells were plated on a 96-well tissue culture plate and infected with Ads at different 
titers per cell or mock infected on the next day.  To visualize viral cytotoxicity, the MTT Cell 
Growth Kit of Millipore (Schwalbach, Germany) was used according to the manufacturer’s 
instructions.  Briefly, six days post infection 10 µl MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide) was added to the medium, cells were incubated at 37 °C for  
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150 min, followed by the addition of 100 µl acidic isopropanol and an incubation time of       
20 min shaking on a rotor. The absorbance was measured at 560 nm and 630 nm. The 
absorbance of 630 nm was substracted from the 560 nm absorption. Results were expressed as 
percentage of infected cells relative to uninfected cells, setting mock 100%. 
 
3.2.6 Quantifying viral cell entry, transcription and replication  
Viral uptake was determined by quantifying E4 copy number of total cellular DNA using 
qPCR (3.1.2).  To analyze viral cell entry, 6 x 10
5
 cells were seeded in a 24-well tissue culture 
plates and infected with the indicated viruses at 1, 10 or 100 ifu/cell or mock infected the next 
day.  At 1 h and 3 h after infection, cells were washed with PBS and trypsinized.  
Subsequently, cells were collected by centrifugation and washed twice with PBS prior to DNA 
isolation using the QIAamp
®
 DNA Blood Mini Kit (Qiagen, Hilden, Germany) according to 
the manufacturer’s instructions.  
To analyze E1A mRNA expression levels of total cellular mRNA and DNA E4 copy number in 
the supernatant of infected cells, 1 x 10
5
 cells were plated one day before infection.  The next 
day, cells were infected with the indicated viruses at 10 ifu per cell or mock infected.  E1A 
mRNA expression levels were determined collecting cells 48 h after infection, purifying total 
RNA with the RNeasy Mini kit (Qiagen, Hilden, Germany), reverse transcribed into cDNA 
(iScript
TM
 cDNA Synthesis Kit, BioRad, Hercules, CA) and finally, a qRT-PCR (3.1.2) was 
performed as previously described (Zhu et al., 2004). 
E4 copy numbers in the supernatant were determined by collecting 200 µl supernatant of the 
infected cells daily until 4 days post infection.  Viral DNA was isolated using QIAamp
®
 DNA 
Blood Mini Kit (Qiagen, Hilden, Germany) and viral replication was quantified by qPCR 
(3.1.2).  
To monitor Ad5 E1A and Ad5 pTP expression upon infection, 2 x 10
5
 cells were seeded per 
well of a 6-well tissue culture plate one day before infection.  The next day, cells were infected 
with 10 ifu per cell of the indicated viruses and mRNA was isolated at 6 h, 12 h, 24 h and 48 h 
post infection using RNeasy Mini kit (Qiagen, Hilden, Germany).  Afterwards mRNA was 
reverse transcribed into cDNA (iScript
TM
 cDNA Synthesis Kit, BioRad, Hercules, CA, USA), 
followed by qRT-PCR (3.1.2) to analyze the expression levels. 
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3.2.7 Half-life determination of E1A mRNA 
Half-life of Ad5 E1A mRNA was determined by treating the cells with 10 µg/ml     
actinomycin D.  Initially, 2 x 10
5
 cells were seeded per well of a 6-well tissue culture plate and 
the next day cells were infected with the indicated viruses.  At 12 h post infection 10 µg/ml of 
actinomycin D was added to the medium of the infected cells.  Cells were collected at several 
time points, mRNA was isolated which was then reverse transcribed into cDNA and mRNA 
degradation was determined by using qRT-PCR (3.1.2).  
 
3.2.8 Growth characterizations 
To verify growth of HMAM4 and HMAM5 cells, 15,000 cells per well were plated on a 6-well 
tissue culture plate.  Cells were counted in triplicates daily for 10 to 12 days with a 
hemocytometer.  As a control cell line, the breast cancer cell line MDA-MB-231 was used.  
Furthermore, growth of HMAM5 cells cultured in DMEM containing different concentrations 
of FBS (2%, 5% and 10%) was also determined. 
 
3.2.9 Anchorage independence determination 
To analyze anchorage independent growth, two layers of agar and media were prepared.  A      
1 ml 1.2% agar and 1 ml of preheated 10% FBS DMEM was combined receiving the lower 
layer.  1ml of this solution was then added to each well of a 5 cm tissue culture plate.  After the 
lower layer hardened, the upper layer was prepared.  A 0.6% agar solution was preheated in a 
45 °C water bath.  Afterwards, 1 ml of the 0.6% agar solution was combined with 1 ml of a      
2 x 10
4
 cells/ml single cell suspension.  Subsequently, 0.5 ml of the upper layer was added on 
the top of the lower layer.  In the last step, 1x DMEM solution was added on the top of the 
upper layer and the tissue culture plate was incubated at 37 °C for 15 days. Finally, the 
developed colonies were counted. 
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3.3 Biochemistry 
3.3.1 Preparation of protein extracts 
For preparation of protein extracts, cells were washed twice with PBS, harvested with trypsin 
and centrifuged for 5 min at 600 x g at RT.  Then, cell pellets were resuspended either in cell 
lysis buffer I (0.1% NP-40, 50mM Tris-HCl (pH 8.0), 100mM KCl, 1mM DTT, 1mM PMSF) 
or in cell lysis buffer II (1% NP-40, 20mM Tris-HCl (pH 8.0), 150mM NaCl, 5mM EDTA, 
1mM PMSF and 1x Roche Protease Mix).  Cells resuspended in lysis buffer I were sonicated 
for 5 min using the Biorupter and centrifuged for 10 min at 4 °C and 20,800 x g to remove 
unsolubilized membranes.  Protein extracts were then used for a co-immunoprecipitation 
(3.3.2.3).  Cells resuspended in cell lysis buffer II were incubated for 1.5 h on ice, afterwards 
sonicated for 5 min and finally centrifuged at 1,000 x g and 4 °C for 15 min. The protein 
concentration for protein extracts was determined using Bradford protein assay (Bio-Rad 
Laboratories GmbH, Munich, Germany) and Bovine Serum Albumin (BSA) (Sigma Aldrich, 
Munich, Germany) as a standard.  Protein samples were stored at -80 °C until further use. 
 
3.3.2 SDS-PAGE and Immunoblotting 
Proteins extracted from tissue cultured cells and after co-immunoprecipitation (3.3.2.3) were 
separated according to their size with SDS-PAGE and transferred to Trans-Blot nitrocellulose 
(Bio-Rad Laboratories GmbH, Munich, Germany) or polyvinylidene fluoride (BioTrace 
PVDF) (Pall Corporation, Dreieich, Germany) membranes according to established protocols.  
After transfer of the proteins to the membrane, membrane was blocked for 1 h with 5% (w/v) 
milkpowder in 1x TBS-Tween (TBS-T; 0.1% Tween-20).  Immunostaining was carried out by 
diluting the respective antiserum in blocking solution or in 5% (w/v) milkpowder PBS-Tween 
(PBS-T; 0.1% Tween-20) or in 5% (w/v) BSA (Sigma Aldrich, Munich, Germany) and 
incubating the membranes overnight (ON) at 4 °C.  The next day, membrane was washed twice 
for 10 min and once for 5 min with either TBS-T or PBS-T.  Detection of the primary 
antibodies was determined by incubating with a secondary antibody that contains a horseradish 
peroxidase conjugate and is specific for the immunoglobulin G of the first antibodies species, 
for 1 h at RT.  After repeating the washing steps with TBS-T or PBS-T, BM 
Chemoluminescence Blotting Substrate (POD) reagents (Roche Diagnostics, Mannheim, 
Germany) were added in a mixture of 1:100 on the membrane for 1 min.  Chemoluminescence 
was detected by light sensitive x-ray films (Super RX, Fuji-Film, Duesseldorf, Germany).  The 
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prestained PageRuler, range 170-10 kDa and the PageRuler unstained protein ladder 200-10 
kDa (Fermentas, St. Leon-Rot, Germany) were used as molecular weight standards. 
 
3.3.2.1 Determination of viral protein expression 
To determine the Ad E1A expression level, Western immunoblot analysis was performed. 
Cells were infected with Ad5 Wild type (WT), Ad5/3 luc, Ad5/3 WT, Ad5/3 CXCR4 and 
Ad5/3 CXCR4 UTR at 1 ifu/cell.  Cells were harvested 5 days post infection and lysed in cell 
lysis buffer II (3.3.1).  30 µg of proteins were subjected to a 10% SDS-PAGE and proteins 
were then transferred to nitrocellulose membranes. 
 
3.3.2.2 eIF4E protein expression level 
eIF4E protein levels in Ad5 WT or Ad5/3 WT infected cells were quantified by Western 
immunoblot analysis.  5 x 10
5
 cells were plated 1 day before infection on 10 cm tissue culture 
plate.  The next day, cells were infected with 10 ifu/cell of Ad5 WT or Ad5/3 WT. Cells were 
collected 24 h, 48 h and 72 h post infection.  Protein lysates were prepared using cell lysis 
buffer II (3.3.1) and 30 µg of protein were subjected to a 15% SDS-PAGE.  Next, proteins 
were transferred to a nitrocellulose membrane ON at 30 mA and RT.  
 
3.3.2.3 Co-immunoprecipitation 
To perform a co-immunoprecipitation in which the eIF4E binding partners were precipitated,    
3 x 10
6
 MDA-MB-231 cells and 4 x 10
6
 MCF-7 cells were plated 1 day before infection.  The 
next day, cells were infected with 50 ifu per cell of Ad5 WT, Ad5/3 WT and Ad5/3 CXCR4 
UTR.  All cells were collected at the indicated time points.  Protein lysates were prepared by 
adding the appropriate amount of cell lysis buffer I (3.3.1).  700 µg of protein extract was 
incubated with 5 µl (0.5 µg/ml) agarose beads which are covalently bound to eIF4E antibody 
(Santa Cruz Biotechnologies, Heidelberg, Germany).  Samples were incubated for 1.5 h at 4 °C 
by rotation.  Afterwards, samples were pelleted by centrifugation at 1000 x g for 1 min at 4 °C 
and supernatant was carefully removed.  Then, four washing steps were performed using 1 ml 
of cell lysis buffer I without Roche protease inhibitor mix.  After the final washing step, 
supernatants were discarded and pellets were resuspended in 20 µl 2 x Lämmli-Buffer.  Finally 
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samples were subjected to a 15% SDS-PAGE and proteins were transferred on a PVDF 
membrane ON at 30 mA and RT.  
 
3.4 In vivo experiments 
3.4.1 Establishment of an in vivo syngeneic tumor model 
The protocol number for this experimental setup was P-07-050.  To verify tumor take efficacy 
in syngeneic female Syrian hamsters, cultured HMAM4B and HMAM5 cells were 
subcutaneously injected into each hind flank of the animals.  Animals were shaved at the site of 
injection, anesthesized with isoflurane and then 1 x 10
7
 cells were injected subcutaneously.  
Tumor development and growth was monitored daily using a digital caliper.  Finally, the tumor 
volume was quantified by measuring the smallest (d) and the largest (D) diameter with the 
caliper.  The absolute tumor volume was then determined using the following formula:            
V = D x d
2
 x 0.52 
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4. Results 
4.1 Triple-level targeted oncolytic Adenovirus, combining 
transductional, transcriptional and translational targeting 
To date, virotherapy is a promising tool to treat cancer.  However, optimization of tumor 
specific targeting and replication of virions used as anticancer agents is still needed.  Therefore, 
several targeting strategies have been established in the past years, but unfortunately every 
single targeting strategy exhibits some disadvantages.  The disadvantage of transductional 
targeting is the infection of normal cells expressing the cellular attachment receptor of the 
tropism modified Ad vector on their surface.  Tropism modified vectors do not distinguish 
between cancer and normal cells; they bind to cells expressing their cellular attachment 
receptor.  Once, they entered the cell the vectors start to replicate and induce cytotoxicity 
through cell lysis.  Their replication is not cancer cell restricted.  Tumor specific promoters 
(TSP) are used to restrict Ad replication to cancer cells. Nevertheless, they demonstrate also a 
small background activity in normal cells so that replication in some normal cells is possible.  
Theretofore, combining targeting strategies was a reasonable approach to increase the cancer 
specificity profile in normal cells.  Recently, it was shown by Stoff-Khalili et al. that the 
combination of either transductional and transcriptional targeting or transcriptional and 
translational targeting enhanced the cancer specificity profile and at the same time maintained 
the replication efficiency in cancer cells (Alemany et al., 2000; Stoff-Khalili et al., 2008; Stoff-
Khalili et al., 2007).  Assembling and replication efficiency was not impaired in both virions 
upon inserting two control elements into the viral genome.  These results indicated that the 
combination of several modifications in the Ad genome is feasible without affecting the Ad 
replication.  Based on these findings, the aim of this study was to construct a conditionally 
replicating adenovirus (CRAd) that is combining all three targeting strategies.  The 
combination of transductional, transcriptional and translational targeting was hypothesized to 
further increase specificity of CRAd replication for breast cancer cells.  Construction of a 
CRAd containing three levels of control is a novel approach to gain breast cancer specificity in 
the field of virotherapy.  The systemic administration of triple-level targeted CRAds could be 
enabled because of the reduction of unspecific replication in normal cells.  In this study, a 
triple-level targeted CRAd was constructed carrying the Ad3 fiber knob domain (transductional 
targeting), the human CXCR4 promoter (transcriptional targeting) and the 5’UTR sequence of 
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rat FGF-2 (translational targeting) upstream of the Ad5 E1A gene.  This newly constructed 
CRAd was named Ad5/3 CXCR4 UTR (Figure 5).  
 
 
 
4.1.1 Incorporation of Ad3 fiber knob, human CXCR4 promoter and rat 
5’UTR-sequence of FGF-2 mRNA into Ad5 genome 
The backbone plasmid pVK 500 FB5/3 and the shuttle plasmid pShuttle.CXCR4-UTR-E1A 
were recombined using the E.coli strain BJ5183.  The virus was rescued on HEK-293 cells 
after transfection of the viral plasmid DNA and further propagation was carried out on A549 
cells.  After the successful rescue of the newly constructed triple-level CRAd Ad5/3 CXCR4 
UTR, several PCRs were performed, to analyze whether all control elements were incorporated 
within the genome of Ad5/3 CXCR4 UTR.  PCR primers were designed to specifically align to 
the Ad3 fiber knob region and another set was designed to align upstream in the CXCR4 
promoter region and downstream in the 5’UTR region of the FGF-2. DNA of the viral stock 
solutions was isolated and analyzed via PCR.  PCR products for Ad3 fiber knob were detected 
in samples containing the DNA of Ad5/3 WT, Ad5/3 CXCR4 and Ad5/3 CXCR4 UTR at the 
 
Figure 5: Strategy to develop translational and transcriptional targeting as an addition to transductional 
targeting.  
A) Shuttle plasmid harboring a CXCR4-promoter-controlled E1A gene with the FGF2 5’UTR-sequence, 
pShuttle.CXCR4-UTR-E1A.  B) A backbone vector containing a fiber knob domain of serotype 3 instead of 
serotype 5 whereas the shaft and the tail remain from the serotype 5.  C) Both vectors were used in an E.coli 
recombination system to attain recombinant genomes with the pShuttle.CXCR4-UTR-E1A vector to produce 
the pAd.CXCR4-UTR-E1A.Fb5/3 vector.  
  Results 
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expected size of 350 bp except for Ad5 WT, shown in Figure 6A.  Clearly, this result 
demonstrated that all viruses carrying the Ad5/3 fiber chimera incorporated the Ad3 fiber knob 
in their genome.  Furthermore, a PCR product of the human CXCR4 promoter and the 5’UTR 
sequence of FGF-2 was only observed in the DNA sample of Ad5/3 CXCR4 UTR (Figure 6B), 
indicating that incorporation of the CXCR4 promoter and the 5’UTR sequence upstream of the 
Ad5 E1A region was successful.  Moreover, sequencing analyses of the modified regions in the 
Ad5/3 CXCR4 UTR genome confirmed the incorporation of the control elements and revealed 
that no mutations were present within those regions. 
Taken together, PCR and sequencing results demonstrated that the Ad5 fiber knob was 
successfully exchanged with the Ad3 fiber knob and that the human CXCR4 promoter and the 
5’UTR sequence of FGF-2 were incorporated into the Ad5/3 CXCR4 UTR genome.  
 
 
 
4.1.2 Ad5/3 CXCR4 UTR gains differential oncolytic activity in breast 
cancer cells compared to normal cells in vitro 
The concept of oncolytic virotherapy is based on cancer cell specific infection, replication and 
spread of released progeny virions to neighboring cancer cells.  Modification of Ad vectors is 
an easy approach to target and restrict Ad replication to breast cancer cells.  Thus, after 
modification of Ad vectors, the analysis of the replication efficiency and the oncolytic activity 
on breast cancer cells needs to be evaluated to confirm the hypothesized enhancement of 
specificity.   
 
Figure 6: Incorporation of all three control elements in Ad5/3 CXCR4 UTR after recombination. 
DNA was purified from viral stock solutions of Ad5 WT, Ad5/3 WT, Ad5/3 CXCR4 and Ad5/3 CXCR4 UTR 
and examined for the presence of A) Ad3 fiber knob and B) CXCR4 promoter and 5’ UTR sequence of FGF-2 
in PCR.  The correct band for the PCR product is indicated with an arrow at A) 350 bp and B) 513 bp. 
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To investigate oncolytic activity of Ad vectors cytotoxicity assays were performed: Crystal 
Violet (CV) staining (Figure 7) and the MTT assay (Figure 8).  Therefore, cytolytic activity of 
Ad5/3 WT, Ad5 CXCR4, Ad5/3 CXCR4 and the newly constructed Ad5/3 CXCR4 UTR was 
determined in different breast cancer cell lines (MDA-MB-231, MCF-7 and ZR-75-1) and 
compared to the one observed in normal human cell lines (human fibroblasts and HMEC).  In 
the breast cancer cell lines MCF-7 and ZR-75-1, the observed oncolytic activity of the       
Ad5/3 CXCR4 UTR virus was different compared to that observed in breast cancer cell line       
MDA-MB-231 (Figure 7C).  For oncolytic potency, Ad5/3 CXCR4 UTR displayed a lesser 
cytotoxic activity compared to Ad5/3 CXCR4 and Ad5/3 WT in MCF-7 and ZR-75-1 breast 
cancer cells; whereas in MDA-231-MB cells Ad5/3 CXCR4 UTR showed an oncolytic activity 
that was nearly comparable to Ad5/3 CXCR4 (Figure 7C).  In MCF-7 cells, cell killing by 
Ad5/3 CXCR4 UTR was detectable at a 0.1 MOI whereas in ZR-75-1 cells, cytotoxicity was 
only detectable at 10 MOI.  Furthermore, cell killing by Ad5/3 CXCR4 UTR was only one 
order of magnitude potency less effective in MCF-7 cells compared to Ad5/3 CXCR4 and 
Ad5/3 WT.  In ZR-75-1 cells on the other hand, the oncolytic activity of Ad5/3 CXCR4 UTR 
was decreased at around three potencies compared to the one of Ad5/3 CXCR4 and Ad5/3 WT 
(Figure 7C).  Moreover, in MDA-MB-231 a nearly comparable oncolytic activity of         
Ad5/3 CXCR4 UTR and Ad5/3 CXCR4 was observed at 1 MOI as seen in Figure 7C.  
However, the oncolytic activity of Ad5/3 CXCR4 UTR was enhanced in MCF-7 compared to 
Ad5 WT, but was reduced in MDA-MB-231 and ZR-75-1 cells. 
In contrast to this result, in human fibroblasts (NHDF), the cytotoxicity of Ad5/3 CXCR4 UTR 
was attenuated compared to the cytotoxicity of Ad5/3 CXCR4 and Ad5/3 WT, about two to 
three potencies (Figure 7B).  In addition, Ad5/3 CXCR4 UTR displayed a lower oncolytic 
activity compared to Ad5 WT in NHDF infected cells. In HMEC infected cells then cell killing 
by Ad5/3 CXCR4 UTR was detected at a concentration of 10 MOI.  The cytolytic activity of 
Ad5/3 CXCR4 UTR was decreased about one order of magnitude potency compared to Ad5/3 
CXCR4 and at around two potencies compared to Ad5 WT and Ad5/3 WT in HMECs.        
Ad5 WT and Ad5/3 WT displayed cytotoxicity even at the lowest concentration of 0.01 MOI 
in HMEC cells and 0.01 MOI for Ad5/3 WT and 0.1 MOI for Ad5 WT in NHDF cells    
(Figure 7B).  In this regard, Ad5/3 CXCR4 UTR showed a reduced cytotoxic potential 
compared to Ad5 WT, Ad5/3 WT and Ad5/3 CXCR4 in human fibroblasts and HMEC cells.  
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To confirm the results of the CV staining, a different technique was employed to determine 
cytotoxicity, the Millipore MTT assay.  In this assay, MTT is added to the culture medium.  
Viable cells metabolize MTT in their mitochondria to formazan visible as violet crystals.  The 
crystals are then dissolved in acidic isopropanol and the absorbance of the formazan is 
measured.  Therefore, the lack of color is an indicator for cell cytotoxicity.   
At the highest concentration of 100 MOI infection with Ad5/3 CXCR4 UTR displayed an 
oncolytic activity in MDA-MB-231, MCF-7 and ZR-75-1 cells, which was the same to the one 
 
Figure 7: Reduced oncolytic activity of Ad5/3 CXCR4 UTR in breast cancer and normal cells. 
A) Scheme of CV-plate. B) Normal human cell lines human fibroblasts (NHDF) and HMEC and C) Human breast 
cancer cell lines MDA-231-MB, MCF-7 and ZR-751 were infected with Ad5/3 luc (non-replicating control),       
Ad5 WT, Ad5/3 WT, Ad5/3 CXCR4 and Ad5/3 CXCR4 UTR at indicated virus concentrations. Oncolytic activity 
was monitored by staining viable cells with 0.1% CV. Representative data of three independent CV stainings. 
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seen for Ad5/3 WT and Ad5/3 CXCR4 (Figure 8A).  However, at a concentration of 10 MOI 
of Ad5/3 CXCR4 UTR cell killing was only about 20 to 35% in the breast cancer cell lines 
whereas Ad5/3 WT and Ad5/3 CXCR4 displayed around 80% cell killing (Figure 8A).  Also, 
more than 50% of cell killing was obtained using Ad5/3 WT at a concentration of 1 MOI in 
MCF-7 and ZR-75-1 cells.  Cell killing by Ad5/3 CXCR4 UTR mimicked the one of Ad5 WT 
in all three breast cancer cell lines and demonstrated an even stronger oncolytic activity at the 
highest concentration of 100 MOI (Figure 8A).  In addition, in MCF-7 and ZR-75-1 cells the 
difference in cytotoxicity between Ad5/3 WT and Ad5/3 CXCR4 was greater than compared to 
the one seen in MDA-MB-231 cells.  
In human fibroblasts NHDF the cytolytic activity did not reflect the one detected with the CV 
staining.  The highest cytotoxicity was measured in Ad5/3 CXCR4 UTR infected NHDFs at 
100 MOI as seen in Figure 8B.  Ad5 WT and Ad5/3 WT showed only 20% cell killing at     
100 MOI and Ad5/3 CXCR4 did not demonstrate any cytolytic activity.  In the lower 
concentrations of all viruses cytotoxicity was not detectable in NHDFs whereas in the CV 
staining the oncolytic activity was clearly present upon infection with these viruses         
(Figure 7B).  Therefore, the results of the MTT-Assay and the CV staining were contradictory 
for NHDFs.  As a result, another human fibroblast cell line, PHF Pa2, was included.  In human 
fibroblast PHF Pa2 and HMEC on the other hand, infection with Ad5/3 CXCR4 UTR showed 
a gain of security compared to Ad5 WT, Ad5/3 WT and Ad5/3 CXCR4 (Figure 8B).  Ad5/3 
CXCR4 UTR demonstrated only 30% cell killing at a concentration of 1 MOI in HMECs 
whereas the cell killing by Ad5 WT and Ad5/3 CXCR4 was about 60% and the one for Ad5/3 
WT was even around 90%.  In PHF Pa2 cells, cytolytic activity of Ad5/3 CXCR4 UTR was 
only 20% at the highest concentrations of 10 and 100 MOI (Figure 8B).  In contrast, Ad5 WT, 
Ad5/3 WT and Ad5/3 CXCR4 displayed 80% cell killing at 100 MOI and 60% cell killing at 
10 MOI.   
Taken together, Ad5/3 CXCR4 UTR demonstrated the same oncolytic activity in breast cancer 
cells at 100 MOI as the other Ad vectors whereas the results for the lower concentrations were 
different in the MTT assay compared to the CV staining.  This result could be explained by the 
different incubation times of the assays.  In addition, oncolytic activity of Ad5/3 CXCR4 UTR 
was greater than Ad5 WT in MDA-MB-231 cells and the same in MCF-7 and ZR-75-1 cells.  
It was shown that Ad5/3 CXCR4 UTR gained cancer specificity and at the same time lost 
oncolytic potency for breast cancer cells.   
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Figure 8: Comparable oncolytic potency of Ad5/3 CXCR4 UTR to Ad5 WT in breast cancer cells. 
A) Breast cancer cell lines, MDA-MB-231, MCF-7, ZR-75-1 and B) Normal cell lines, human mammary epithelial 
cells (HMEC) and human fibroblasts (NHDF and PHF Pa2) were infected with Ad5/3 luc (non replicating control), 
Ad5 WT, Ad5/3 WT, Ad5/3 CXCR4 and Ad5/3 CXCR4 UTR at the indicated virus concentrations.  Cell survival 
was determined by using MTT.  Percentage of survived cells was calculated setting non-infected cells (mock) as 
100%.  Average ± standard deviation of three independent MTT-assays is displayed.  Experiments were performed 
in quadruplicates. 
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4.1.3 E1A protein expression is reduced in Ad5/3 CXCR4 UTR infected 
cells 
To determine how the integration of the 5’UTR sequence into the Ad5 genome altered the Ad5 
E1A protein expression, E1A protein concentrations were analyzed in infected MDA-MB-231 
cells by immunoblot analyses.  Cells were infected with 1 MOI of the indicated viruses, 
harvested 5 days post infection and E1A protein was detected using a specific anti-Ad5 E1A 
antibody.  It was expected that the gain of security would result from reduced E1A translation 
due to the insertion of the 5’UTR sequence in normal cells and would be less in breast cancer 
cell lines.  Indeed, in normal cell lines, human fibroblasts (NHDF) and HMECs, the E1A 
protein expression of Ad5/3 CXCR4 UTR was nearly absent compared to Ad5 WT, Ad5/3 WT 
and Ad5/3 CXCR4, as seen in Figure 9B.  In contrast, Ad5 WT, Ad5/3 WT and Ad5/3 CXCR4 
displayed nearly the same high expression of E1A protein in NHDFs and in HMECs.  In breast 
cancer cell lines the Ad5 E1A protein of Ad5/3 CXCR4 UTR was detectable after infection 
(Figure 9 A).  However, compared to the very high E1A expression in Ad5/3 WT and Ad5/3 
CXCR4 infected breast cancer cells, the E1A protein concentration of Ad5/3 CXCR4 UTR was 
significantly reduced.  Ad5 WT expression of E1A protein was only slightly reduced compared 
to Ad5/3 WT and Ad5/3 CXCR4 infected breast cancer cells, but significantly increased 
compared to Ad5/3 CXCR4 UTR (Figure 9A).  The highest expression of Ad5/3 CXCR4 UTR 
E1A was detectable in infected MDA-MB-231 cells.  These results reflected the CV staining 
and MTT-Assays in which the oncolytic activity of Ad5/3 CXCR4 UTR was higher in MDA-
MB-231 cells at 1 MOI compared to HMEC and NHDF, in which the oncolytic activity was 
only detectable at 10 MOI.  
To summarize, Ad5 E1A protein expression was reduced in Ad5/3 CXCR4 UTR infected 
breast cancer cells more than expected.  
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4.1.4 Replication efficiency is decreased in Ad5/3 CXCR4 UTR infected 
MDA-MB-231 cells 
Protein expression of E1A was relatively low in Ad5/3 CXCR4 UTR infected breast cancer 
cells. To confirm impairment in Ad replication, the replication efficiency of                      
Ad5/3 CXCR4 UTR infected cells was examined.  Replication efficiency of Ads can be 
detected by analyzing viral genome copies in the supernatant of infected cells in a time course.  
Based on the number of viral DNA copies detected in the supernatant, it is possible to 
determine how efficiently progeny virions are released from the infected cells.  This method is 
usually used to analyze if modifications within the viral genome are interfering with the 
assembly and release of progeny virions.   
 
Figure 9: Decreased Ad5 E1A protein levels in Ad5/3 CXCR4 UTR infected cells. 
A) Breast cancer cell lines MDA-MB-231, MCF-7 and ZR-75-1 and B) Normal cell lines human fibroblasts and 
HMEC.  Cells were infected with Ad5/3 luc (non-replicating Ad), Ad5 WT, Ad5/3 WT, Ad5/3 CXCR4 and Ad5/3 
CXCR4 UTR at a concentration of 1 ifu per cell.  Protein samples were prepared after 5 days of infection, proteins 
were then separated on a 10% SDS-PAGE and protein levels of Ad5 E1A were finally determined performing 
immunoblot analyses with a specific anti Ad5 E1A antibody.  Detection of β-actin served as loading control.  These 
results are representative data of three independent immunoblot experiments. 
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In the following experiment, the human breast cancer cell line MDA-MB-231 was infected 
with 10 MOI of the indicated viruses and supernatant was collected daily for 4 days after 
infection.  Viral DNA copy numbers in the supernatant were determined using qRT-PCR. As 
shown in Figure 10, replication efficiency of Ad5/3 CXCR4 UTR was significantly reduced 
compared to the one of Ad5 WT, Ad5/3 WT and Ad5/3 CXCR4.  At day 2 the copy numbers 
started to increase for Ad5 WT, Ad5/3 WT and Ad5/3 CXCR4 (Figure 10).  The release of 
progeny virions in Ad5/3 CXCR4 UTR infected MDA-MB-231 cells started to increase at   
day 3.  At 4 days after the infection, the concentration of virions present in the supernatant of 
Ad5/3 CXCR4 UTR infected MDA-MB-231 cells was drastically increased in the supernatant 
compared to day three.  
In summary, the release of progeny virions demonstrated a lag-phase in Ad5/3 CXCR4 UTR 
infected MDA-MB-231 cells indicating that the replication cycle of Ad5/3 CXCR4 UTR was 
inhibited during early infection. This experiment confirmed the previous results of reduced 
E1A gene transcription and decreased oncolytic activity of Ad5/3 CXCR4 UTR in breast 
cancer cell lines.  
 
 
 
 
 
Figure 10: Ad5/3 CXCR4 UTR showed a lag phase in replication efficacy. 
MDA-231-MB cells were infected with Ad5 WT, Ad5/3 WT, Ad5/3 CXCR4, Ad5/3 CXCR4 UTR and a non-
replicating virus (Ad5 LacZ) at a viral concentration of 10 MOI.  Growth medium was collected at days 0, 1, 2, 
3 and 4 post infection.  DNA was isolated and E4 copy number was quantified by qRT-PCR.  Experiment was 
repeated twice and triplicates were measured with the qRT-PCR of each sample.  Average values ± standard 
deviation is displayed in the figure. 
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4.1.5 Different titration method does not reveal inaccurate relative Ad 
titers  
Determining Ad titers of the viral stock solutions is an important step in the field of 
virotherapy.  Titrating of Ad stocks can be performed using different techniques divided into 
two categories: quantification of either infectious or physical particle titer.  One of the widely 
used methods is the determination of infectious units using the embryonic kidney cell line     
HEK-293.  However, titration for infectious units of Ad using HEK-293 cells produces a 
disadvantage for Ad vectors that are modified in the fiber knob region.  This is because binding 
of fiber-modified Ads to a different cellular receptor that have a lower expression on HEK-293 
cells compared to CAR could result in an inaccurate ifu concentration of the assayed Ad 
vector.  The HEK-293 cells were initially immortalized by transfecting these cells with the Ad5 
genome.  The left arm of the Ad5 genome was incorporated into the chromosome 19 of    
HEK-293 cells during this process; therefore this cell line provides several Ad proteins in 
trans.  The expression of these proteins can lead to a second disadvantage to determine the real 
infectious unit of a modified oncolytic Ad vector.  A different technique to titer a viral stock 
solution is to analyze the viral DNA copy/particle number by performing qPCR (Heim et al., 
2003).  Determining Ad titers using qPCR has several advantages: it is a reproducible and 
sensitive method, and it is cell line and receptor independent.  However, a major disadvantage 
of this method is that it does not distinguish between vectors with incomplete Ad assembly and 
non-encapsidated DNA.  Therefore, the results of the qPCR may not present an infectious titer.  
To examine whether titration for infectious units using HEK-293 cells resulted in an inaccurate 
titer of Ad5/3 CXCR4 UTR, viral copy number of viral stocks was determined using          
qRT-PCR.  Viral DNA was isolated from viral stocks and then viral E4 gene copy number was 
determined by performing qPCR.  After quantification of viral copy number, MDA-MB-231 
cells were infected with the indicated MOIs of a non-replicating Ad5 (Ad5 LacZ), with 
replicating Ads (Ad5 WT, Ad5/3 WT, Ad5/3 CXCR4 and Ad5/3 CXCR4 UTR), or were mock 
infected.  In this analysis, CV staining was performed to monitor oncolytic activity.  The cells 
were infected with a higher viral copy number per cell than infectious units because 
quantification of DNA copy numbers also included the non-encapsidated DNA and partially 
replicated DNA.  Therefore, MDA-MB-231 cells were infected with higher MOIs to reach the 
same result as observed when ifu titers were used to infect the cells.  
As presented in Figure 11, Ad5/3 CXCR4 UTR exhibited a diminished oncolytic activity in 
MDA-MB-231 cells compared to Ad5/3 WT and Ad5/3 CXCR4 infecting the cells with viral 
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copy number whereas on the other hand it showed the same oncolytic activity as Ad5 WT.  
Both Ad5 WT and Ad5/3 CXCR4 UTR demonstrated cytotoxicity above 20 MOI.  On the 
other hand, infection of MDA-MB-231 cells with viral copy numbers of Ad5/3 WT and   
Ad5/3 CXCR4 displayed an equal oncolytic activity for both viruses at 0.2 MOI (Figure 11). 
Taken together, the two different titration methods resulted in a similar oncolytic activity of 
Ad5/3 CXCR4 UTR in the breast cancer cell line MDA-MB-231.  These results indicated that 
titration for infectious units did not result in an inaccurate relative titer of the viral stocks. 
 
 
 
4.1.6 Viral cell entry of Ad5/3 CXCR4 UTR is comparable to the one of 
Ad5/3 WT and Ad5/3 CXCR4 
Titration of viral stock solutions with a different method could not reveal the reason for the 
reduced replication efficiency and E1A protein expression in Ad5/3 CXCR4 UTR infected 
breast cancer cells.  To exclude that an impaired viral cell entry caused the delayed viral 
replication and E1A protein expression, viral cell entry of Ad5/3 CXCR4 UTR was 
investigated. Consequently, MDA-MB-231 breast cancer cells were infected with the indicated 
viral concentrations of Ad5 WT, Ad5/3 WT, Ad5/3 CXCR4 and Ad5/3 CXCR4 UTR or mock 
infected. At 1 h and 3 h after addition of the viruses, cells were collected and DNA was 
isolated.  E4 copy number was then determined in 100 ng of total cellular DNA using qPCR.  
 
Figure 11: Reduced oncolytic activity of Ad5/3 CXCR4 UTR in MDA-MB-231 upon viral copy number 
titer infection. 
MDA-MB-231 cells were infected with Ad5 LacZ (non-replicating Ad), Ad5 WT, Ad5/3 WT, Ad5/3 CXCR4 
and Ad5/3 CXCR4 UTR at the indicated titers of viral copy number per cell.  Oncolytic activity was monitored 
2 weeks after infection, staining viable cells with 0.1% CV.  Shown is a representative result of three 
independent experiments. 
  Results 
 
59 
As shown in Figure 12, viral cell entry efficiency of Ad5/3 WT, Ad5/3 CXCR4 and          
Ad5/3 CXCR4 UTR was comparable after 1 h and 3 h of viral addition for all viral 
concentrations.  In addition, the concentration of E4 copy number in total cellular DNA was 
increased 3 h after viral addition compared to the concentrations seen after 1 h (Figure 12A and 
B).  The lowest viral entry was detectable in the lowest viral concentration and increased with 
increasing viral concentration.  Viral cell entry of Ad5 WT on the other hand, was reduced 
compared to the other three viruses as displayed in Figure 12A and B.  Ad5 WT demonstrated 
nearly the same level of viral cell entry efficiency at a concentration of 10 ifu per cell which 
was seen for the other viruses at a concentration of 1 ifu per cell.  In addition, viral cell entry at 
100 ifu per cell of Ad5 WT was comparable to the one seen at 10 ifu per cell for Ad5/3 WT, 
Ad5/3 CXCR4 and Ad5/3 CXCR4 UTR (Figure 12A and B).  This result was expected due to 
the lower expression of CAR on the surface of MDA-MB-231 cells compared to the high 
expression of the Ad3 fiber knob receptor.   
Taken together, viral cell entry of Ad5/3 CXCR4 UTR was not altered compared with      
Ad5/3 WT and Ad5/3 CXCR4 in MDA-MB-231 breast cancer cells and could be excluded as 
potential explanation for delayed Ad5/3 CXCR4 UTR replication.   
 
  
 
Figure 12: No impairment of Ad5/3 CXCR4 UTR cell entry in MDA-MB-231 cells. 
Shown are: Ad5 E4 copy numbers of total cellular DNA after A) 1 h and B) 3 h of viral addition to            
MDA-MB-231 breast cancer cells.  MDA-MB-231 cells were infected with 1 ifu, 10 ifu or 100 ifu per cell of 
Ad5 WT, Ad5/3 WT, Ad5/3 CXR4 and Ad5/3 CXCR4 UTR and incubated with virus for 1 or 3 h.  Cells were 
harvested and total DNA was isolated.  Ad5 E4 copy number was subsequently determined in 100 ng of total 
cellular DNA employing qPCR.  qPCR samples were measured in duplicates and average values ± standard 
deviation of three independent experiments are displayed.   
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4.1.7 eIF4E protein expression is not dysregulated by Ad3 fiber knob 
binding 
The constructed Ad5/3 CXCR4 UTR revealed a reduced expression of Ad5 E1A gene, as well 
as replication efficiency and oncolytic activity compared to the dual-level targeted oncolytic 
Ads (Ad5/3 CXCR4 and Ad5 CXCR4 UTR).  Nonetheless, the Ad5/3 CXCR4 UTR 
demonstrated cancer specificity by maintaining breast cancer oncolytic activity over normal 
cells.  The only difference between the triple-level targeted Ad5/3 CXCR4 UTR and the dual-
level targeted oncolytic Ads is the addition of the Ad 3 fiber knob to Ad 5 CXCR4 UTR and 
addition of the 5’UTR sequence to Ad5/3 CXCR4.  Therefore, it was hypothesized that the 
binding of Ad3 fiber knob to its cellular attachment receptor could activate an intracellular 
signaling cascade.  This cascade could dysregulate eIF4E protein expression, leading to a 
reduced translation efficiency of E1A in Ad5/3 CXCR4 UTR infected cells.  Overexpression of 
eIF4E in infected cells is essential for efficient translation an E1A mRNA that has incorporated 
a complex GC rich 5’UTR sequence.  Inhibition or repression of eIF4E expression upon Ad3 
fiber knob binding could explain the reduced replication efficiency and expression of E1A as 
seen in Ad5/3 CXCR4 UTR infected breast cancer cells compared to Ad5/3 CXCR4 infected 
breast cancer cells.  Thus, to investigate the underlying mechanism of the reduced translation 
of Ad5/3 CXCR4 UTR E1A, the eIF4E protein level was analyzed in Ad5 WT and Ad5/3 WT 
infected breast cancer cells.  MDA-MB-231 and MCF-7 cells were infected with 10 ifu of the 
viruses per cell and cell lysates were collected daily up to 72 h after infection.  Immunoblot 
analyses were performed to detect the eIF4E protein expression.  As shown in Figure 13, the 
eIF4E protein expression was not affected upon the binding of Ad3 fiber knob to its cellular 
attachment receptor in both breast cancer cell lines. Infection of Ad5 WT or Ad5/3 WT did not 
alter the eIF4E protein expression at 24 h, 48 h or 72 h after infection. Furthermore, eIF4E 
protein concentrations were comparable in Ad5 WT infected MDA-MB-231 (Figure 13A) and 
MCF-7 (Figure 13B) cells compared to Ad5/3 WT infected cells.   
Hence, binding of Ad3 fiber knob to breast cancer cells did not induce a signaling cascade that 
in return interfered with the eIF4E protein expression.  This result led to the suggestion that the 
free concentration of eIF4E might be deregulated due to an impaired phosphorylation of       
4E-BP. 
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4.1.8 Phosphorylation of 4E-BP1 is delayed in Ad5/3 CXCR4 UTR infected 
breast cancer cells 
The phosphoprotein eIF4E is present at a limiting quantity within a normal cell and crucial for 
translation initiation (Duncan et al., 1987).  Usually eIF4E activity is regulated by the 4E-BP 
by binding eIF4E and therefore inactivating it (Fadden et al., 1997; Pause et al., 1994).  
Phosphorylation of 4E-BP on several sites is diminishing the interaction with eIF4E leading to 
the release of eIF4E and resulting in enhanced translation initiation (Fadden et al., 1997; Pause 
et al., 1994).  Upon release from 4E-BP, eIF4G can bind to eIF4E and form eIF4F essential for 
translation initiation. The ras-ERK and PI3 kinase/Akt pathway are both involved in the 
phosphorylation of 4E-BP at multiple sites (Gingras et al., 2001).  It was shown in the past, that 
upon Ad5 infection phosphorylation of 4E-BP1 and 4E-BP2 was increased resulting in the 
liberation of eIF4E and formation of the translation initiation complex (Gingras and 
Sonenberg, 1997).  Furthermore, the authors could display that phosphorylation of 4E-BP was 
impaired upon deletion or mutation of the Ad5 E1A gene suggesting a role of Ad5 E1A in the 
4E-BP phosphorylation upon Ad5 infection (Gingras and Sonenberg, 1997).  In addition, it was 
published that Ad5 binding and infection activates the PI3K pathway and therefore, inducing 
phosphorylation of 4E-BP (Li et al., 1998).   
Based on those publications it was hypothesized that binding of Ad3 fiber knob to its cellular 
attachment receptor is interfering with the phosphorylation of the 4E-BP and therefore 
reducing the translation of E1A in Ad5/3 CXCR4 UTR infected cells.  A reduced concentration 
 
Figure 13: No influence on the eIF4E protein expression upon Ad5 WT or Ad5/3 WT infection in breast 
cancer cells. 
Immunoblot analyses of A) MDA-MB-231 and B) MCF-7 cells infected with 10 ifu per cell of Ad5 WT or 
Ad5/3 WT are displayed.  Cells were collected at the indicated time points after infection, protein lysates were 
prepared and 30 µg of protein was subjected to a 10% SDS-PAGE.  eIF4E protein expression was monitored 
using a specific eIF4E antibody.  Β-actin served as a loading control.  Shown is a representative data of three 
independent experiments. 
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of free eIF4E could diminish the translation of the Ad5/3 CXCR4 UTR E1A gene containing 
the long GC-rich UTR-sequence of rat FGF-2.  Immunoblot analyses detecting eIF4E protein 
expression after infection revealed that binding of Ad3 fiber knob did not influence the eIF4E 
protein expression. Thus, it was speculated that if Ad3 fiber knob binding would inhibit 
phosphorylation of 4E-BP, the concentration of free eIF4E would be reduced and in return the 
E1A gene expression of Ad5/3 CXCR UTR.  
Consequently, the phosphorylation level of 4E-BP1 was analyzed in Ad5 WT, Ad5/3 WT and 
Ad5/3 CXCR4 UTR infected MCF-7 and MDA-MB-231 breast cancer cells.  Cells were 
infected with 50 ifu per cell and harvested at the indicated time points post infection.  
Subsequently, a co-immunoprecipitation for eIF4E was performed to determine the level of 
unphosphorylated 4E-BP still bound to eIF4E.  The different phosphorylation forms of 4E-BP1 
can be displayed by using a specific anti 4E-BP antibody.  Hyperphosphorylated forms (γ and 
δ) demonstrate a slow mobility on SDS-PAGEs compared to the unphosphorylated (α) and 
hypophosphorylated (β) forms (Beretta et al., 1996; Fadden et al., 1997; Gingras et al., 1996; 
Pause et al., 1994).   
As shown in Figure 14A, only two bands of 4E-BP1 were detected, indicating that the co-
immunoprecipitation worked and that only unphosphorylated 4E-BP forms were precipitated 
together with the eIF4E.  Unphosphorylated 4E-BP1 concentration started to decrease after 6 h 
of Ad5 WT addition to MDA-MB-231 cells.  In contrast to this result, infection with        
Ad5/3 WT induced phosphorylation of 4E-BP1 already at 3 h after viral addition.  
Unphosphorylated 4E-BP1 was nearly absent after 24 h of Ad5/3 WT addition on            
MDA-MB-231 cells.  Infection of MDA-MB-231 cells with Ad5/3 CXCR4 UTR displayed the 
same time dependent phosphorylation as Ad5/3 WT but demonstrating a lag phase of 3 h.  At 
24 h after addition of virions, unphosphorylated 4E-BP1 was still detectable in                  
Ad5/3 CXCR4 UTR infected cells whereas it was completely absent in Ad5/3 WT infected 
cells (Figure 14A).  In MCF-7 cells on the other hand, infection with Ad5 WT did not 
demonstrate a phosphorylation of 4E-BP due to the detection of the same concentration 24 h 
after viral addition compared to the one seen at time point zero (Figure 14B).  However, 
infection with Ad5/3 WT and Ad5/3 CXCR4 UTR showed a decline in the unphosphorylated 
forms of 4E-BP1 after 6 h of viral addition (Figure 14B).   
To summarize, phosphorylation of 4E-BP1 upon infection with Ad5/3 CXCR4 UTR was 
delayed compared to infection with Ad5/3 WT but displayed an improved phosphorylation of 
4E-BP compared to Ad5 WT infected breast cancer cells.  Therefore, delayed phosphorylation 
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of 4E-BP1 in Ad5/3 CXCR4 UTR could be explained by the suggestion that Ad5 E1A is 
involved in the initiation of 4E-BP phosphorylation upon Ad infection (Gingras and 
Sonenberg, 1997).   
 
 
 
4.1.9 Delayed expression of E1A and pTP of Ad5/3 CXCR4 UTR in   
MDA-MB-231 cells 
The eIF4E protein expression and phosphorylation of 4E-BP were not altered upon the Ad3 
fiber knob binding as hypothesized and therefore not likely responsible for the decreased E1A 
expression.  Detection of a reduced E1A protein concentration and delayed release of progeny 
virions of Ad5/3 CXCR4 UTR in breast cancer cell lines indicated an impaired E1A gene 
transcription.  To determine whether E1A gene transcription was decreased, E1A mRNA 
expression levels were quantified by qRT-PCR in infected MDA-MB-231 cells.  Cells were 
infected with 10 MOI of the indicated viruses and harvested 48 h post infection.  Subsequently, 
RNA was isolated and concentration of E1A mRNA was determined by performing qRT-PCR.  
As seen in Figure 15, the E1A mRNA expression of Ad5/3 CXCR4 UTR was significantly 
 
Figure 14: 4E-BP phosphorylation was time dependent in Ad5/3 CXCR4 UTR infected breast cancer 
cells. 
A) MDA-MB-231 and B) MCF-7 cells were infected with 50 ifu per cell of Ad5 WT, Ad5/3 WT and         
Ad5/3 CXCR4 UTR.  Cells were collected at indicated time points after the addition of Ads on the breast cancer 
cell lines.  Protein lysates were prepared and 800 µg of protein was used to perform a co-immunoprecipitation 
against eIF4E.  Samples were then subjected to a 15% SDS-PAGE and immunoblot analyses were performed to 
detect non-phosphorylated 4E-BP1 with a specific antibody against 4E-BP1.  eIF4E served as a loading control.  
Each figure represents a representative of two individual performed experiments. 
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decreased in MDA-MB-231 cells compared to Ad5 WT, Ad5/3 WT and Ad5/3 CXCR4.  
Ad5/3 WT and Ad5/3 CXCR4 displayed a higher E1A gene transcription than Ad5 WT, 
indicating a higher transcription efficiency of Ad5/3 WT and Ad5/3 CXCR4.  However, E1A 
gene transcription of Ad5/3 CXCR4 UTR was increased compared to the non-replicating    
Ad5 LacZ.  This result showed that Ad5 E1A transcription is reduced compared to Ad5 WT, 
Ad5/3 WT and Ad5/3 CXCR4, but still present within the breast cancer cell.   
 
 
 
To further investigate the decreased transcription of E1A gene, the Ad5 E1A and pTP mRNA 
levels were investigated at different time points after infection.  A time course could reveal 
whether Ad5 E1A gene expression is present at the beginning of Ad5/3 CXCR4 UTR and is 
then inhibited during the process of Ad replication or if Ad5 E1A gene expression is inhibited 
right from the beginning.  Ad5 E1A is the earliest gene that is expressed during Ad5 infection 
cycle.  Ad5 E1A protein is necessary to induce transcription of the early genes that are located 
downstream of the E1A gene (Berk et al., 1979) and essential to stimulate the cell gene 
expression and proliferation as modulator.  Thus, with an impaired or reduced Ad5 E1A 
transcription, the whole Ad5 replication pathway is also affected.  The transcription of the Ad5 
E2 gene is also initiated by Ad5 E1A.  Ad5 E2 transcription is necessary to start Ad DNA 
 
Figure 15: Significant reduction of Ad5/3 CXCR4 UTR E1A mRNA levels in MDA-MB-231 cells. 
MDA-MB-231 breast cancer cells were infected with Ad5 WT, Ad5/3 WT, Ad5/3 CXCR4, Ad5/3 CXCR4 
UTR and non-replicating Ad5 LacZ at a virus concentration of 10 ifu per cell.  Cells were collected 48 h post 
infection, RNA was isolated and reverse transcribed into cDNA.  E1A levels were then analyzed via qRT-PCR. 
The experiment was repeated twice and triplicates of cDNA samples were evaluated by qRT-PCR.  *, p < 0.05 
Ad5 WT, Ad5/3 WT and Ad5/3 CXCR4 versus Ad5/3 CXCR4 UTR. 
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replication because Ad5 E2B encodes for the proteins Ad Pol and Ad pTP.  Both proteins form 
a stable heterodimer that is critical for initiation of viral genome replication (Liu et al., 2003).   
In this experiment, the transcription levels of Ad5 E1A and pTP genes were analyzed to 
investigate Ad5 genome replication.  MDA-MB-231 cells were infected with 10 ifu per cell of 
Ad5/3 WT, Ad5/3 CXCR4 and Ad5/3 CXCR4 UTR or mock infected.  Cells were collected at 
the indicated time points after viral infection and RNA was isolated.  The mRNA levels of Ad5 
E1A and pTP were then analyzed performing qRT-PCR and results were normalized to human 
GAPDH levels.  As seen in Figure 16 at time point 0 (2 h after addition of virus) Ad5 E1A 
mRNA levels were already slightly elevated in MDA-MB-231 cells infected with Ad5/3 WT 
compared to Ad5/3 CXCR4 and Ad5/3 CXCR4 UTR.  At 6 h post infection Ad5 E1A 
expression started to increase in Ad5/3 WT and Ad5/3 CXCR4 infected MDA-MB-231 cells 
while it decreased in Ad5/3 CXCR4 UTR infected cells (Figure 16).  Following infection, Ad5 
E1A mRNA levels steadily increased in Ad5/3 WT and Ad5/3 CXCR4 infected MDA-MB-231 
cells at a similar rate, showing nearly the same E1A mRNA concentration after 48 h of 
infection.  Ad5/3 CXCR4 UTR on the other hand showed a 24 h lag phase in E1A expression 
that started to increase 24 and 48 h after the infection with Ad5/3 CXCR4 UTR.  A comparable 
time dependent mRNA transcription rate between the viruses as seen for Ad5 E1A was 
observed for Ad5 pTP (Figure 16).  At 12 h post infection the expression of Ad5 pTP increased 
in Ad5/3 WT and Ad5/3 CXCR4 infected MDA-MB-231 cells at an equal rate whereas pTP 
expression was delayed in Ad5/3 CXCR4 UTR infected cells.  The pTP mRNA concentration 
increased around 36 h post infection in MDA-MB-231 cells infected with Ad5/3 CXCR4 UTR.   
In summary, these results demonstrated that Ad5/3 CXCR4 UTR E1A and pTP mRNA 
transcription was delayed in MDA-MB-231 cells compared to Ad5/3 WT and Ad5/3 CXCR4.  
This result showed that the delayed expression of E1A reduces the replication efficiency of 
Ad5/3 CXCR4 UTR in breast cancer cells. 
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4.1.10 E1A mRNA half life is not altered in Ad5/3 CXCR4 UTR infected 
MDA-MB-231 cells 
After investigating that Ad5 E1A transcription was repressed early in Ad5/3 CXCR4 UTR 
infection, it was hypothesized that E1A mRNA might be degraded early during the Ad 
infection cycle.  This degradation could be activated upon Ad3 fiber knob binding.  After a 
period of time induced degradation of E1A mRNA would diminish and E1A expression could 
be initiated.  To examine this hypothesis, the E1A mRNA half life in Ad5/3 CXCR4 UTR 
infected MDA-MB-231 cells was analyzed and compared to E1A mRNA half lives in      
Ad5/3 WT and Ad5/3 CXCR4 infected MDA-MB-231 cells.   
Therefore, MDA-MB-231 cells were infected with 100 ifu per cell of Ad5/3 WT, Ad5/3 
CXCR4 and Ad5/3 CXCR4 UTR for 12 h.  Subsequently, cells were treated with 10 µg/ml 
actinomycin D.  Actinomycin D is a chemical reagent that intercalates into DNA and blocks 
RNA synthesis by hindering the RNA polymerase enzyme to elongate RNA chains (Goldberg 
et al., 1962).  E1A mRNA half life was finally quantified performing qRT-PCR.  Actinomycin 
D was dissolved in DMSO.  Thus, to exclude the possibility that DMSO itself induced the 
degradation of Ad5 E1A mRNA or Ad5 pTP mRNA, DMSO alone was added to another set of 
cells infected with Ad5/3 WT in the same concentration as actinomycin D.  These cells served 
as negative control.   
 
Figure 16: Ad5/3 CXCR4 UTR displayed a lag phase in E1A and pTP gene transcription. 
A) E1A mRNA and B) pTP mRNA level were analyzed by qRT-PCR of infected MDA-MB-231 cells.  Cells 
were infected with 10 ifu per cell of Ad5/3 WT, Ad5/3 CXCR4 and Ad5/3 CXCR4 UTR and 0 h, 6 h, 12 h, 24 h 
and 48 h after infection cells were harvested, RNA was isolated and 0.6 µg of mRNA were then transcribed into 
cDNA, which was analyzed in triplicates by qRT-PCR.  Figure shows the average value ± standard deviation of 
three independent experiments. 
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As displayed in Figure 17, the E1A mRNA concentration started to decrease after 2 h of 
incubation with actinomycin D for all three viruses.  No difference was observed in the 
degradation rate of E1A mRNA of Ad5/3 WT, Ad5/3 CXCR4 and Ad5/3 CXCR4 UTR  
(Figure 17).  Upon actinomycin D treatment the E1A mRNA was degraded for all three viruses 
at a comparable rate whereas Ad5/3 WT infected cells not treated with actinomycin D 
demonstrated a time dependent increase of E1A mRNA.  This result demonstrated that DMSO 
alone does not induce Ad5 E1A mRNA degradation and that the effect seen in the treated cells 
was mediated by actinomycin D.   
Taken together, E1A mRNA of Ad5/3 CXCR4 UTR revealed the same half life in           
MDA-MB-231 cells compared to Ad5/3 WT and Ad5/3 CXCR4.  Thus, degradation of Ad 
E1A mRNA that is activated by Ad3 fiber knob binding was not induced and cannot explain 
the repression of E1A transcription in Ad5/3 CXCR4 UTR infected breast cancer cells. 
 
 
 
 
 
Figure 17: The E1A mRNA half life of Ad5/3 CXCR4 UTR was not impaired in MDA-MB-231 cells. 
MDA-MB-231 cells were infected with 100 ifu per cell of Ad5/3 WT, Ad5/3 CXCR4 or Ad5/3 CXCR4 UTR.  
12 h post infection cells were treated with 10 µg/ml actinomycin D and collected at the indicated time points.  
For each time point MDA-MB-231 cells infected with Ad5/3 WT and not treated with actinmycin D were 
collected as a negative control.  RNA was isolated, transcribed into cDNA and half life was measured with 
qRT-PCR.  Samples were measured in triplicates.  Average values ± standard deviation of three independent 
experiments are shown.  Values were normalized to background levels of E1A in samples containing no reverse 
transcriptase.  Results are expressed as percentage of the results after addition of actinomycin D relative to time 
point 0 h with the E1A mRNA concentration at 0 h set as 100%. 
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4.1.11 Efficient cytotoxicity of Ad5/3 CXCR4 UTR in HEK-293 cells 
As previously mentioned, HEK-293 cells contain the left arm of the Ad5 genome incorporated 
into its chromosome 19.  Recombinant Ads containing restricted expression or deletion of E1A 
should display a comparable oncolytic activity in this cell line as wild-type Ad.  It was shown, 
that transcription of Ad5/3 CXCR UTR was repressed early during infection and after a 24 h 
lag phase transcription was initiated.  This result suggested that the repressed E1A gene 
expression is the limiting factor in the Ad5/3 CXCR4 UTR infection pathway.  Thus, it was 
proposed that Ad5/3 CXCR4 UTR should demonstrate comparable oncolytic potency to  
Ad5/3 WT or Ad5/3 CXCR4 in HEK-293 cells because these cells express the E1A gene and 
several other genes of the Ad5 genome necessary to support Ad replication.   
Therefore, HEK-293 cells were infected with indicated MOIs of Ad5 WT, Ad5/3 WT,      
Ad5/3 CXCR4 and Ad5/3 CXCR4 UTR and cytolytic activity of viruses was monitored using 
CV staining.  As seen in Figure 18, Ad5/3 CXCR4 UTR and Ad5/3 WT demonstrated the same 
cytolytic potency in HEK-293 cells, displaying cell killing at the lowest concentration of     
0.01 MOI.  In addition, both mediated killing in HEK-293 cells more efficiently than Ad5 WT 
and Ad5/3 CXCR4, suggesting that the additional expression of specific Ad5 proteins such as 
the E1A protein, are necessary to increase the Ad5/3 CXCR4 UTR oncolytic activity for breast 
cancer cells.  Transcription of E1A is a crucial step in the Ad replication pathway since E1A 
initiates the transcription of the other early genes which are essential for adenoviral genome 
replication. 
Taken together, Ad5/3 CXCR4 UTR showed an increased cytolytic activity in HEK-293 cells 
compared to breast cancer cells. This result suggested that expression of Ad5 WT E1A gene 
induced the transcription efficiency of Ad5/3 CXCR4 UTR, causing increased cytolytic 
activity.   
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To confirm the hypothesis whether the stable expression of Ad5 WT E1A in HEK-293 cells 
induced the enhanced cytolytic activity of Ad5/3 CXCR4 UTR, it was investigated if the stable 
expression in MDA-MB-231 cells would result in the same outcome.  Meric et al. established 
the MDA-MB-231/E1A cell line (Meric et al., 2000), expressing Ad5 WT E1A and the    
MDA-MB-231/N cell line transfected with an empty vector and served as control cell line.  
Hence, MDA-MB-231/E1A and MDA-MB-231/N cells were infected with indicated MOIs of 
Ad5 WT, Ad5/3 WT, Ad5/3 CXCR4 and Ad5/3 CXCR4 UTR.  Oncolytic activity was 
monitored by staining viable cells with CV.  
Immunoblot analyses of protein lysates from MDA-MB-231/E1A and MDA-MB-231/N 
revealed Ad5 WT E1A expression in MDA-MB-231/E1A while this expression was absent in 
MDA-MB-231/N cells transfected with the empty vector (Figure 19A).  Unexpectedly, the 
presence of the Ad5 WT E1A protein in MDA-MB-231 cells did not enhance the oncolytic 
potency of Ad5/3 CXCR4 UTR compared to the one of Ad5/3 WT and Ad5/3 CXCR4.  In fact, 
transfected MDA-MB-231 cells were somehow less sensitive to Ad5/3 CXCR4 UTR and    
Ad5 WT infection (Figure 19B and C) compared to non-transfected MDA-MB-231 cells 
(Figure 7).  Furthermore, Ad5/3 CXCR4 UTR displayed a higher oncolytic activity in      
MDA-MB-231/E1A cells compared to MDA-MB-231/N cells.  Oncolytic activity of Ad5 WT 
was only detectable at the highest concentration of 100 MOI in MDA-MB-231/N cells.  
However, no difference in the oncolytic activity was observed between Ad5/3 WT and     
Ad5/3 CXCR4 in MDA-MB-231/E1A or MDA-MB-231/N infected cells.  In both cell lines 
cell killing of Ad5/3 WT was detectable at a concentration of 0.01 MOI and for Ad5/3 CXCR4 
at 0.1 MOI (Figure 19B and C). 
 
Figure 18: Increased oncolytic activity of Ad5/3 CXCR4 UTR in HEK-293 cells. 
HEK-293 cells were infected with the indicated titers of Ad5 WT, Ad5/3 WT, Ad5/3 CXCR4 and Ad5/3 
CXCR4 UTR.  One week after infection, cells were stained with 0.1% CV to monitor oncolytic activity. This 
figure is a representative of three independent experiments. 
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To summarize, Ad5 WT E1A protein expression in MDA-MB-231 cells was not sufficient to 
restore the oncolytic activity of Ad5/3 CXCR4 UTR compared to the level seen in HEK-293 
cells.   
 
 
 
One disadvantage of titering fiber knob modified Ad vectors on cell lines is the expression 
pattern of the compatible cellular attachment receptor.  A disadvantage to titer Ad vectors 
containing a transcriptional or translational control element on HEK-293 cells is the 
incorporated left arm of the Ad5 genome that supports Ad replication and abolishes the 
restriction incorporated into the genome.  It was proposed that titration for infectious units of 
Ad5/3 CXCR4 UTR on a different cell line that is not stably expressing Ad proteins, would 
result in a different ifu concentration of the viral stocks.  Therefore, viral stocks of Ad5 WT, 
Ad5/3 WT, Ad5/3 CXCR4 and Ad5/3 CXCR4 UTR were quantified using A549 cells to 
analyze whether ifu titers would be different compared to the ones titered using HEK-293 cells.  
 
Figure 19: Stable expression of E1A did not enhance oncolytic potency of Ad5/3 CXCR4 UTR. 
A) Western Blot analysis of MDA-MB-231 stable transfected with either Ad5 E1A gene (MDA-MB-231/E1A) 
or an empty vector (MDA-MB-231/N).  Cells were harvested, protein lysates were prepared and then 30µg of 
protein was subjected to a 10% SDS-PAGE.  Detection of Ad5 E1A protein was performed with an antibody 
specific for Ad5 E1A.  Β-actin served as a loading control.  Crystal violet analyses of infected B) MDA-MB-
231/E1A and C) MDA-MB-231/N cells.  Cells were infected with the indicated titers of Ad5 WT, Ad5/3 WT, 
Ad5/3 CXCR4, Ad5/3 CXCR4 UTR and the non-replicating Ad5 LacZ.  Oncolytic activity was determined 
staining viable cells with 0.1% CV.  These figures are representatives of three independent experiments. 
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Ifu titers quantified on A549 cells were nearly the same for Ad5 WT, Ad5/3 WT and        
Ad5/3 CXCR4 compared to the ones determined on HEK-293 cells.  The only exception was 
the ifu concentration for Ad5/3 CXCR4 UTR.  Ifu concentration of Ad5/3 CXCR4 UTR was 
significantly reduced after titration on A549 cells, about three potencies (not shown).  Next, 
MDA-MB-231, MDA-MB-231/N and MDA-MB-231/E1A breast cancer cells were infected 
with the indicated viral concentrations and oncolytic activity was investigated by staining 
viable cells with CV solution.  An enhanced oncolytic potency of Ad5/3 CXCR4 UTR was 
obtained in all three cell lines (Figure 20) compared to the oncolytic potency observed with 
ifus titered on HEK-293 cells (Figure 7 and Figure 19).  Oncolytic activity of Ad5/3 CXCR4 
UTR was detectable until the concentration of 0.01 MOI.  Furthermore, Ad5/3 CXCR4 UTR 
killed breast cancer cells with nearly the same efficiency as Ad5/3 WT and Ad5/3 CXCR4 and 
with a higher efficiency than Ad5 WT (Figure 20).  In contrast, Ad5 WT did not display any 
increase in oncolytic activity in MDA-MB-231/E1A and MDA-MB-231/N cells but showed a 
high oncolytic activity on control MDA-MB-231 cells.  This result indiciated that transfection 
of this cell line might have altered the receptor expression of CAR on its surface.   
In summary, the ifu quantification using A549 cells that do not support Ad5 replication due to 
stable Ad5 gene expression resulted, in an improved oncolytic activity of Ad5/3 CXCR4 UTR 
in MDA-MB-231 cells.  Thus, this result suggested that HEK-293 cells provide a specific Ad5 
protein impaired in Ad5/3 CXCR4 UTR that is essential to obtain efficient Ad replication in 
cells.   
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4.2 Characterization of the Syrian hamster breast cancer cell line 
The second aim of this study was to establish a novel breast cancer animal model that is 
permissive for Ad replication and also immunocompetent.  Recently, it was reported that the 
Syrian hamster is permissive for Ad5 replication and immunocompetent (Thomas et al., 2006).  
Unfortunately, until to date there was no Syrian hamster breast cancer model available to 
analyze CRAds specifically designed to treat breast cancer.  Therefore, mammary tumors were 
induced in Syrian hamsters upon MNU treatment in our research group (Coburn et al., 2011).  
Tumor sections stained positive for several breast cancer markers such as HER-2/neu and 
revealed epithelial origin indicating that developed tumors were originated from mammary 
epithelial cells.  One of the primary tumors was used to establish a Syrian hamster breast 
cancer cell line in cell culture.  Two different morphologic phenotypes of cells were observed 
after initiating the tumor cells into cell culture, a uniformly round and a more elongated shaped 
one.  Those two cell types were cultivated separately as HMAM4A (round morphology) and 
HMAM4B (elongated morphology) (Coburn et al., 2011). 
 
Figure 20: Titration on A549 cells increased oncolytic activity of Ad5/3 CXCR4 UTR. 
A) MDA-MB-231, B) MDA-MB-231/E1A and C) MDA-MB-231/N cells were infected with Ad5 WT, Ad5/3 
WT, Ad5/3 CXCR4, Ad5/3 CXCR4 UTR and Ad5 LacZ (non-replicating Ad) at indicated titers.  The ifu 
concentrations of viral stock solutions were quantified on A549 cells.  Viable cells were stained with 0.1% CV 
to visualize oncolytic potency.  Figures are representative data of three independent experiments. 
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4.2.1 Syrian hamster breast cancer cells induce tumor formation in 
syngeneic Syrian hamsters 
To analyze whether the established Syrian hamster breast cancer cell line HMAM4B was 
capable to induce tumor formation, 1 x 10
7
 HMAM4B cells were injected subcutaneously into 
both hind flanks of syngeneic untreated female Syrian hamsters and tumor formation was then 
monitored.  
After injection of HMAM4B cells in vivo, a significant tumor growth rate was monitored with 
a tumor take rate about 50% (Figure 21A).  Furthermore, a lag phase of tumor detection 
between the time point of HMAM4B injection and tumor development was detected. This lag 
phase was variable between the different animals and injection sides, and ranged from 15 to 36 
days (Figure 21A).  Tumors developed after injection of HMAM4B cells were 
histopathologically analyzed by a pathologist.  One of the developed tumors was further 
passaged into cell culture and the cell line HMAM5 was established.  HMAM5 cells were also 
subcutaneously injected into the hind flanks of syngeneic untreated female Syrian hamsters and 
tumor formation was monitored.  The tumor take rate (around 70%) after injection of the 
HMAM5 cell line was greater compared to the one after HMAM4B injection (Figure 21A and 
B).  Mean body weight growth characteristics of hamsters (Figure 21C) and tumor volumes in 
vivo (Figure 21B) revealed that after a lag phase of 21 days, tumor growth was similar in all 
animals until they were sacrificed at the upper limit allowed in the protocol (20% of total body 
weight).   
Immunohistochemical analyses for the molecular markers p63 and cytokeratin were performed 
on tumors that were induced upon HMAM4B and HMAM5 subcutaneous injection to 
determine the molecular subtype of the hamster mammary tumors.  Breast cancer can be 
divided into four distinct molecular classifications: luminal A (ER+, PR+, HER2-), luminal B 
(ER+, PR+, HER2+), basal (ER-, PR-, HER2-) and basal-like HER-2/neu positive (ER-, PR-, 
HER+).  P63 and cytokeratin are molecular markers for basal categorized breast cancers.  It 
was shown that most luminal breast cancer tumors are stained negative for these two markers 
and basal breast cancer tumors are stained positive (Matos et al., 2005; Ribeiro-Silva et al., 
2005).  Tumors derived after subcutaneous injection of HMAM4B or HMAM5 cells were 
negative for both basal molecular markers p63 and cytokeratin 5/6, indicating that those tumors 
can be categorized as luminal breast cancer tumors (Coburn et al., 2011). 
Taken together HMAM4B and HMAM5 Syrian hamster breast cancer cells were able to induce 
tumor formation in syngeneic untreated female Syrian hamsters upon subcutaneous injection 
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into the hind flanks. In addition, it was distinguished that mammary tumors developed from 
MNU-treatment were originated from mammary epithelial cells and can be categorized as 
luminal breast cancer. 
 
 
 
 
Figure 21: HMAM4B and HMAM5 cells induced tumor formation in syngeneic female Syrian hamsters. 
Shown are: A) Tumor formation after the injection of HMAM4B cells, B) mean tumor growth (n =7) at each site 
after s.c injection of HMAM5 cells and C) mean body weight (n = 10) of syngeneic untreated female Syrian 
hamsters injected with HMAM5 cells.  1 x 10
7
 HMAM4B or HMAM5 cells were s.c. injected into the hind flanks   
of syngeneic untreated female Syrian hamsters.  Tumor growth was monitored from the day of injection with a 
digital caliper.  For injection of HMAM4B cells a total of three animals were injected whereas the animal number 
for the HMAM5 injection was ten.  Two hamsters in which HMAM5 cells were injected were euthanized at day 
65 (E1) and at day 79 (E2) due to excessive tumor burden.  Each data point in B and C represents the average 
value ± standard error at each time point. 
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4.2.2 HMAM5 cells displayed anchorage independent growth and             
24 h doubling time during exponential growth phase 
HMAM4B cells were able to be passaged more than 15 times and HMAM5 cells were even 
passaged more than 40 times, suggesting that both cell lines were immortal carcinoma cell 
lines and not passage-limited like primary cells.  To determine whether both cell lines have 
cancerous characteristics several experiments were performed.  First, the anchorage 
independence assay was used to investigate whether the newly established Syrian hamster 
breast cancer cell lines could grow in soft agar like other breast cancer cell lines.  Anchorage 
independent growth is one of the best properties to study in vitro correlation with 
tumorigenecity (Colburn et al., 1978; Freedman and Shin, 1974; Shin et al., 1975).  To 
proliferate, normal cells require growth factors and cell adhesion to an underground.  Cancer 
cells on the other hand gained the capacity to proliferate without adhesion to an underground.  
This independent growth is a key marker for tumorigenicity.   
Therefore, HMAM4A, HMAM4B, HMAM5 and MDA-MB-231 were plated on soft agar and 
incubated for three weeks. Anchorage independent growth was quantified by counting colony 
formation with a cell number greater than approximately 50 cells.  HMAM4A, HMAM4B and 
HMAM5 each displayed an anchorage independent growth on soft agar indicated by the 
formation of colonies (Figure 22).  The number of colonies formed by HMAM5, HMAM4A 
and HMAM4B was similar to the one detected of the human breast cancer cell line          
MDA-MB-231, indicating a cancerous character for the established Syrian hamster breast 
cancer cell lines.  
 
 
Figure 22: Syrian hamster breast cancer cell lines showed anchorage independent growth. 
0.5 x 10
4
 cells of human MDA-MB-231, HMAM4A, HMAM4B and HMAM5 cell lines were plated on 0.5% 
soft agar in complete DMEM containing 10% FBS and incubated at 37°C.  Positive colonies greater than 50 
cells were counted after three weeks in culture.  Each data point represents the average ± standard error of three 
independent experiments. 
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Furthermore, cell doubling time of HMAM5 and HMAM4B cells during the exponential phase 
was quantified by performing a growth curve for both cell lines.  1 x 10
4
 cells were plated and 
cell number of triplicates was determined daily until 10 to 12 days after plating the cells.  
Figure 23A presents the growth curve of HMAM5, HMAM4B and MDA-MB-231 cells.  Both 
Syrian hamster breast cancer cell lines displayed a quick growth with a doubling time of 
approximately 24 h during the exponential phase, which was comparable to the observed 
growth curve of human MDA-MB-231 cells.  
In addition, growth of HMAM5 cells was analyzed in medium containing different percentages 
of FBS (2%, 5% and 10%).  This was examined, to determine whether the growth rate of 
HMAM5 cells could slowed down by reducing the FBS concentration without any 
morphological changes of the cells. 1.5 x 10
4
 HMAM5 cells were plated and cell numbers were 
determined daily in triplicates with a hemocytometer.  HMAM5 cells cultured in medium 
containing 5% or 10% FBS demonstrated a similar growth rate whereas cells cultured in       
2% FBS containing medium displayed a slower doubling time (Figure 23B). Furthermore, no 
morphological changes were detectable between the cells cultured in 10%, 5% or 2% FBS 
containing media.  
 
 
 
 
Figure 23: HMAM5 and HMAM4B cells displayed a 24h doubling time during exponential growth. 
Shown are: A) Representative growth curve of HMAM4B, HMAM5 and MDA-MB-231 cells and B) 
representative growth curve of HMAM5 in DMEM containing either 2%, 5% or 10% FBS.  1 x 10
4
 cells were 
plated to monitor growth rates of the newly established HMAM5 and HMAM4B cell lines compared to MDA-
MB-231 cells.  To analyze the growth rate of HMAM5 cells cultured in DMEM containing different 
concentrations of FBS 1.5 x 10
4
 cells were plated.  Cell number of triplicates was determined daily.  Each data 
point represents the average ± standard error of triplicates. 
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Besides the determination of anchorage independent growth and the doubling time of the 
newly established Syrian hamster breast cancer cell lines, it was of interest to quantify the 
chromosome number of the cell line. Aberrations in the chromosome numbers are good 
indicators for cancerous characteristic in a cell line.  For that reason, cytogenetic analyses were 
performed on the HMAM5 cell line by Applied Genomics Laboratories, Inc. (Melbourne, FL, 
USA) using a standard giemsa banding method (Seabright, 1971).  Syrian hamsters contain 
usually 44 (2n) chromosomes (Romanenko et al., 2007).  Metaphases of HMAM5 cells were 
analyzed performing a cytogenetic analysis.  A total of 100 metaphases was examined and the 
average chromosome number of these metaphases was 74 (Coburn et al., 2011). This result 
was also observed for HMAM4B cells upon cytogenetic analysis.  Furthermore, 5 metaphases 
of HMAM5 cells were further karyotyped and multiple copies of chromosomes A3, C11, C14, 
C15, E20 and F21 were detected as well as a number of unknown chromosomes (UC) (Coburn 
et al., 2011).  Several copy numbers of chromosomes indicated that the established HMAM4B 
and HMAM5 Syrian hamster breast cancer cell lines have cancerous character. 
Immunohistochemical staining demonstrated already that the mammary tumors in the Syrian 
hamster originated from epithelial cells and could be categorized as luminal breast cancer. To 
further determine if the Syrian hamster breast cancer cell line derived from a luminal A or 
luminal B tumor, the estrogen dependence of HMAM5 cells was determined in our laboratory.  
Several commercially available anti-ER antibodies were examined whether they cross react 
with the Syrian hamster breast cancer cell line; unfortunately none of the antibodies did.  
Consequently, the estrogen dependence was determined using the anti-estrogen agent 
tamoxifen.  Tamoxifen is a non-steroidal estrogen antagonist that inhibits the growth of 
estrogen-responsive cells (Smith et al., 2000).  Human breast cancer cell line MCF-7 was used 
as a positive control for an ER positive breast cancer and human breast cancer cell line    
MDA-MB-231 as ER negative breast cancer cells to determine the responsiveness to 
tamoxifen.  Treatment with tamoxifen decreased the proliferation equally in MCF-7 and 
HMAM5 cells in a dose-dependent manner (Coburn et al., 2011).  MDA-MB-231 cells on the 
other hand, were rather insensitive to tamoxifen treatment, and proliferation was only slightly 
inhibited at high concentrations of tamoxifen.  These results suggested that the Syrian hamster 
breast cancer cell line HMAM5 was derived from a luminal B subtype mammary carcinoma. 
Taken together, HMAM5 and HMAM4B cells showed anchorage independent growth and a 
similar growth curve compared to human MDA-MB-231 cells. Furthermore, it was shown that 
cell growth was reduced by culturing HMAM5 cells in medium containing 2% FBS. 
Cytogeneic analyses and anchorage independent growth indicated tumorigenic characteristics 
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for the Syrian hamster breast cancer cell lines. In addition, it was shown, that the HMAM5 cell 
line derived from a mammary tumor categorized as luminal B. 
 
4.3 Replication efficiency of oncolytic Ads on HMAM5 cells 
The HMAM5 breast cancer cell line including the Syrian hamster in vivo model was proposed 
to be a useful animal model to determine toxicity and cancer specificity profile of newly 
generated oncolytic vectors for virotherapy.  To investigate this proposition several in vitro 
experiments were performed, analyzing the replication efficacy of established CRAds on the 
Syrian hamster breast cancer cell line.  The main goal of this study was to verify the 
compatibility of the model to investigate newly constructed Ad vectors specifically designed to 
target breast cancer.  Ad5 WT, Ad5/3 WT, Ad5 CXCR4, Ad5 ∆24, Ad5 ∆24 RGD and    
Ad5/3 CXCR4 viruses were used to infect HMAM5 cells and analyze the oncolytic efficiency 
in HMAM5 cells compared to hamster fibroblasts isolated from a female Syrian hamster.   
In this regard, the Ad5-∆24-RGD is an oncolytic Ad of great interest because it is the first fiber 
modified conditionally replicative competent human Ad used in a clinical trial (Page et al., 
2007).  A 24bp deletion in the constant region 2 (CR2) of the E1A gene is present in the Ad 
vectors Ad5 ∆24 and Ad5 ∆24 RGD.  Those Ads are unable to bind retinoblastoma (Rb), a 
tumor suppressor/cell cycle regulator protein.  Interaction of Ad5 E1A with Rb allows Ad to 
induce S-phase in the infected cell.  Therefore, viruses containing this deletion are reduced in 
their ability to overcome the G1-S checkpoint and replicate efficiently only in cells where this 
interaction is not necessary, e.g., tumor cells defective in the Rb-p16 pathway, or in rapidly 
cycling normal cells featuring phosphorylation of Rb (Fueyo et al., 2000; Heise et al., 2000).  
This pathway may be inactive in all human tumors (Sherr, 1996).   
In Ad5 ∆24 RGD the 24bp deletion is combined with a genetic modification in the HI loop to 
overcome the CAR-dependent infection.  The HI-loop is exposed on the fiber knob and it is 
possible to incorporate up to 83 amino acids into the HI-loop without deleterious effects on 
viral replication.  Incorporation of the arginine-glycine-aspartate (RGD) sequence motif to the 
HI-loop targeted the Ad in particular towards ανβ cell surface integrins expressed at high levels 
on most cancer cells (Mathias et al., 1998; Wickham et al., 1993).  In the past, studies have 
shown successful results in cancer treatment using the RGD-modified Ads (Dmitriev et al., 
1998; Kasono et al., 1999).  Bauerschmitz et al. showed an increased cellular infectivity and an 
enhanced progress in the therapeutic effects of a preclinical ovarian cancer model with the use 
  Results 
 
79 
of Ad5-∆24-RGD (Bauerschmitz et al., 2002).  Studies about its efficacy have been performed 
in order to translate this approach into an early-phase clinical trials for patients with ovarian 
cancer.   
 
4.3.1 Ad5 ∆24 RGD displays a significant E1A mRNA and protein 
expression in HMAM5 cells 
To determine viral oncolytic potency it is of great importance to analyze the E1A mRNA and 
protein expression in infected cells.  E1A is a key player during the Ad replication cycle 
because it is essential to initiate the transcription of the other early genes and the viral genome 
replication.  Thus, if expression of E1A is at a low level, the replication efficiency in return 
will be also reduced.  Therefore, Ad5 E1A mRNA levels of several established Ad vectors 
were analyzed in HMAM5 cells and hamster fibroblasts.  Both cell types were infected with  
10 ifu per cell of Ad5 WT, Ad5/3 WT, Ad5 CXCR4, Ad5 ∆24, Ad5 ∆24 RGD, Ad5/3 CXCR4 
and a non-replicating Ad (Ad5/3 luc or Ad5 LacZ).  48 h post infection, cells were harvested, 
RNA was isolated and E1A mRNA levels were determined by qRT-PCR.   
Ad5 ∆24 RGD displayed higher E1A mRNA levels in HMAM5 cells compared to hamster 
fibroblasts as presented in Figure 24A and 24B.  Furthermore, high levels of Ad5 WT E1A 
mRNA were detectable in HMAM5 cells after 48 h of infection (Figure 24B).  Ad5/3 WT and 
Ad5 CXCR4 E1A mRNA levels were comparable to Ad5 WT E1A mRNA levels in hamster 
fibroblasts (Figure 24A), but significantly reduced in HMAM5 cells (Figure 24B).  E1A levels 
of Ad5 ∆24 and Ad5/3 CXCR4 on the other hand were increased in HMAM5 cells and 
comparable to the ones of Ad5 WT, Ad5/3 WT and Ad5 CXCR4 in the hamster fibroblasts.  
The most prominent E1A mRNA levels were detectable in Ad5 ∆24 RGD infected HMAM5 
cells after 48 h. 
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After the determination of successful E1A transcription for some Ad vectors in HMAM5 cells, 
the E1A protein expression was investigated by infecting hamster fibroblasts and HMAM5 
cells.  Cells were infected with the same viruses and with the same concentration as for the 
E1A mRNA quantification.  At 48 h after infection, cells were harvested and protein levels 
were detected performing immunoblot analyses with a specific antibody for Ad5 E1A.  As seen 
in Figure 25A and 25B, Ad5 ∆24 RGD displayed a significant higher protein expression in 
hamster fibroblasts and in HMAM5 cells compared to the other Ad vectors.  However, in 
hamster fibroblasts E1A protein expression of Ad5 WT and Ad5 ∆24 was detectable as a faint 
signal whereas in HMAM5 cells, E1A protein expression was only detectable in                  
Ad5 ∆24 RGD infected cells (Figure 25A and B).  E1A protein expression in Ad5/3 WT,    
Ad5 CXCR4 and Ad5/3 CXCR4 infected hamster fibroblasts and HMAM5 cells, was not 
detectable, even after long exposure times.  
Taken together, immunoblot analyses results were in accordance with the results observed for 
the E1A mRNA expression, demonstrating an increased transcription and translation of the 
E1A gene in Ad5 ∆24 RGD infected cells.  Besides, the significant high expression of         
Ad5 ∆24 RGD E1A in hamster fibroblasts, the discrepancy of E1A expression to the other Ad 
vectors was higher in HMAM5 cells.  These results were suggesting that Ad5 ∆24 RGD was 
 
Figure 24: E1A mRNA expression of Ad5 ∆24 RGD was significantly increased in HMAM5 cells. 
A) Hamster fibroblasts and B) HMAM5 cells were infected with 10 ifu per cell of Ad5 WT, Ad5/3 WT,       
Ad5 CXCR4, Ad ∆24, Ad5 ∆24 RGD, Ad5/3 CXCR4 and a non-replicating Ad5 or mock infected.  48 h post 
infection mRNA was isolated, transcribed into cDNA and E1A mRNA levels were quantified in triplicates by 
qRT-PCR.  Average values ± standard deviation of two independent experiments are displayed.                     
***, p < 0.0005. 
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able to infect specifically HMAM5 cells and initiate E1A expression and viral genome 
replication compared to other Ad vectors. 
 
 
 
4.3.2 Viral replication of Ad5 ∆24 RGD in HMAM5 is significantly 
increased compared to Ad5 WT 
After successful E1A expression and viral genome replication, the analysis of viral release is 
essential to determine the replication efficiency of constructed Ad vectors for virotherapy. 
Therefore, the E4 copy number in the supernatant of infected hamster fibroblasts and HMAM5 
cells was quantified using qPCR.  
In this experiment, 1 x 10
5
 cells were plated and infected the next day with 10 MOI of         
Ad5 WT, Ad5/3 WT, Ad5 CXCR4, Ad5 ∆24, Ad5 ∆24 RGD, Ad5/3 CXCR4 and a non-
replicating Ad or mock infected.  Supernatant of infected cells was collected daily, DNA was 
isolated and viral release was analyzed by determining the Ad5 E4 copy number by qPCR. 
Viral replication efficacy of Ad5 CXCR4, Ad5 ∆24, Ad5/3 CXCR4 and Ad5 LacZ were not 
detectable in hamster fibroblasts as presented in Figure 26A.  However, a slight increase in 
Ad5 E4 copy number was detectable for Ad5 WT, Ad5/3 WT and Ad5 ∆24 RGD at day 4 after 
infection.  In HMAM5 cells on the other hand, great replication efficiency was observed for 
 
Figure 25: E1A protein expression was dominant in Ad5 ∆24 RGD infected HMAM5 cells. 
Ad5 E1A protein expression was determined in A) Hamster fibroblasts and B) HMAM5 cells infected with 10 ifu 
per cell of Ad5 WT, Ad5/3 WT, Ad5 CXCR4, Ad5 ∆24, Ad5 ∆24 RGD, Ad5/3 CXCR4 and Ad5/3 luc (non-
replicating virus) or mock infected.  48 h post infection cells were harvested and 30 µg of protein were subjected 
on a 10% SDS-PAGE.  Afterwards proteins were transferred onto a nitrocellulose membrane and 
immunodetection was carried out by using anti-Ad5 E1A and anti-β-actin (loading control).  Shown are 
representative results of three independent experiments. 
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Ad5 ∆24 RGD starting at day 1, until it reached a plateau phase at day 3 and day 4 after 
infection (Figure 26B). Both Ad5 WT and Ad5 ∆24 displayed similar release of progeny 
virions but were significantly reduced compared to Ad5 ∆24 RGD at day 4. As seen in    
Figure 26A and B, viral release of Ad5/3 WT and Ad5/3 CXCR4 was not detectable in 
HMAM5 cells and in hamster fibroblasts.  Ad5 CXCR4 on the other hand showed a slight 
increase of E4 copy number at day 4 in HMAM5 cells, but in hamster fibroblasts the release of 
progeny virions was not detectable.  
To summarize, Ad5 ∆24 RGD displayed specific viral replication in the Syrian hamster breast 
cancer cell line HMAM5 compared to hamster fibroblasts. In addition, Ad5 WT and Ad5 ∆24 
demonstrated also a specificity of viral replication in HMAM5 cells but to a lower extent than 
Ad5 ∆24 RGD. All other viral vectors demonstrated no release of progeny virions in HMAM5 
cells and hamster fibroblasts, indicating that those viruses can not replicate in the Syrian 
hamster cells. 
 
 
 
4.3.3 Enhanced oncolytic activity of Ad5 ∆24 RGD in HMAM5 cells 
It was already shown that Ad5 ∆24 RGD displayed a significantly increased E1A mRNA and 
protein expression plus viral replication in HMAM5 cells and therefore, oncolytic activity was 
determined using the CV method.  Briefly, 5 x 10
3
 cells were plated and infected the next day 
 
Figure 26: Increased replication efficacy of Ad5 ∆24 RGD in HMAM5 cells. 
Shown are: E4 copy numbers detected in the supernatant of A) Hamster fibroblast and B) HMAM5 cells 
infected with Ad5 WT, Ad5/3 WT, Ad5 CXCR4, Ad5 ∆24, Ad5 ∆24 RGD, Ad5/3 CXCR4 and a non-
replicating Ad.  1 x 10
5
 cells were plated and on the next day infected with 10 ifu per cell of the indicated 
viruses.  200 µl of supernatant was collected daily, DNA was isolated and E4 copy number was determined in 
triplicates using qPCR.  Average values ± standard deviation of three independent experiments are shown. 
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with the indicated titers of Ad5 WT, Ad5/3 WT, Ad5 CXCR4, Ad5 ∆24, Ad5 ∆24 RGD, 
Ad5/3 CXCR4 and the non-replicating Ad5/3 luc.  Oncolytic activity was then monitored by 
staining viable cells with CV solution.  Figure 27 presents the results of the CV staining in 
hamster fibroblasts and HMAM5 cells.  Cytolytic activity of Ad5 WT and Ad5 ∆24 RGD was 
observed at 1,000 MOI in hamster fibroblasts and at 100 MOI for Ad5 ∆24 RGD whereas no 
cell killing was detectable in hamster fibroblasts infected with Ad5/3 WT, Ad5 ∆24, and  
Ad5/3 luc (Figure 27A).  In contrast, in HMAM5 cells Ad5 ∆24 RGD demonstrated oncolytic 
activity at 10 MOI, revealing a gain of specificity for HMAM5 breast cancer cells compared to 
hamster fibroblasts (Figure 27B).  Furthermore, cell killing was also observed in Ad5 ∆24 
infected HMAM5 cells at a viral concentration of 1,000 MOI, suggesting also a gain in 
specificity for HMAM5 breast cancer cells compared to hamster fibroblasts.  Ad5 WT 
displayed the same cytolytic activity at 1,000 MOI in HMAM5 cells as observed in hamster 
fibroblasts (Figure 27A and B). 
To summarize, Ad5 ∆24 and Ad5 ∆24 RGD showed an enhanced oncolytic activity in 
HMAM5 cells compared to hamster fibroblasts with Ad5 ∆24 RGD displaying the greater 
infectivity rate than Ad5 ∆24.  The same oncolytic activity of Ad5 WT was observed in 
hamster fibroblasts and in HMAM5 cells whereas Ad5/3 WT and Ad5/3luc did not display any 
oncolytic potency for both cell lines. 
 
 
 
 
Figure 27: Oncolytic activity of Ad5 ∆24 RGD was increased in HMAM5 cells. 
Crystal violet analysis was performed on A) Hamster fibroblasts and B) HMAM5 cells infected with Ad5/3 luc 
(non-replicating Ad5), Ad5 WT, Ad5/3 WT, Ad5 CXCR4, Ad5 ∆24, Ad5 ∆24 RGD and Ad5/3 CXCR4.  Cells 
were infected with indicated MOIs and stained 2 weeks later with 0.1% CV.  Figures are representative data 
from three independent experiments. 
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5. Discussion 
5.1 Construction of an oncolytic adenovirus containing transductional, 
transcriptional and translational targeting 
Virotherapy is an innovative approach to treat breast cancer which is still the second leading 
cause of cancer death in women (Jemal et al., 2011).  The Ad-based virotherapy represents a 
therapeutic method to achieve efficient tumor cell oncolysis by cancer specific replication and 
release of the progeny virions that are capable of further propagating in surrounding tumor 
cells but not in those of normal tissues (Alemany et al., 2000; Biederer et al., 2002; Mathis et 
al., 2005; Stoff-Khalili et al., 2006; Vile et al., 2000).  Nevertheless, the overall efficacy of  
Ad-based virotherapy needs to be improved with different approaches such as transductional, 
transcriptional or translational targeting, due to sub-optimal vector delivery and unspecific 
replication.  Each targeting strategy by itself bears some disadvantages such as background 
replication efficiency in normal cells.  Clearly, the specificity of Ads as anti-tumor agents in 
cancer therapy is desperately necessary, so that they can accomplish their safety profile and 
achieve their full benefit in terms of clinical efficacy.  In the present study, a novel oncolytic 
Ad harboring transductional, transcriptional and translational targeting was successfully 
constructed to gain tumor specificity in virotherapy and reduce the Ad background replication 
efficiency in normal cells.  The Ad5 fiber knob was replaced with the serotype 3 knob to 
achieve transductional targeting.  Furthermore, the Ad5 E1A promoter was exchanged with the 
human CXCR4 promoter (transcriptional targeting) and finally, we introduced the translational 
control of Ad5 E1A by inserting the 5’-UTR sequence of FGF-2   
After successful rescue of the triple-level targeted Ad construct, designated                       
Ad5/3 CXCR4 UTR, PCR and sequencing analyses demonstrated the correct insertion of all 
three control elements into the genome of the Ad5/3 CXCR4 UTR virus.  An essential step in 
developing of a novel oncolytic Ad is to determine the functionality for killing the specific 
cancer type in vitro.  In normal cells a gain of cancer specificity was detectable after the 
infection of Ad5/3 CXCR4 UTR.  Unfortunately, Ad5/3 CXCR4 UTR displayed a reduced 
oncolytic activity between one to two orders of magnitude depending on the breast cancer cell 
line treated compared to other Ad vectors including Ad5/3 WT and Ad5/3 CXCR4.  However, 
compared to Ad5 WT, the Ad5/3 CXCR4 UTR demonstrated an equal oncolytic activity using 
breast cancer cells and a lower cytolytic activity using normal cells.  Moreover, the E1A 
protein expression was expected to be reduced in normal cells compared to breast cancer cells 
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due to the incorporation of the 5’UTR sequence.  Indeed, the E1A protein concentration was 
shown to be nearly absent in normal cells while it was clearly detectable in infected breast 
cancer cell lines.  Nevertheless, the E1A protein expression of Ad5/3 CXCR4 UTR and 
therefore also E1A translation was reduced in all breast cancer cell lines included in this 
experimental setup compared to the other Ad vectors.  Furthermore, it was possible to show 
that release of progeny virions was significantly reduced in MDA-MB-231 cells infected with                 
Ad5/3 CXCR4 UTR compared to Ad5 WT, Ad5/3 WT and Ad5/3 CXCR4.  Those 
experiments confirmed the lower efficacy of Ad5/3 CXCR4 UTR to kill breast cancer cells 
compared to the other Ad vectors.  The disadvantages of a different receptor expression pattern 
and the expression of several Ad genes in HEK-293 cells can lead to an inaccurate titer of fiber 
or replication modified Ads.  Re-titration of viral stocks for viral DNA copy number was cell 
line independent, but did not result in a change in the oncolytic activity of                         
Ad5/3 CXCR4 UTR in MDA-MB-231 cells observed compared to Ad5/3 WT and            
Ad5/3 CXCR4.  Overall, Ad5/3 CXCR4 UTR still demonstrated a lower oncolytic activity than 
Ad5/3 CXCR4.  This result revealed that the titration method was not the limiting factor that 
induced reduced oncolytic activity of Ad5/3 CXCR4 UTR compared to other Ads.  
Furthermore, it was demonstrated that viral cell entry efficiency of Ad5/3 WT, Ad5/3 CXCR4 
and Ad5/3 CXCR4 UTR in MDA-MB-231 cells was comparable using different concentrations 
at either 1 h or 3 h post infection.  As expected, viral cell entry of Ad vectors containing the 
Ad5/3 fiber chimera was increased compared to Ad5 WT, due to the higher expression of the 
Ad3 cellular attachment receptor on breast cancer cells than the Ad5 receptor CAR.  This 
finding clearly showed that the viral cell entry of Ad5/3 CXCR4 UTR was not impaired and 
even greater compared to Ad5 WT, leading to the speculation that an unknown cellular factor 
might be responsible for the delayed replication efficiency of Ad5/3 CXCR4 UTR in breast 
cancer cells.   
Incorporation of all three targeting strategies involved the new combination of Ad3 fiber knob 
with the 5’UTR sequence of FGF-2.  Desmoglein-2 was recently characterized as the primary 
cellular attachment receptor for Ad serotype 3 (Wang et al., 2011).  However, nothing is 
known so far regarding the interaction of Ad3 fiber knob and the Desmoglein-2 receptor to 
mediate activation of intracellular signaling cascades.  These cascades could alter eIF4E 
protein expression or the phosphorylation level of 4E-BP, resulting in a reduced translation of 
E1A mRNA and therefore, reduced replication efficiency of Ad5/3 CXCR4 UTR.  However, 
the investigation of eIF4E protein expression levels after Ad5/3 WT and Ad5 WT infection in 
two different breast cancer cell lines, MDA-MB-231 and MCF-7, did not reveal any effect.  
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Even after a longer incubation time, the expression pattern of Ad5 WT and Ad5/3 WT infected 
breast cancer cells was not altered, indicating that Ad3 fiber knob binding is not dysregulating 
the protein expression of eIF4E.  The phosphorylation of 4E-BP in MDA-MB-231 cells was 
shown to be initiated upon Ad5/3 WT or Ad5/3 CXCR4 UTR infection and occurred at a rate 
even faster compared to Ad5 WT.  On the other hand, phosphorylation of 4E-BP in MCF-7 
cells was absent after Ad5 WT infection and clearly detectable after Ad5/3 WT and          
Ad5/3 CXCR4 UTR infection.  One reason for this result could be a lower expression of CAR 
on the surface of MCF-7 cells compared to MDA-MB-231 cells.  Another possibility is 
exemplified by the finding that in several breast cancer cell lines, the PI3K pathway is altered 
and enhanced phosphorylation of 4E-BP already exists (Hernandez-Aya, 2011).  Evidence for 
this possibility is indicated in the results in which a lower concentration of non-phosphorylated 
4E-BP was detected at time point zero compared to MDA-MB-231 cells.  These findings 
showed that Ad3 fiber knob binding does not alter 4E-BP phosphorylation in a negative 
manner, and therefore, Ad5/3 CXCR4 UTR translation efficiency is not likely to be impacted.  
All the possible alternatives that were proposed to explain the reduced E1A translation were 
disproven experimentally.  E1A is the earliest gene that is transcribed and initiates the 
transcription of all other early genes within the Ad genome.  Therefore, impaired E1A 
transcription affects the Ad replication efficiency.  It was possible to clearly show that E1A 
transcription was significantly reduced in Ad5/3 CXCR4 UTR infected MDA-MB-231 cells 
compared to the other Ad vectors.  A time dependent analysis of E1A and pTP (essential in a 
complex with Ad DNA Polymerase for Ad genome replication) gene expression displayed a 
delayed expression in Ad5/3 CXCR4 UTR infected MDA-MB-231 cells between 24 h to 48 h.    
These findings tempted to speculate that an unknown cellular factor might restrict the 
transcription of Ad5/3 CXCR4 UTR early in infection.  Moreover, the degradation of E1A 
mRNA could be induced due to the incorporation of the 5’UTR-sequence into the Ad5 genome 
upon Ad3 fiber knob binding resulting in low levels of E1A mRNA early during infection.  
The Ad5/3 CXCR4 UTR E1A mRNA stability was not altered by comparing the half-lives of 
Ad5/3 WT and Ad5/3 CXCR4 E1A with the one of Ad5/3 CXCR4 UTR   This result showed 
that a change in the E1A mRNA stability in the Ad infection cycle is not responsible for the 
decreased oncolytic activity of Ad5/3 CXCR4 UTR compared to other Ads in breast cancer 
cells.   
As mentioned earlier, HEK-293 cells express several Ad5 proteins due to incorporation of the 
left arm of the Ad5 genome.  Hence, Ad vectors that contain a control element upstream of the 
E1A open reading frame to restrict E1A expression to tumor cells, should demonstrate the 
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same cytolytic activity in HEK-293 cells.  It was shown that Ad5/3 CXCR4 UTR displayed the 
same cytolytic activity as Ad5/3 WT in infected HEK-293 cells and even a greater cyolytic 
activity than Ad5/3 CXCR4.  Surprisingly, stable expression of the E1A gene could not induce 
an enhanced oncolytic activity because Ad5/3 CXCR4 UTR still displayed a reduced oncolytic 
activity in MDA-MB-231 cells stably expressing E1A (MDA-MB-231/E1A) compared to 
Ad5/3 WT and Ad5/3 CXCR4.  Moreover, atypical cell killing was detected in                 
MDA-MB-231/E1A cells and MDA-MB-231 cells transfected with the empty vector      
(MDA-MB-231/N) after Ad5 WT infection.  This result led to the speculation that the 
transfection of MDA-MB-231 cells reduced the expression of CAR on the cell surface 
resulting in a decreased Ad5 WT entry and cell killing.  Furthermore, the morphology of the 
transfected MDA-MB-231 cell lines was changed which underlines the assumption that 
transfection might have altered also receptor expression on the surface.  In addition, Ad5/3 
CXCR4 UTR displayed also a lower efficacy in cell killing in the transfected cell line 
compared to the untransfected cell line.  This finding indicated that the transfection of the cell 
line was changing a factor that further reduced the oncolytic activity of Ad5/3 CXCR4 UTR.  
Nevertheless, it was possible to demonstrate that E1A by itself is not sufficient to restore the 
oncolytic activity using Ad5/3 CXCR4 UTR. 
Moreover, re-titration of viral stocks on A549 cells, which are not providing Ad5 proteins, 
revealed a three orders of magnitude lower infectious titers Ad5/3 CXCR4 UTR compared to 
the infectious titer using HEK-293 cells.  MDA-MB-231 cells infected with the viruses 
displayed a greater oncolytic activity of Ad5/3 CXCR4 UTR compared to that seen when titers 
were determined using HEK-293 cells.  These results support the speculation that HEK-293 
cells provide an unknown factor that can diminish the delayed expression of                      
Ad5/3 CXCR4 UTR observed using breast cancer cells.  Most likely, this unknown factor is 
the combination of several Ad proteins that are stably expressed in this cell line.  Besides, the 
E1A gene that was not able to enhance oncolytic activity by itself, the E1B and the E2 genes 
are also expressed in HEK-293 cells.  The E1B gene encodes two proteins: the E1B 19K and 
the E1B 55K protein.  The functions of these proteins involve the inhibition of apoptosis and 
the further modification of the intracellular environment to enable viral protein production 
(Chinnadurai, 1998; White, 1998).  The E2 gene encodes three proteins: the Ad DNA 
polymerase (Ad pol), the pTP, and the DNA binding protein (DBP).  DBP encompasses several 
functions including early and late gene expression and viral DNA replication (Hay et al., 1995; 
Van der Vliet, 1995).  In addition, the heterodimer complex of Ad pol and pTP is critical for 
viral DNA replication (Hay et al., 1995; Van der Vliet, 1995).  Since these Ad proteins embody 
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essential functions during the Ad replication cycle, it can be speculated that they provided an 
enhanced oncolytic activity of Ad5/3 CXCR4 UTR in HEK-293 cells, thereby overcoming any 
restricting factors observed in the other cell lines tested.  
Findings within this study were leading to the assumption, that virus trafficking in infected 
cells is altered due to Ad3 fiber knob modification.  This trafficking alteration could result in 
impairment of E1A early transcription.  Viral entry and trafficking studies have demonstrated 
that Ads can use clathrin-dependent endocytosis, macropinocytosis, phagocytosis, caveolin-
dependent endocytosis or a combination of all these mechanisms to enter the cell; this use is 
dependent on the cell type and the binding receptor (Henaff et al., 2011; Meier et al., 2002).  
The primary internalization of Ad5 is mediated through clathrin-coated vesicles by integrin 
activation in vitro (Mathias et al., 1998; Wickham et al., 1993).  In contrast, group B Ads 
(including Ad3 and Ad35) can employ macropinocytosis for internalization into cells (Amstutz 
et al., 2008; Kalin et al., 2010).  Moreover, accumulation of receptors on the cell surface that 
use clathrin can disrupt the cell membrane and induce macropinocytosis (Doherty and 
McMahon, 2009).  Trafficking studies of Ads containing fiber chimera illustrated that upon 
exchange of the fiber, the trafficking of Ad5 was changed to the serotype from which the fiber 
was derived (Miyazawa et al., 2001; Miyazawa et al., 1999).  Furthermore, it has been shown 
that the pH susceptibility is different for Ad serotypes and therefore the time of viral escape 
from the endosome.  Subgroup C Ads escape from early endosomes (Gastaldelli et al., 2008), 
whereas Ad37 (a member of subgroup D) is transferred to the lysosome before escape 
(Leopold and Crystal, 2007); and Ad3 (subgroup B member) has a slower escape from the 
endosome than Ad2 (a subgroup C member) (Amstutz et al., 2008).  In addition, Amstutz et al. 
demonstrated that clathrin plays only a minor role in Ad3 endocytosis.   
The trafficking of Ad5/3 fiber chimeras has not yet been investigated.  It is possible that the 
internalization and the trafficking pathway of an Ad5/3 fiber chimera mimic that of Ad 
serotype 3 rather than Ad serotype 5.  Until recently, the primary cellular attachment receptor 
of Ad serotype 3 has been disputed.  Initially, CD46 and CD80 and CD86 have been identified 
as receptors for Ad serotype 3 (Fleischli et al., 2007; Short et al., 2004; Sirena et al., 2004), but 
their function was debated (Marttila et al., 2005; Segerman et al., 2003).  However, Wang et al. 
recently published that Desmoglein-2 is the primary cellular attachment receptor (Wang et al., 
2011) and so far it is only known that multimerization of the Ad3 fiber knob is necessary to 
bind efficiently to the receptor and to induce opening of epithelial junctions (Wang et al., 
2011).  Hence, little is known to date about Ad3 internalization upon binding to Desmoglein-2 
and the subsequent trafficking of Ad3 in endosomes.  Furthermore, it is not clear whether Ad3 
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employs also macropinocytosis upon Desmoglein-2 binding as it was shown for CD46 binding.  
Another potential reason for reduced oncolytic activity of Ad5/3 CXCR4 UTR is that binding 
of Ad3 fiber knob activates an unknown factor, which inhibits E1A expression by binding in 
the 5’UTR sequence of rat FGF-2 and works as a repressor.  It is speculated that this inhibition 
is diminished with time after the infection, and then E1A transcription can be initiated.   
Alternatively, a mutation of a gene within the Ad5/3 CXCR4 UTR genome essential to initiate 
the early transcription of E1A could be a different explanation.  Amstutz et al. investigated the 
endocytotic uptake of Ad3 in epithelial and hematopoietic cells.  These investigators showed 
that Ad3 uptake into cells upon CD46 binding occurs through macropinocytosis and that this 
uptake is controlled by the activation of the C-terminal binding protein 1 (CtBP1) which is a 
transcriptional co-repressor (Amstutz et al., 2008).  CtBP activation and translocation during 
Ad infection overlaps with transcriptional suppression of cellular genes (Barnes et al., 2003).  
Some of the targets of CtBP include the histone acetyl transferases, the E1A associated protein 
p300, and Ad5 E1A itself (Boyd et al., 1993; Chinnadurai, 2002; Senyuk et al., 2005).  Studies 
of CtBP binding to E1A were performed using plasmids that either contained the sequence for 
12S E1A or the whole E1A gene (Zhang et al., 2000).  It was shown that CtBP binds to the 
sequence motif Pro-Leu-Asp-Leu-Ser (PLDLS) located at the C-terminus of E1A.  Binding of 
CtBP represses the E1A transcription which can be reversed by acetylation of the Lys-239 
(Zhang et al., 2000).  Mutation of this amino acid to Arg increased the binding of CtBP 
compared to WT and caused a repression of E1A transcription (Zhang et al., 2000).  These 
findings led to the hypothesis that a mutation in the CtBP binding region of E1A could enhance 
the repression effect of CtBP and cause a reduced E1A transcription of Ad5/3 CXCR4 UTR 
early during the Ad infection cycle.  Sequencing of the whole Ad5/3 CXCR4 UTR genome is 
in progress and should answer this possibility. 
In conclusion, the generation of a triple-level targeted oncolytic Ad was achieved and a gain in 
cancer specificity was detected in normal cells.  However, at the same time the triple-level Ad 
displayed a lower oncolytic activity on breast cancer cells than previously generated dual-level 
or single-level targeted oncolytic Ad vectors.  Furthermore, the examinations of several 
hypotheses could show that a repressed E1A transcription in Ad5/3 CXCR4 UTR infected cells 
was the limiting factor.  The presence of several Ad5 proteins could omit this restriction and 
induce a great cytolytic activity of Ad5/3 CXCR4 UTR in HEK-293 cells.  Unfortunately, it 
was not possible to identify the factor(s) responsible for inhibiting E1A transcription in    
Ad5/3 CXCR4 UTR infected cells.  Therefore, further experimental investigations are needed 
to address this question.  Furthermore, trafficking studies and analysis of the CtBP binding site 
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could reveal whether those two aspects are responsible for the reduced oncolytic activity of 
Ad5/3 CXCR4 UTR in breast cancer cells.  Sequencing analyses of the whole                   
Ad5/3 CXCR4 UTR genome should give new understandings whether a mutation in a specific 
Ad gene is triggering the delayed expression of Ad5/3 CXCR4 UTR or not.  Identifying the 
factor that represses the transcription of the Ad5/3 CXCR4 UTR E1A gene could give new 
insights into the transcriptional regulation of oncolytic Ad vectors.  Revealing this factor could 
lead to an optimization of the Ad5/3 CXCR4 UTR vector.  To finally conclude, the 
combination of the Ad5/3 fiber chimera and the 5’UTR sequence in this study demonstrated a 
reduced efficacy for the Ad vector.  This combination is not a suitable approch for a triple-level 
targeted Ad due to the decreased oncolysis in breast cancer cells.  Future intentions to construct 
a triple-level targeted Ad should either use a different transductional targeting or a different 
translational targeting.  Incorporation of specific motifs into the HI-loop or incorporation of a 
specific cell ligand could be an alternative to the serotype fiber chimera.  An alternative for 
cancer specific control of E1A expression is the addition of a 3’-UTR element that controls the 
cancer-selective mRNA stability as described by Ahmed et al. (Ahmed et al., 2003).  
Furthermore, another possibility to improve the triple-level construction is the insertion of a 
specific miRNA target sequence which’s activity is reduced in breast cancer cells and up 
regulated in normal cells.  Ultimately, an optimized triple-level Ad vector would be a 
promising tool to specifically target and kill breast cancer cells.  A future goal in combining 
different targeting strategies is to identify specificity to kill also breast cancer stem cells.  
Breast cancer stem cells or cancer stem cells in general are thought to induce cancer 
development.  It will be important to understand the oncolytic activity of triple-level Ad 
vectors for this cell population. 
 
5.2 Establishment of a Syrian hamster breast cancer cell line 
In the field of cancer biology, well-characterized cancer cell lines are an important tool to study 
cancer biology and investigate new treatment options in vitro.  For in vivo examinations in the 
development of breast cancer and in preclinical studies of a new anticancer therapeutic agent, 
human xenograft cells are injected into immuno-compromised animals.  In spite of this, 
differences in gene expression, gene activity and function between species can result in 
disparities in toxicity and efficacy outcome (Mirzaee et al., 2010; Quintieri et al., 2008).  
Therefore, novel breast cancer models are clearly needed.  In the past several years, Syrian 
hamsters have been employed for a number of diverse cancer chemoprevention and 
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carcinogenesis models, but none included the mammary carcinogenesis.  Thus, our group used 
MNU to promote the development of spontaneous mammary tumors in female Syrian hamsters 
(Coburn et al., 2011).  It was possible to demonstrate that the developed primary tumors were 
of mammary and epithelial origin.   
In this study, the first immortalized mammary carcinoma cell line from female Syrian hamsters 
was established.  Two cell lines, HMAM4B and HMAM5, were passaged more than 30 times 
and re-cultured in vitro.  In addition, both cell lines showed a similar growth rate compared to 
the human breast cancer cell line MDA-MB-231 and displayed anchorage independent growth 
by colony formation in soft agar.  The rapid growth during the exponential phase and the 
anchorage independent growth are two markers characteristic of cancer cells.  Multiple copy 
numbers of chromosomes were determined in both Syrian hamster breast cancer cell lines with 
an average chromosome number of 74 in both whereas the normal chromosome number for 
Syrian hamster is 44 (2n) (Romanenko et al., 2007).  Those in vitro data indicated that the 
Syrian hamster cell lines HMAM4B and HMAM5 were immortalized breast cancer cell lines.  
In addition, upon reinjection of the cell line HMAM4B into recipient hamsters, tumor 
formation was induced with a take rate of about 50%.  Cells isolated from developed tumors, 
were able to grow in cell culture (HMAM5) and were also transplantable into recipient 
hamsters with a tumor formation take rate of 70%.  These in vivo experiments showed that both 
breast cancer cell lines are able to induce tumor development upon subcutaneous injection into 
syngeneic Syrian hamsters, which is an indicator for tumorigenicity.  Furthermore, negative 
staining for the molecular markers p63 and cytokeratin 5 demonstrated that the tumors induced 
by the subcutaneous injection of HMAM4B and HMAM5 cells were of luminal origin.  
Moreover, it was shown that the cell lines were derived from a luminal B subtype mammary 
tumor due to the susceptibility to tamoxifen.   
Usually, evaluation for efficacy of newly constructed oncolytic Ad vectors is performed in 
immunodeficient mice using human xenograft tumor models.  Unfortunately, biodistribution 
and toxicity of oncolytic vectors in this animal model does not accurately reflect that observed 
in humans because Ad replication is species specific.  Recently, it has been demonstrated that 
Syrian hamsters are permissive for human Ad5 replication and that several Syrian hamster 
cancer cell lines except for breast cancer were established to study oncolytic Ad vectors 
(Bortolanza et al., 2007; Spencer et al., 2009; Thomas et al., 2006).  In this study, two new 
Syrian hamster breast cancer cell lines, HMAM4B and HMAM5, were successfully 
established.  Importantly, these cell lines can be used as a syngeneic model in evaluating the 
efficacy of newly designed oncolytic Ad vectors.   
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Here, in this study it was demonstrated that Ad5 ∆24 RGD, an oncolytic Ad previously tested 
in clinical trials for ovarian cancer, showed increased killing of HMAM5 cells compared to 
Ad5 WT.  The Ad5 Δ24 vector also showed an increase in specificity to lyse HMAM5 cells, 
since Syrian hamster fibroblasts were lysed with a lower efficacy.  In addition, E1A mRNA 
transcription and Ad replication efficiency of Ad5 ∆24 RGD were significantly increased in 
HMAM5 cells compared to the other viruses tested.  Surprisingly, Ad5/3 WT, Ad5 CXCR4 
and Ad5/3 CXCR4 did not display replication efficiency or oncolytic activity in the HMAM5 
cells or the hamster fibroblasts.  This finding was likely due to the possibility that Syrian 
hamster breast cancer cells and normal cells do not express Desmoglein-2, the Ad3 receptor.  
Furthermore, Syrian hamster breast cancer cells may not express the CXCR4 gene.  Because no 
commercial antibodies are available that cross-react with Syrian hamster CXCR4 or 
Desmoglein-2, the expression levels of these proteins in HMAM5 cells could not be measured.  
Also, the genome of the Syrian hamster is not fully sequenced and consequently, the cDNA 
sequences for Syrian hamster CXCR4 or   Desmoglein-2 are not available.  Thus, mRNA 
levels of these genes could not be determined.  Stable transfection of the HMAM5 cell line 
with a plasmid expressing the human   Desmoglein-2 sequence could be used to circumvent the 
lack of receptor problem.   
Taken together, these results showed that a novel immortalized Syrian hamster breast cancer 
cell line was established.  This cell line maintained the ability to initiate tumor formation upon 
subcutaneous injection into syngeneic female Syrian hamsters.  To conclude, this immortalized 
cell line could be very useful to the research community because spontaneous primary 
mammary carcinomas in Syrian hamsters are rare.  Furthermore, this cell line is a promising 
test system to preclinically evaluate some oncolytic Ad vectors for their efficacy, which do not 
contain a serotype chimeric fiber and no human specific incorporation in their genome.  This 
Syrian hamster breast cancer cell line could be further improved for fiber knob chimeras by 
genetic transfections of the corresponding receptors.  A future goal would be that the Syrian 
hamster breast cancer model could serve as a novel animal system besides mice and rats to 
study chemopreventive agents in an intact immune system.  Nevertheless, before the 
introduction of the Syrian hamster breast cancer model in the field of virotherapy as a suitable 
animal model to preclinically evaluate some oncolytic Ad vectors, in vivo experiments need to 
be performed to confirm this assumption and the previous results of the in vitro studies.  A 
pilot study including six female Syrian hamsters was performed to determine the dose of viral 
injection.  The results of this pilot study revealed promising effects on tumor reduction after 
the injection of Ad5 ∆24 RGD.  This pilot study needs to be expanded to include a larger 
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number of animals per treatment arm as well as control treatment arms.  The final future goal is 
to employ the Syrian hamster breast cancer model to evaluate the biodistribution and toxicity 
of oncolytic Ads in a preclinical animal model.   
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8. Abstract 
Breast cancer is still one of the most frequently diagnosed cancer types in women. Although a 
variety of treatment options and early detection methods are now available, breast cancer 
remains one of the leading causes of cancer death among women. Therefore, new therapy 
approaches are sorely needed. Virotherapy employing oncolytic adenoviruses (Ads) represents 
a promising tool for treating a wide array of neoplastic diseases including breast cancer. 
Critical for an effective therapeutic index is selective killing of breast cancer cells while 
avoiding killing normal cells. Besides the generation of cancer specific oncolytic vectors, new 
animal models which are immunocompetent and permissive for adenovirus replication are 
desperately needed to evaluate oncolytic Ad vector functions in a preclinical model. Herein, a 
novel oncolytic Ad was constructed to target breast cancer by incorporating three cancer 
control elements into the Ad5 genome: 1) transductional, 2) transcriptional and 3) mRNA 
translational targeting. A modified triple-level targeted oncolytic Ad (Ad5/3 CXCR4 UTR) 
incorporating a serotype 5/3 chimeric fiber was generated. This construct used the human 
CXCR4 gene promoter and the 5’-untranslated region (UTR) from rat Fibroblast Growth 
Factor-2 mRNA to regulate Ad E1A gene transcription and translation. It was hypothesized 
that this novel vector would improve the therapeutic index by selective targeting of human 
breast cancer cells. While it was achieved to construct a replication competent Ad5/3 CXCR4 
UTR, this vector displayed a lower oncolytic activity in breast cancer cells compared to Ad5/3 
WT and Ad5/3 CXCR4. Since multiple vector modifications could negatively influence virus 
replication, we examined their effects. We could detect no effects of Ad5/3 knob modification 
on eIF4E protein expression or on phosphorylation of 4E-BP, which are necessary for the 
translational targeting element. Furthermore, stable expression of E1A in MDA-MB-231 cells 
could not provide an increased oncolytic activity of Ad5/3 CXCR4 UTR to the level observed 
in HEK-293 cells. However, we could show that E1A transcription was delayed in Ad5/3 
CXCR4 UTR infected MDA-MB-231 cells compared to the other viruses infected MDA-MB-
231 cells. Thus, this may lead to the assumption that HEK-293 cells provide an unknown factor 
that is ameliorating the combination effect of transductional, transcriptional and mRNA 
translational targeting that limits oncolytic activity of Ad5/3 CXCR4 UTR.   
In the next step, our group succeeded in establishing two Syrian hamster breast cancer cell 
lines (HMAM4B and HMAM5) from N-methyl-N-nitrosurea (MNU)-induced mammary 
tumors of female Syrian hamsters. It could be demonstrated that these two cell lines maintained 
characteristic cancerous and tumorigenic features. Furthermore, these cell lines induced tumor 
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formation in syngeneic female Syrian hamsters upon subcutaneous injection. Functional in 
vitro assays of oncolytic Ads on HMAM5 cells, demonstrated a specificity of oncolytic Ad 
replication and oncolysis in the HMAM5 cell line compared to normal Syrian hamster 
fibroblasts. These results showed that the HMAM5 cell line can be used to evaluate the breast 
cancer efficacy of oncolytic Ad vectors in an immunocompetent preclinical model.   
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9. Zusammenfassung 
Das Mammakarzinom ist immer noch der häufigste maligne Tumor der Frau weltweit. Obwohl 
es mittlerweile eine große Anzahl von Therapiemöglichkeiten und Methoden zur frühen 
Erkennung gibt, bleibt das Mammakarzinom eine der Haupttodesursachen unter 
Krebspatientinnen. Deswegen sind neue Therapieansätze dringend notwendig. Die 
Virotherapie stellt eine viel versprechende neue Therapieform für ein breites Spektrum von 
Krebserkrankungen inklusive Brustkrebs dar. Eine Art der Virotherapie setzt die so genannten 
onkolytischen Adenoviren (Ad) ein. Kritisch für einen effektiven therapeutischen Index ist das 
selektive Abtöten von Tumorzellen durch Ads bei gleichzeitiger Schonung von gesundem 
Gewebe. Neben der Generierung neuer onkolytischer Vektoren für tumorspezifische 
Zellzerstörung, ist die Entwicklung eines immunkompetenten und für Ad Replikation 
permissiven Tiermodells von großer Notwendigkeit, um onkolytische Vektoren präklinisch zu 
testen. In dieser Arbeit wurde erstmals ein onkolytisches Ad generiert, das spezifisch 
Mammakarzinomzellen zerstören soll, indem die drei folgenden Targeting Strategien in das 
adenovirale Genom inkorporiert wurden: 1) Transduktionales, 2) Transkriptionales und 3) 
Translationales Targeting. Das neu generierte onkolytische triple-level Ad (Ad5/3 CXCR4 
UTR) beinhaltet einen serotypischen 5/3 chimären Fiber als transduktionales Targeting, den 
humanen CXCR4 Genpromoter als transkriptionales Targeting und die 5’UTR Sequenz des 
Fibroblast Growth Factor-2 (FGF-2) der Ratte als translationales Targeting upstream des 
viralen E1A Genes. Dieser virale Vektor sollte durch ein gesteigertes selektives Targeting von 
Mammakarzinomzellen den therapeutischen Index erhöhen. Bedauerlicherweise wurde im 
Vergleich mit Ad5/3 WT und Ad5/3 CXCR4 eine geringere onkolytische Aktivität des 
replikationskompetenten Ad5/3 CXCR4 UTR in Brustkrebszellen festgestellt. Einen Einfluss 
der Bindung des Ad3 Fiber Knobs auf die eIF4E Protein Expression und die 4E-BP 
Phosphorylierung, welche wichtig für die Translationinitiation sind, konnte nicht festgestellt 
werden. Allerdings konnte gezeigt werden, dass die verringerte onkolytische Aktivität des 
Ad5/3 CXCR4 UTR auf eine verzögerte E1A Transkription zurückzuführen war. Die 
Annahme, dass ein Abbau der E1A mRNA durch die Ad3 Fiber Knob Bindung stattfindet, 
wurde in dieser Arbeit durch mRNA Stabilitätsanalysen widerlegt. Des Weiteren konnte 
gezeigt werden, dass es trotz einer stabilen E1A Expression in MDA-MB-231 Zellen zu keiner 
erhöhten onkolytischen Aktivität des Ad5/3 CXCR4 UTR kommt, welche in HEK-293 Zellen 
erkennbar war. Aus diesem Grund ist anzunehmen, dass HEK-293 Zellen einen unbekannten 
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Faktor exprimieren, der zu einer erhöhten onkolytischen Aktivität des Ad5/3 CXCR4 UTR 
führt.  
Im nächsten Schritt, konnte unsere Gruppe erfolgreich zwei Zelllinien (HMAM4B and 
HMAM5) aus N-methyl-N-nitrosurea (MNU)-induzierten Mammakarzinomen des weiblichen 
Goldhamsters isolieren. Die Eigenschaften von Krebszellen konnten in diesen Zelllinen 
erhalten werden und es konnte gezeigt werden, dass die HMAM4B und die HMAM5 Zelllinie 
immortalisiert sind. Außerdem konnten nach subkutaner Injektion dieser Zellen 
Mammakarzinome in genetisch identischen weiblichen Goldhamstern induziert werden. 
Funktionalitätsuntersuchungen in vitro von verschiedenen etablierten onkolytischen Ads in der 
HMAM5 Zelllinie zeigten, dass eine spezifische Vermehrung des Ad5 Δ24 RGD und 
Onkolyse in den HMAM5 Zellen stattfindet im Gegensatz zu normalen Goldhamster 
Fibroblasten. Die hier neu etablierte Goldhamster Mammakarzinomzelllinie HMAM5 kann 
somit zur Evaluierung von humanen onkolytischen Ad für das Mammakarzinom eingesetzt 
werden. Zukünftige in vivo Studien könnten zeigen, dass das neu generierte Mammakarzinom 
Modell des Goldhamsters als immunokompetenes Tiermodell eingesetzt werden kann, um 
onkolytische Ad Vektoren präklinisch zu testen. 
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10. Abbrevations 
Ad   adenovirus 
ADP   adenovirus death protein 
Ad2   adenovirus serotype 2 
Ad3   adenovirus serotype 3 
Ad5   adenovirus serotype 5 
Ad35   adenovirus serotype 35 
Ad5/3 adenovirus Type 5, containing a fiber chimera, carrying the fiber knob of Ad3 
Ad5 CXCR4 adenovirus serotype 5, human CXCR4 promoter instead of E1A promoter 
Ad5/3 CXCR4  adenovirus serotype 5, 5/3 fiber chimera, human CXCR4 promoter  
Ad5 ∆24   adenovirus serotype 5, 24bp deletion in E1A gene 
Ad5 ∆24 RGD adenovirus serotype 5, 24bp deletion in E1A gene, RGD-motif in H1-loop 
bp base pair 
BRCA1, 2 breast cancer susceptibility gene 1, 2 
BSA bovine serum albumin 
CAR coxsackie and adenovirus receptor 
CEA carcinoembryonic antigen 
CRAd   conditionally replicating adenovirus 
CR2   constant region 2 of E1A 
CtBP1   C-terminal binding protein 1 
CV   crystal violet 
DMEM   dulbeccos modified eagles medium 
DMSO   dimethylsulfoxide 
DNA   deoxyribonucleic acid 
EDTA   ethylenediaminetetraacetic acid 
ER   estrogen receptor 
eIF4E   eukaryotic initiation factor 4E 
Fab   antibody fragment 
FBS   fetal bovine serum 
FGF-2   fibroblast growth factor-2 
g   gravitational acceleration 
GAPDH  glyceraldehyde 3-phosphate dehydrogenase 
h   hour 
HER2   human epidermal growth factor receptor 2, erb-B2 
HPRT1   hypoxanthine phosphoribosyltransferase 1 
HRP   horseradish peroxidase 
Ifu   infectious units 
kDa   kilo Dalton 
kbp   kilo basepairs 
l   liter 
µg   microgram 
µl   microliter 
µM   micro Molar 
mA   milli Amper 
mg   milligramm 
ml   milliliter 
mM   milli Molar 
min   minute 
MNU   N-methyl-N-nitrosourea 
MOI    multiple units of infection 
mRNA   messenger ribonucleic acid 
MTT   3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
ng   nanogramm 
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nm   nanometer 
ON   over night 
PAGE   polyacrylamide gel electrophoresis 
PARP   poly (ADP-ribose) polymerase 
PBS   phosphate-buffered saline 
PBS-T   phosphate-buffered saline containing tween 
PCR   polymerase chain reaction 
PR   progesterone receptor 
qPCR   quantitative polymerase chain reaction 
qRT-PCR  quantitative reverse transcriptase polymerase chain reaction 
pTP   preterminal protein 
Rb   retinoblastoma 
RGD   Arg-Gly-Asp motif 
RNA   ribonucleic acid 
RT   room temperature 
SDS   sodium dodecyl sulphate 
sec   second 
TBS   tris-buffered saline 
TBS-T   tris-buffered saline containing tween 
TP   terminal protein 
TSP   tumor specific promoter 
U   units 
UTR   untranslated region 
VEGEF  vascular endothelial growth factor 
WT   wild type 
4E-BP   eIF4E Binding Protein 
 
 
   114 
11. Danksagungen 
An erster Stelle möchte ich mich bei Frau PD Dr. Mariam Stoff-Khalili und Herrn Prof. Dr. Dr. 
h.c. Herbert Pfister, für ihre Unterstützung und wissenschaftliche Betreuung bedanken.  
Mein ganz besonderer Dank gilt Herrn Prof. Michael Mathis für seine Betreuung in allen 
praktischen und theoretischen Belangen und dafür, dass ich insgesamt ein Jahr lang während 
meiner Doktorarbeit in seinem Labor in Shreveport, Louisiana arbeiten durfte.  
Ich danke Frau Dr. Hildegrad Büning und Frau Prof. Dagmar Knebel-Mörsdorf für ihre 
Begleitung als Tutoren meiner Doktorarbeit, für ihre hilfreichen Ratschläge und für ihre 
Bereitschaft die vorliegende Arbeit zu bewerten. 
Des Weiteren möchte ich mich bei Herrn Prof. Jonathan Howard und Herrn Prof. Hinrich 
Abken für ihre Bereitschaft die vorliegende Arbeit vor der Mathematisch-
Naturwissenschaftlichen und der Medizinischen Fakultät der Universität zu Köln zu vertreten.  
Weiterhin gilt mein Dank Frau Dr. Grosskopf-Kroiher, die den Beisitz meiner Disputation 
übernehmen wird und die mir während meiner Doktorarbeit mit Rat und Tat zur Seite stand im 
Dschungel des IPMM. 
Ich möchte mich besonders bei Shilpa Bhatia, Hany Sakr, Rosa Guo, Yoshi Odaka and Dr. 
Elysse Orchard bedanken, für die tolle Integrierung in die Gruppe in Shreveport, für das 
Unterrichten der virologischen Methoden und für die fachliche Diskussionsbereitschaft. Bei 
Bing Cheng bedanke ich mich besonders für die tolle Unterstützung im Umgang mit den 
Hamstern. 
Bei Frau Ute Sandaradura de Silva möchte ich mich herzlich für die technische und persönliche 
Assistenz bedanken. Ohne Sie wären die ersten Jahre noch schwerer gewesen als das sie 
ohnehin schon waren. 
Ein besonderer Dank gilt auch Dr. Baki Akgül, den ich immer um fachliche Hilfe bitten konnte 
und der mir immer mit einem guten Rat zur Seite stand. 
Bei Christine Herwartz, Martin Hufbauer, Dali Lazic, und Darko Jordanovski für die feucht-
fröhlichen Abende und die tolle Gruppengemeinschaft trotz unterschiedlicher 
Arbeitsgruppenleiter. Bei Paolo Marcuzzi, Steffi Taute, Elena Knops, Maria Neumann-Fraune, 
Susanna Trapp, Finja Schweitzer und Eva Heger möchte ich mich ganz herzlich für fachliche 
und vor allem freundschaftliche Unterstützung bedanken. Auch allen anderen Mitarbeitern des 
Instituts für Virologie gilt mein Dank für ein schönes Arbeitsklima.  
Den Labormitgliedern der Arbeitsgruppe Langer: Flobo, Clojack und Chef, die mir auch nach 
meiner Diplomarbeit noch mit Rat und Tat zur Seite standen. 
Ein ganz besonderer Dank gilt Juliane Röper, die mit mir das Auslandssemester in Australien 
verbracht hat und seitdem meine Schulter zum anlehnen ist, in allen labortechnischen und 
persönlichen Sachen.  
Jedoch der meiste Dank gilt meiner Familie, besonders meinen Eltern, meinen Schwestern 
Anika und Jasmin, meiner Tante Elke und meinem Freund Michael, die mich immer unterstützt 
und an mich geglaubt haben, egal wie groß die Hürde war, die ich nehmen musste. Ich liebe 
euch. 
 
 
   115 
12. Eidesstattliche Erklärung 
Ich versichere, dass ich die mir vorgelegte Dissertation selbständig angefertigt, die benutzten 
Quellen und Hilfsmittel vollständig angegeben und die Stellen der Arbeit - einschließlich 
Tabellen, Karten, und Abbildungen - , die anderen Werken im Wortlaut oder dem Sinn nach 
entnommen sind, in jedem Einzelfall als Entlehnung kenntlich gemacht habe; dass diese 
Dissertation noch keiner anderen Fakultät oder Universität zur Prüfung vorgelegen hat; dass sie 
– abgesehen von unten angegebenen Teilpublikationen – noch nicht veröffentlicht worden ist 
sowie, dass ich eine solche Veröffentlichung vor Abschluss des Promotionsverfahrens nicht 
vornehmen werde. 
Die Bestimmungen dieser Promotionsordnung sind mir bekannt. Die von mir vorgelegte 
Dissertation ist von Herrn Prof. Dr. Dr. h.c. Herbert Pfister betreut worden. 
 
Teile der vorliegenden Dissertation sind unter folgenden Titeln veröffentlicht worden: 
Coburn, M. A., Brueggemann, S., Bhatia, S., Cheng, B., Li, B. D., Li, X. L., Luraguiz, N., 
Maxuitenko, Y. Y., Orchard, E. A., Zhang, S., Stoff-Khalili, M.A., Mathis, J.M., Kleiner-
Hancock, H.E. (2011). Establishment of a mammary carcinoma cell line from Syrian hamsters treated 
with N-methyl-N-nitrosourea. Cancer Lett 312, 82-90. 
 
Ich versichere, dass ich alle Angaben wahrheitsgemäß nach bestem Wissen und Gewissen 
gemacht habe und verpflichte mich, jedmögliche, die obigen Angaben betreffenden 
Veränderungen, dem Promotionsausschuss unverzüglich mitzuteilen. 
 
 
................................................    .............................................. 
Datum        Sabrina Brüggemann 
 
 
 
 
 
   116 
13. Lebenslauf 
Persönliche Daten 
Name    Sabrina Brüggemann 
Wohnort   Maarweg 221 
    50825 Köln 
Geburtstag   20.10.1983 
Geburtsort   Köln 
Familienstand   ledig   
Nationalität   deutsch 
 
Ausbildung 
Promotionsarbeit:  AG Stoff-Khalili, Institut für Virologie, Universität zu Köln 
(seit 03/2009)   „Oncolytic Virotherapy for Breast Cancer” 
 
10/2003 bis 01/09  Diplom Biologie an der Universität zu Köln, Note: sehr gut (1) 
Diplomarbeit:   AG Prof. Thomas Langer, Universität zu Köln 
Titel:  „Characterization of PRELI-like proteins in mouse embryonic 
fibroblasts” 
 
2003 Schulabschluss  Städt. Johann-Gottfried-Herder-Gymnasium, Köln 
    Abitur: 2,2 (Leistungskurse: Mathematik, Biologie) 
 
Auslandserfahrungen 
Auslandssemester SS 2006    Study Abroad, Science, University of Sydney 
Collaboration:  LSU Health Sciences Center, Department of Cellular Biology 
(30.03.2009 - 23.09.2009, and Anatomy, Group of Prof. Dr. M. Mathis, Gene Therapy,  
05.09.2011 – 31.03.2012) Shreveport, LA, USA 
 
Meetings 
21-25.11.2009 ESGCT Congress in Hannover, Germany 
Poster: Triple level targeting of an oncolytic adenovirus for 
effective killing of breast cancer cells, Sabrina Brueggemann, 
Rosa Franco Guo, J. Michael Mathis, Mariam Stoff-Khalili
 
22-25.10.2010 ESGCT Congress in Milan, Italy 
Poster: Generation of an adenoviral chimeric fiber 5/3 
incorporating a transcriptional and translational control 
element, Sabrina Brueggemann, Rosa Franco Guo, Ute Sandaradura 
de Silva, Baki Akguel, H. Pfister, M.A: Stoff-Khalili, J.M. Mathis 
 
 
  
117 
 
 
Praktika    
23.10.2000 – 3.11.2000  Behindertenheim in Cork (Irland), Tätigkeit: Betreuer 
16.03.2005 – 24.03.2005 Gemeinschaftspraxis für Laboratoriumsmedizin 
                                               Dres. med. Wisplinghoff und Kollegen, Tätigkeit: Laborantin 
 
EDV-Kenntnisse  Microsoft Word, Excel und Powerpoint, CorelDraw, Vector NTI, 
Sigma Plot, BD Quantity One 
 
Sprachkentnisse:  Englisch (sehr gut), Französisch (Schulkenntnisse), Spanisch 
(Schulkenntnisse) 
 
Nebentätigkeiten  seit Jul. 2000 , Reisswolf GmbH, Köln, Büroaushilfe 
                                       seit Juni 2003 - 2007, TOYS’R’US Köln, Kassiererin/ Aushilfe 
 
Freizeitinteressen  Basketball (Damenmannschaft, TV Dellbrück seit 2005) 
    Tanzen (Standardtänze, Hip Hop seit 2003) 
 
 
 
 
 
 
 
 
 
 
 
 
-----------------------       ------------------------------- 
         Datum            Sabrina Brüggemann 
